

Prospectus dated 17 April 2026



Roquette Frères

(incorporated as a société anonyme in the Republic of France)

€600,000,000 Undated Deeply Subordinated Fixed to Reset Rate Non-Call 6 Notes

Issue price: 100 per cent.

The €600,000,000 Undated Deeply Subordinated Fixed to Reset Rate Non-Call 6 Notes (the "**Notes**") of Roquette Frères (the "**Issuer**" or "**Roquette**") will be issued on 21 April 2026 (the "**Issue Date**").

The obligations of the Issuer in respect of principal and interest of the Notes (including for the avoidance of doubt, any Arrears of Interest and Additional Interest Amount) constitute direct, unconditional, unsecured and deeply subordinated obligations (*titres subordonnés de dernier rang*) of the Issuer and rank and will rank at all times *pari passu* without any preference among themselves and (i) *pari passu* with all other present and future Parity Securities of the Issuer, (ii) junior to present and future *prêts participatifs* granted to the Issuer and *titres participatifs* issued by the Issuer and to Ordinary Subordinated Obligations and Unsubordinated Obligations of the Issuer and (iii) in priority to any Junior Securities, as further defined and set out in the Condition 2 "Status of the Notes" of the Terms and Conditions.

The Notes do not contain events of default, including any cross default.

Unless previously redeemed in accordance with the Condition 5 "Redemption and Purchase" in the Terms and Conditions of the Notes and subject to the further provisions described in the Condition 4 "Interest" in the Terms and Conditions, the Notes will bear interest (i) from (and including) the Issue Date to (but excluding) 21 April 2032 (the "**First Reset Date**"), at an interest rate per annum of 6.000 per cent., (ii) from (and including) the First Reset Date to (but excluding) 21 April 2037 (the "**First Step-up Date**"), at an interest rate per annum which shall be equal to the sum of the Reference Rate (as defined herein) in respect of the relevant Reset Period (as defined herein) and the Relevant Margin (as defined herein), (iii) from (and including) the First Step-up Date to (but excluding) 21 April 2052 (the "**Second Step-up Date**"), at an interest rate *per annum* which will be subject to a reset every five years and shall be equal to the sum of the Reference Rate in respect of the relevant Reset Period and the Relevant Margin and (iv) from (and including) the Second Step-up Date, at an interest rate *per annum* which will be subject to a reset every five years and shall be equal to the sum of the Reference Rate in respect of the relevant Reset Period and the Relevant Margin.

Payment of interest on the Notes may be deferred in whole or in part at the option of the Issuer under certain circumstances, as set out in the Condition 4.6 "Interest and deferral of interest - Interest Deferral" in the Terms and Conditions.

The Notes are undated obligations of the Issuer and have no fixed maturity date. However, the Issuer will have the right to redeem the Notes in whole, but not in part, at par (i) on any day in the period commencing on (and including) 21 January 2032 (being the date falling three months prior to the First Reset Date (the "**First Call Date**")) and ending on (and including) the First Reset Date, and (ii) on any Interest Payment Date thereafter, as defined and further described in the Condition 5.2 "Redemption and Purchase – Optional Redemption" in the Terms and Conditions. The Issuer may also, at its option, redeem in whole, but not in part, the Notes then outstanding at any time (other than (i) during the period from (and including) the First Call Date to (and including) the First Reset Date or (ii) on any subsequent Interest Payment Date) at the Make-whole Redemption Amount, as defined and further described in the Condition 5.3 "Redemption and Purchase – Make-whole Redemption by the Issuer" in the Terms and Conditions of the Notes. The Issuer may also, at its option, redeem all, but not some only, of the Notes at any time upon the occurrence of a Gross-Up Event, a Withholding Tax Event, a Tax Deduction Event, an Accounting Event, an Equity Credit Rating Event or a Change of Control Event, each as further described and defined in the Condition 5 "Redemption and Purchase" in the Terms and Conditions. The Issuer may also, at its option, redeem all but not some only of the outstanding Notes at par in the event that at least seventy-five (75) per cent. of the initial aggregate principal amount of the Notes has been purchased or redeemed by the Issuer, in accordance with the provisions set out in Condition 5.7 "Redemption and Purchase – Redemption following Substantial Repurchase Event" in the Terms and Conditions of the Notes.

This document (including the documents incorporated by reference therein) constitutes a prospectus (a "**Prospectus**") for the purposes of Article 6 of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, as amended (the "**Prospectus Regulation**") in respect of, and for the purposes of giving information with regard to, Roquette and its fully consolidated subsidiaries, taken as a whole (the "**Group**"), which is necessary to enable investors to make an informed assessment of the assets and liabilities, financial position, profit and losses and prospects of Roquette and the Group.

This Prospectus has been approved by the *Autorité des marchés financiers* (the "**AMF**") in France in its capacity as competent authority pursuant to the Prospectus Regulation. The AMF only approves this Prospectus as meeting the standards of completeness, comprehensibility and consistency imposed by the Prospectus Regulation. Such approval should not be considered as an endorsement of the Issuer or of the quality of the Notes which are the subject of this Prospectus. Investors should make their own assessment as to

the suitability of investing in the Notes. This Prospectus will be valid until the date of admission of the Notes to trading on Euronext Paris. After such date, this Prospectus will no longer be valid and the obligation to supplement this Prospectus in the event of significant new factors, material mistakes or material inaccuracies will no longer apply.

Application has been made to Euronext Paris for the Notes to be admitted to trading on the regulated market of Euronext Paris ("**Euronext Paris**") with effect from the Issue Date. Euronext Paris is a regulated market (a "**Regulated Market**") for the purposes of the Markets in Financial Instruments Directive 2014/65/EU of 15 May 2014, as amended, appearing on the list of regulated markets issued by the European Securities and Markets Authority (the "**ESMA**").

The Notes will be issued in dematerialised bearer form (*au porteur*) in the denomination of €100,000 each. Title to the Notes will be evidenced in accordance with Articles L.211-3 *et seq.* and R.211-1 *et seq.* of the French *Code monétaire et financier* in the books of the Account Holders. No physical document of title (including *certificats représentatifs* pursuant to Article R.211-7 of the French *Code monétaire et financier*) will be issued in respect of the Notes. The Notes will, upon issue, be inscribed in the books of Euroclear France ("**Euroclear France**") which shall credit the accounts of the Account Holders. "**Account Holder**" shall mean any intermediary institution entitled to hold, directly or indirectly, accounts on behalf of its customers with Euroclear France, and includes Euroclear Bank SA/NV ("**Euroclear**") and the depositary bank for Clearstream Banking, SA ("**Clearstream**").

As of the date of this Prospectus, the Issuer's long-term senior debt and short-term senior debt have been respectively rated BBB with a negative outlook and A-2 by S&P Global Ratings Europe Limited ("**S&P**"). The Notes have been rated BB+ by S&P. S&P is established in the European Union and is registered under Regulation (EC) 1060/2009, as amended (the "**CRA Regulation**") and is included in the list of registered credit rating agencies published on the website of the ESMA (<https://www.esma.europa.eu/credit-rating-agencies/cra-authorisation>) in accordance with the CRA Regulation. A rating is not a recommendation to buy, sell or hold securities and may be subject to suspension, change or withdrawal at any time by the assigning credit rating agency without notice.

Prospective investors should have regard to the factors described under the section headed "Risk factors" in this Prospectus.

Copies of this Prospectus will be published on the websites of the Issuer (<https://www.roquette.com>) and of the AMF (www.amf-france.org) and the documents incorporated by reference will only be available on the website of the Issuer.

Joint Global Coordinators and Joint Bookrunners

Crédit Agricole CIB
Natixis

Goldman Sachs Bank Europe SE
Société Générale Corporate & Investment Bank

Joint Bookrunners

BNP PARIBAS

CIC Corporate & Institutional Banking

J.P. Morgan

This Prospectus constitutes a prospectus for the purposes of Article 6 of the Prospectus Regulation. This Prospectus is to be read in conjunction with all the documents which are incorporated herein by reference (see Section "Documents Incorporated by Reference" below).

This Prospectus does not constitute an offer of, or an invitation by or on behalf of, the Issuer or the Joint Bookrunners (as defined in "Subscription and Sale" below) to subscribe or purchase any of the Notes. The distribution of this Prospectus and the offering of the Notes in certain jurisdictions may be restricted by law. The Issuer and the Joint Bookrunners do not represent that this Prospectus may be lawfully distributed, or that any Notes may be lawfully offered or sold, in compliance with any applicable registration or other requirements in any such jurisdiction, or pursuant to an exemption available thereunder, or assume any obligation or responsibility for facilitating any such distribution, offering or sale. In particular, no action has been or will be taken by the Issuer or any of the Joint Bookrunners which is intended to permit a public offering of any Notes or distribution of this Prospectus in any jurisdiction where action for that purpose is required. Accordingly, Notes may not be offered or sold, directly or indirectly, and neither this Prospectus nor any offering material may be distributed or published in any jurisdiction, except under circumstances that will result in compliance with any applicable laws and regulations. Persons into whose possession this Prospectus comes are required by the Issuer and the Joint Bookrunners to inform themselves about and to observe any such restrictions. For a description of further restrictions on offers and sales of Notes and the distribution of this Prospectus, see Section "Subscription and Sale" below.

*The Notes have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "**Securities Act**"). Subject to certain exceptions, the Notes may not be offered, sold or delivered within the United States or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the Securities Act ("**Regulation S**")).*

Potential purchasers and sellers of the Notes may be required to pay taxes or other documentary charges or duties in accordance with the laws and practices of the country where the Notes are transferred or other jurisdictions (including as a result of change in law). Potential investors are advised to ask for their own tax adviser's advice on their individual taxation with respect to the acquisition, holding, sale and redemption of the Notes. Only these advisers are in a position to duly consider the specific situation of the potential investor.

No person is or has been authorised to give any information or to make any representations other than those contained in this Prospectus and, if given or made, such information or representations must not be relied upon as having been authorised by, or on behalf of, the Issuer or the Joint Bookrunners.

Neither the delivery of this Prospectus nor any sale made in connection herewith shall, under any circumstances, create any implication that there has been no change in the affairs of the Issuer or the Group, since the date hereof or that there has been no adverse change in the financial position of the Issuer since the date hereof or that the information contained in it or any other information supplied in connection with the Notes is correct as of any time subsequent to the date on which it is supplied or, if different, the date indicated in the document containing the same.

The Joint Bookrunners have not separately verified the information or representation contained or incorporated by reference herein. To the fullest extent permitted by law, the Joint Bookrunners accept no responsibility whatsoever for the information or representation contained or incorporated by reference in this Prospectus or any other information provided by the Issuer or in connection with the Notes or their distribution or for any other statement, made or purported to be made by the Joint Bookrunners or on their behalf in connection with the Issuer or the offering and issue of the Notes. None of the Joint Bookrunners makes any representation, express or implied, or accepts any responsibility, with respect to the accuracy or completeness of any of the information contained or incorporated by reference in this Prospectus in connection with the Issuer. The Joint Bookrunners accordingly disclaim all and any liability whether arising in tort or contract or otherwise (save as referred to above) which they might otherwise have in respect of this Prospectus or any such information or statement.

Neither this Prospectus nor any other information supplied in connection with the Notes or their distribution is intended to provide the basis of any credit or other evaluation or should be considered as a recommendation by the Issuer or the Joint Bookrunners that any recipient of this Prospectus or any other information supplied in connection with the Notes or their distribution should purchase any of the Notes. None of the Joint Bookrunners acts as a fiduciary to any investor or potential investor in the Notes. Each investor contemplating subscribing or purchasing Notes should make its own independent investigation of the financial condition and affairs, its own appraisal of the creditworthiness, of the Issuer or the Group and of the terms of the offering, including the merits and risks involved. For further details, see Section "Risk Factors" herein. The contents of this Prospectus are not to be construed as legal, business or tax advice. Each prospective investor should subscribe for or consult its own advisers as to legal, tax, financial, credit and related aspects

of an investment in the Notes. None of the Joint Bookrunners has reviewed or undertakes to review the financial condition or affairs of the Issuer or the Group prior to or after the date of this Prospectus nor to advise any investor or potential investor in the Notes of any information coming to the attention of any of the Joint Bookrunners.

EU MIFID II PRODUCT GOVERNANCE / PROFESSIONAL INVESTORS AND ELIGIBLE COUNTERPARTIES ONLY TARGET MARKET - Solely for the purposes of each manufacturer's product approval process, the target market assessment in respect of the Notes, taking into account the five categories referred to in item 19 of the Guidelines published by the European Securities and Markets Authority ("**ESMA**") on 3 August 2023, has led to the conclusion that: (i) the target market for the Notes is eligible counterparties and professional clients only, each as defined in Directive 2014/65/EU (as amended, "**MiFID II**"); and (ii) all channels for distribution of the Notes to eligible counterparties and professional clients are appropriate. Any person subsequently offering, selling or recommending the Notes (a "**distributor**") should take into consideration the manufacturers' target market assessment; however, a distributor subject to MiFID II is responsible for undertaking its own target market assessment in respect of the Notes (by either adopting or refining the manufacturers' target market assessment) and determining appropriate distribution channels.

UK MIFIR PRODUCT GOVERNANCE / PROFESSIONAL INVESTORS AND ELIGIBLE COUNTERPARTIES ONLY TARGET MARKET – Solely for the purposes of each manufacturer's product approval process, the target market assessment in respect of the Notes has led to the conclusion that: (i) the target market for the Notes is only eligible counterparties, as defined in the FCA Handbook Conduct of Business Sourcebook ("**COBS**"), and professional clients, as defined in Regulation (EU) No 600/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 ("**UK MiFIR**"); and (ii) all channels for distribution of the Notes to eligible counterparties and professional clients are appropriate. Any person subsequently offering, selling or recommending the Notes (a "**distributor**") should take into consideration the manufacturers' target market assessment; however, a distributor subject to the FCA Handbook Product Intervention and Product Governance Sourcebook (the "**UK MiFIR Product Governance Rules**") is responsible for undertaking its own target market assessment in respect of the Notes (by either adopting or refining the manufacturers' target market assessment) and determining appropriate distribution channels.

IMPORTANT - PRIIPS REGULATION / PROHIBITION OF SALES TO EEA RETAIL INVESTORS - The Notes are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the European Economic Area ("**EEA**"). For these purposes, a retail investor means a person who is one (or both) of: (i) a retail client as defined in point (11) of Article 4(1) of MiFID II; or (ii) a customer within the meaning of Directive 2016/97/EU, where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II. Consequently, no key information document required by Regulation (EU) No 1286/2014 (as amended, the "**PRIIPs Regulation**") for offering or selling the Notes or otherwise making them available to retail investors in the EEA has been prepared and therefore offering or selling the Notes or otherwise making them available to any retail investor in the EEA may be unlawful under the PRIIPs Regulation.

IMPORTANT - PRIIPS REGULATION / PROHIBITION OF SALES TO UK RETAIL INVESTORS – The Notes are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the United Kingdom ("**UK**"). For these purposes, a retail investor means a person who is neither: (i) a professional client, as defined in point (8) of Article 2(1) of Regulation (EU) No 600/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("**EUWA**"); nor (ii) a qualified investor as defined in paragraph 15 of Schedule 1 to the Public Offers and Admissions to Trading Regulations 2024. Consequently, no key information document required by the PRIIPs Regulation as it forms part of UK domestic law by virtue of the EUWA (the "**UK PRIIPs Regulation**") for offering or selling the Notes or otherwise making them available to retail investors in the UK has been prepared and therefore offering or selling the Notes or otherwise making them available to any retail investor in the UK may be unlawful under the UK PRIIPs Regulation.

AN INVESTMENT IN THE NOTES MIGHT NOT BE SUITABLE FOR ALL INVESTORS - Each potential investor in the Notes must determine the suitability of that investment in light of its own circumstances. In particular, each potential investor should:

- (i) have sufficient knowledge and experience to make a meaningful evaluation of the Notes, the merits and risks of investing in the Notes and the information contained or incorporated by reference in this Prospectus or any applicable supplement;
- (ii) have access to, and knowledge of, appropriate analytical tools to evaluate, in the context of its particular financial situation, an investment in the Notes and the impact such investment will have on its overall investment portfolio;

- (iii) *have sufficient financial resources and liquidity to bear all of the risks of an investment in the Notes, including where the currency for principal or interest payments is different from the potential investor's currency;*
- (iv) *understand thoroughly the terms of the Notes and be familiar with the behaviour of any relevant indices and financial markets; and*
- (v) *be able to evaluate (either alone or with the help of a financial adviser) possible scenarios for economic, interest rate and other factors that may affect its investment and its ability to bear the applicable risks.*

Neither the Issuer, nor any of the Joint Bookrunners nor any of their respective affiliates has or assumes responsibility for the lawfulness of the acquisition of the Notes by a prospective investor of the Notes, whether under the laws of the jurisdiction of its incorporation or the jurisdiction in which it operates (if different), or for compliance by that prospective investor with any law, regulation or regulatory policy applicable to it.

The investment activities of certain investors are subject to legal investment laws and regulations, or review or regulation by certain authorities. Each potential investor should consult its legal advisers to determine whether and to what extent (1) the Notes are legal investments for it, (2) the Notes can be used as collateral for various types of borrowing and (3) other restrictions apply to its purchase, sale or pledge of any Notes. Financial institutions should consult their legal advisers or the appropriate regulators to determine the appropriate treatment of the Notes under any applicable risk-based capital or similar rules.

TABLE OF CONTENTS

RISK FACTORS	7
GENERAL DESCRIPTION OF THE NOTES.....	29
DOCUMENTS INCORPORATED BY REFERENCE.....	39
TERMS AND CONDITIONS OF THE NOTES	42
USE OF PROCEEDS	65
DESCRIPTION OF THE ISSUER	66
SUBSCRIPTION AND SALE	119
GENERAL INFORMATION.....	121
PERSON RESPONSIBLE FOR THE INFORMATION GIVEN IN THE PROSPECTUS	125

RISK FACTORS

The following describes the main risk factors that the Issuer considers, as of the date hereof, important to make an investment decision in the Notes and/or may alter its ability to fulfil its obligations under the Notes towards investors. The risks described below are not the only risks the Issuer and its subsidiaries face and they do not describe all of the risks of an investment in the Notes. The inability of the Issuer to pay interest, principal or other amounts on or in connection with any Notes may occur for other reasons and the Issuer does not represent that the statements below regarding the risks of holding any Notes are exhaustive. Additional risks and uncertainties not currently known to the Issuer or that it currently believes to be immaterial could also have a material impact on its business operations or on an investment in the Notes.

Prior to making an investment decision in the Notes, prospective investors should consider carefully all the information contained or incorporated by reference in this Prospectus, including the risk factors detailed below. In particular, prospective investors, subscribers and holders of Notes must make their own analysis and assessment of all the risks associated to the Notes and the risks related to the Issuer, its activities and financial position. They should also consult their own financial or legal advisors as to the risks entailed by an investment in the Notes and the suitability of such an investment in light of their particular circumstances.

The Notes should only be purchased by investors who are financial institutions or other professional investors or qualified investors who are able to assess the specific risks implied by an investment in the Notes, or who act on the advice of financial institutions.

In each sub-category below the Issuer sets out first the most material risks, in its assessment, taking into account the expected magnitude of its negative impact and the probability of its occurrence.

Terms used but not defined in this section shall have the same meaning as those set out in the "Terms and Conditions of the Notes" and on the cover page of this Prospectus.

1. RISK FACTORS RELATING TO THE ISSUER

1.1 Markets and competitive position risks

Roquette may fail to successfully identify external business opportunities or realise the anticipated benefits from its strategic investments or divestments

The Group's growth strategy is driven by the development of collaborations to transform and develop the Group, and by acquisitions aimed at reinforcing its assets. Accordingly, Roquette pursues a strategy of selective acquisitions, divestments, strategic licensing and collaborations in order to reinforce its portfolio. For instance, on 1 May 2025 Roquette has closed the acquisition of IFF Pharma Solutions from International Flavors and Fragrances.

The implementation of this strategy depends on the Group's ability to identify transaction opportunities, mobilise the appropriate resources in order to enter into agreements in a timely manner and execute these transactions on acceptable economic terms. Although Roquette has a well-structured process for selecting and validating external growth opportunities or strategic partnerships in line with its strategy and external advisors, Roquette may not be able to identify transaction opportunities, mobilise the appropriate resources or execute these transactions in a timely manner. Even when such opportunities are identified, Roquette might not be successful in completing these transactions because of the active competition among food and pharmaceuticals groups for business development opportunities.

Once a strategic transaction is agreed upon with a third party, Roquette deploys a transition and integration/divestment team well in advance with a pre-defined operating procedure and risk management procedures to ensure the closing and post-closing integration or divestment proceeds smoothly and in line with the business plan. However, Roquette may not be able to complete the transaction in a timely manner or at all.

*In the case of a post-acquisition integration, such as the integration of Qualicaps Co. Ltd. ("**Qualicaps**"), as well as the **integration** of IFF Pharma Solutions, the return on investment for the Group may be lower than anticipated with no*

guarantee that a transaction will ultimately deliver the intended outcomes or become profitable in the long term. In such situations, the Group implements specific action plans to improve performance and align with strategic objectives.

If Roquette is unable to integrate those activities or businesses quickly or efficiently or to retain the key employees or if Roquette has higher than anticipated integration costs, Roquette's growth objectives could be delayed or ultimately not realised, and expected synergies or anticipated benefits could be adversely impacted.

Roquette may fail to fully deliver its operational efficiency and transformation programme

In 2022, Roquette launched a Group-wide programme named "Compass" (the "**Compass Programme**") focusing on ensuring sustainability, profitability, and operational excellence. It is a long-term strategy and one that is anticipated to position Roquette with a competitive advantage through periods of uncertain market conditions and more stringent regulatory demands.

The objectives of the Compass Programme are to:

- deliver value by fostering excellence and innovation through empowering employees across the Group;
- improve productivity; and
- identify and implement efficiencies to reduce fixed and variable costs.

To deploy this strategy, Roquette must transform certain of its operations, and federate its employees behind this initiative.

In 2023, Roquette has delivered significant cost savings in areas such as procurement and supply chain management, operational efficiency, energy efficiency and waste reduction, and across production, selling, general and administrative functions, and research & innovation, through its excellence programmes. However, such cost savings and manufacturing excellence programmes may not continue to be as successful or the competitiveness programme may not reach its objectives effectively within the targeted timelines.

As of 2026, all the competitiveness initiatives are embedded into a company plan named "Shift & Lead". This company plan will be delivered through four areas: Operations; Cash; Topline and Portfolio; Organisation; Governance and Enablers in order to improve competitiveness, strengthen Roquette's position, and build for long-term success.

If Roquette fails to fully deliver its operational efficiency and implement its Shift & Lead Programme, Roquette's business and financial strategy going forward could be adversely affected over the long term.

Failure to develop and innovate may negatively impact the competitive position of the Group

Some of the Group's growth depends on innovation in products, processes and services. At the date of this Prospectus, the Group has teams in 20 R&D and innovation centers around the world and has developed a global patent portfolio of over 4,000 granted patents or pending applications to protect its innovations. Its R&D efforts may not result in new products and services at a rate, or of a quality, sufficient to gain market acceptance.

Roquette is also investing in further simplification and standardisation across business operations including digitalisation to further enhance operational efficiency, support sustainability standards, promote business resilience, and create competitive advantages. However, the implementation of these transformation initiatives may sometimes not occur at the envisaged pace and/or their full potential may not always lead immediately to the expected results.

To support innovation and developments, determinations of capital expenditure are made in a forward-looking manner through dedicated investment committees according to current understanding of trends and customer demand. The failure to successfully develop new products, methods or technologies, or delays in development of new products, methods or technologies, may lead to the Group's products or technologies becoming superseded or supplement capex costs, could reduce the Group's future sales, and may permit competitors to offer products at lower prices than the Group.

The occurrence of these events could negatively impact the competitive position of the Issuer.

Global economic conditions and an unfavorable financial environment could have negative consequences for Roquette's business

A substantial and lasting slowdown of the global economy, major national economies or emerging markets could negatively affect growth in the global pharmaceutical market and/or food and nutrition markets and, as a result, adversely affect Roquette's business. For instance, unpredictable political conditions that currently exist in various parts of the world could have a material negative impact on its business. In particular, the war in Ukraine, the conflict in the Middle East and the reaction of the international community have been, and may continue to be, a source of instability in global markets, impacting stock market indices, increasing the price of raw materials (such as electricity, oil, gas etc.) or causing fears of shortages, thereby aggravating inflation. The consequences of those events are difficult to predict and will depend on developments outside Roquette's control, including, but not limited to the duration and severity of the conflicts, and the consequences of the ongoing and additional financial and economic sanctions imposed by governments in response. For instance, as a result of the war in Ukraine, the Group has reduced its supply of corn in Ukraine in favor of other Black Sea countries.

In addition, the protectionist tariff measures implemented by the Trump administration, including increases of customs duties on certain goods imported into the United States, have created pressure on international trade flows in several sectors, including agri-food, chemical and pharmaceutical. Further intensification of such tariff policies, or the adoption of similar measures by other major economies, could result in increased export costs, logistical frictions, or more limited access to certain strategic markets for the Group. These developments could therefore have an impact on Roquette's operational and financial environment.

The Group is also closely monitoring the evolution of the geopolitical situation in the Middle East, and in particular the conflict involving Iran. At this stage, the analysis conducted in conjunction with the Health & Pharma Solutions and Nutrition & Bioindustry teams indicates that the Group's logistics flows are already transiting via the Cape of Good Hope, which would not require major route adjustments in the event of a deterioration of the situation in the Gulf of Oman. Nevertheless, the Group remains vigilant regarding several key concerns: potential disruption to maritime logistics arising from ripple effects across the global supply chain and a general rise in transportation costs; a potential adverse impact on energy costs should the conflict persist or escalate; as well as increased exchange rate volatility. In addition, business impacts may arise both from a possible decline in demand in certain directly affected regions and from potential opportunities for pricing adjustments in those areas. These developments could therefore have an impact on the Group's business, financial condition and results of operations.

Other related issues have arisen or are arising such as regional instability, geopolitical uncertainties, adverse effects on raw materials prices and energy costs, supply chains, macroeconomic conditions, inflation, and currency exchange rates in various regions of the world. Collectively, such unstable conditions could, among other things, disturb the international flow of goods and increase the costs and difficulties associated with international transactions. These events could, in particular, result in delays or losses in the Group's product deliveries to its customers or in the supply of raw materials and could therefore have an adverse effect on its sales and earnings.

Such events could also result in the implementation of other protectionist trade measures and import and export licensing requirements, in particular on the pharmaceutical market, which could also adversely affect the Group's results of operations.

Changes in consumer practices, preferences and perceptions may lessen the demand for the Group's products, which could reduce the Group's sales and profitability and harm its business.

The Group delivers ingredients and solutions to several segments of the food and nutrition market (in particular bakery, confectionary, specialized nutrition, savoury, beverages, savoury and dairy) which represents almost 25% of the Group's sales.

Food products are often affected by changes in consumer practices and tastes, national, regional and local economic conditions and demographic trends. Increasing concern among consumers, public health professionals and government agencies about the potential health concerns associated with obesity and inactive lifestyles may have some impact on the composition of the products of some of the Group's customers or represent significant costs or capex for them, and could therefore affect demand for the Group's products.

1.2 Operational risks

Roquette is dependent on the availability of raw materials and energy, including natural gas, as well as various other products

Roquette manufactures its products based upon raw materials – such as corn, wheat, potato, pea and cellulose, and is largely energy-intensive. In addition, many other products are required throughout its facilities, such as chemicals, packaging and spare parts.

The availability of all those products is dependent upon multiple factors. In particular, agricultural raw materials supply can be affected by meteorological events and climate change and energy supply can be impacted by geopolitical events with partial or complete curtailment of supply. Various other type of events could also impact Roquette's suppliers' ability to deliver on time, in full, from their own production capacities to the complex global supply chains involved in their products' deliveries.

Though Roquette produces in different geographies (experiencing different conditions) and has mitigation plans in place (including in-house or external storages, supplier derisking practices), unexpected changes in regulations, business conditions, labor issues, natural disasters, outages, transportation costs or other factors behind its or its suppliers' control can affect these suppliers' ability to deliver materials to Roquette on a timely basis, which would render Roquette unable to manufacture sufficient quantities of its products in a timely manner. These events could have a material adverse effect on Roquette's business, financial condition and results of operations.

Increases in the price of raw materials and energy products and other inputs could harm Roquette's business

At the date of this Prospectus, the Group operates directly via more than 40 industrial sites throughout the world, processing around six million tonnes of agricultural raw materials per year in particular in relation to its Nutrition, Bioindustries & Industries Business Unit (NBI BU). As a result, Roquette purchases significant amounts of raw materials, such as corn, wheat and pea, and energy, such as natural gas and electricity, for the manufacture of its products in its NBI BU.

The price of corn, wheat and other raw materials and energies are subject to significant price volatility as a result of economic and industry conditions, including supply and demand factors such as supply chain disruptions, crop disease and severe weather conditions. The future profitability and growth of the Group depend on its ability to contain operating costs and per unit product costs and to maintain and implement effective cost control programmes, while also maintaining competitive pricing and superior quality products, customer service and support. The ability to maintain a competitive cost structure depends on continued containment of manufacturing, delivery and administrative costs, as well as the implementation of cost-effective purchasing programmes for raw materials, energy and related manufacturing requirements.

Those commodities are generally traded on exchange with significant price volatility. The prices may increase again or remain at high levels for a significant period of time. In addition, prices of other materials used for production have risen more generally as a result of inflationary measures.

Roquette manages these costs with a global margin management approach, in relation to its sales practices, with the use of hedging tools. If Roquette is not able to manage its margin and to pass on increases in its prices to customers, nor to effectively hedge its exposures, then its margins and profitability may be negatively impacted.

Disruption of operations at the Group's industrial sites could harm Roquette's business

The Group operates more than 40 industrial sites worldwide at the date of this Prospectus. The Group's revenues are, and will continue to be, derived primarily from the sale of products manufactured at these industrial sites.

The Group's activities may be subject to disruption if any of its industrial sites experiences a major accident or is damaged by severe weather or other natural disasters. Please also refer to the risk factor entitled "*Roquette's operations may be adversely affected by climate change, natural disasters, severe weather patterns and water scarcity*" below.

In addition, the Group's activities may be subject to unscheduled downtime, or to other operational hazards inherent to the industry, such as equipment failures, fires, explosions, short circuits, pipeline ruptures or transportation accidents. For

instance, in 2022, an electrical fire from a high voltage transformer occurred in the industrial site in Lestrem, France, which led to a production interruption of 4 days. Some of these operational hazards may cause personal injury or loss of life, severe damage to or destruction of property and equipment, or even environmental damage, and may result in the suspension of operations or in modification of the license to operate and the imposition of civil or criminal penalties. The Group's casualty and third-party insurance policies may not adequately cover the operational hazards described above, and the Group may not be able to renew this insurance or renew it on commercially acceptable terms.

The occurrence of these events could negatively impact the business of the Issuer.

Furthermore, the Group's activities may be subject to disruption if it fails to maintain satisfactory labor relations given that the Group has employees domiciled in France, as well as worldwide, who belong to labor unions. In the past, the Group has been affected by national strikes in its industrial sites located in France, in particular in 2023 during the discussions on the pension reform in front of the French Parliament, which led to 11 disruption days from January to April on French sites. Strikes, lockouts or other work stoppages or slowdowns, especially in its industrial sites in France, could have an adverse effect on its business.

Roquette may be subject to risks related to carbon pricing

Many Roquette's manufacturing facilities are located in jurisdictions that use carbon cap and trade systems to regulate emissions of CO₂, including the European Union, Canada and China.

In the European Union, the Group's total Scope 1 GHG emissions in 2025 represented 827 kt of CO₂ for activities subject to the European Carbon scheme, all of which were compensated by the 2025 and previous year free allocation of CO₂ emission allowances to the Group. The free allocation of CO₂ emission allowances by the Group has decreased in the recent years, with a decrease of one third between 2020 and 2025. Based on current assumptions, the free allocation of CO₂ emission allowances should allow the Group to fulfill its obligations until most of the remaining period of the phase IV of the European Union Emissions Trading Scheme (EU ETS) (2021-2030) from a cash perspective. Changes in the production volumes, product portfolio, energy mix, as well as potential evolution in the European carbon emissions regulations beyond 2030 may impact the requirement for carbon allowances. If the free allocation of CO₂ emission allowances is not sufficient to cover the Group's needs, the Group may be required to purchase carbon allowances. The price of carbon allowances can fluctuate significantly. Changes in the price of carbon allowances might negatively impact the results of the Group.

In other relevant jurisdictions, depending on the level of its emissions, the Group may be required to purchase carbon allowances in order to comply with the emissions limitations imposed by such local systems. The price of carbon allowances can fluctuate significantly and have a significant impact on its results.

Roquette's success depends in part on its senior management team and other key employees and its ability to attract, integrate and retain key personnel and qualified individuals in the face of intense competition

The Group has over 11,000 employees around the world whose expertise, know-how, and commitment form an essential asset. The health, safety, and wellbeing of its employees are among its top priorities. In an international landscape marked by a "war for talent" on key skills, the Group may face difficulties in attracting, hiring, and retaining talent in specific geographic regions or in specialized fields in particular the ingredient solutions industry. The Group relies on recruiting and retaining talented people to help it meet its strategic objectives.

The Group's vision is to create a positive, attractive environment that everyone wants to join, where everyone can learn, grow, contribute to the Group's overall performance and be properly recognised for it. Since 2020, the Group has adapted its working methods to meet employee expectations through a "Smart Working" programme enabling employees to carry out their duties more independently with greater flexibility, both on site and remotely.

Several initiatives have been deployed over the years such as a "People Care" programme that is consistent with the Group's core values, a "Talent Review" process that was expanded to include regions to assess and identify employees' skills, potential, and performance to support succession planning, professional development, and talent management within the organization.

The inability to attract, integrate, retain and/or maintain good relationships with highly skilled personnel, in particular those in leadership positions, may weaken the Group's succession plans, may materially adversely affect the

implementation of its strategy and its ability to meet its strategic objectives and could ultimately adversely impact its business or results of operations.

Roquette may fail to obtain and maintain adequate insurance coverage or may choose to self-insure

Roquette has set up an international insurance programmes covering the main risks relating to the Group's activities such as civil and professional liability, operating damages and losses, cyber risks or transport insurance, when such insurance is required, as well as damage to the environment. The Group also has insurance that covers the risks of liability of its directors and corporate officers. Nonetheless, these policies contain exclusions and conditions that could limit Roquette's ability to receive indemnification thereunder, as well as customary sub-limits for particular types of losses.

Furthermore, there may be instances in which Roquette chooses to self-insure, deciding to retain risks that are insurable and face a loss in the event that such risks materialise. For example, Roquette currently maintains a substantial degree of self-insurance for any property loss claim through a captive reinsurance company, as a result of which any claims are first absorbed up to a certain amount by Roquette itself (through the captive) and only amounts in excess thereof are eligible for outside coverage. Roquette has put in place a self-insurance structure adapted to its risks and scale.

Roquette's insurance coverage may not be adequate to cover future claims that may arise, or that it will be able to maintain such insurance coverage. Recent or future acquisitions of Roquette (such as Qualicaps and IFF Pharma Solutions) may also render inadequate its current insurance coverage. The claims for which Roquette is not fully insured, or is not insured at all, may cause significant increases in expenses, and adversely affect Roquette's business, financial condition and results of operations. In addition, changes in the insurance industry have generally led to higher insurance costs and decreased the availability of coverage. The availability of insurance that covers the risks that Roquette typically insures against may decrease, or cease altogether, and the insurance that it is able to obtain may have higher deductibles, higher premiums and more restrictive policy terms.

1.3 Environmental and safety risks

Roquette's activities involve product safety risks

Product safety is a crucial issue for the markets and consumers served by the Group. As a major player in manufacturing and distributing plant-based ingredients in the pharmaceutical and nutraceutical and the food and nutrition markets, the Group may be exposed to the risk of releasing products that are non-compliant for the end customer, which could lead to withdrawal, recall, or public health procedures in the worst-case scenario.

The risk of product safety can occur when there is a proven presence or strong suspicion of contamination of the finished products by contaminants (chemical, microbiological, physical, or allergens). Such an event may have multiple causes:

- during the manufacture of a product at a Group industrial site or at one of the Group's service providers;
- upstream of the factories during the supply of raw materials; or
- downstream during the delivery of products to the end customer.

Direct financial consequences could occur with one or more customers as a result of a quality defect (production stoppage and operating losses, destruction of Roquette product, destruction of customer finished product). There may also be administrative and legal proceedings against Roquette that does not lead to significant provisions.

In addition, the Group's continued success depends on its ability to maintain its reputation as a serious, trustworthy, and responsible company. Although the Group pays close attention to product safety, the Group may not be able to protect itself from the harmful consequences of a potential accident in relation to product safety.

The occurrence of such events, which are likely to seriously damage the Group's reputation and its ability to retain its customers' trust and to attract new customers, could have a material adverse effect on the Group's business, financial position, results of operations or prospects.

Roquette's manufacturing activities involve high-risk processes and substances

Many of Roquette's industrial operations involve high pressure and high temperature processes, which imply risks relating to operational safety, process safety and transport.

These operations also involve substances with risks associated with their chemical composition which can present risks to the health and safety of workers, neighboring populations and the environment if mishandled. At the date of this Prospectus, Roquette has two facilities which are classified as "lower-tier" establishments and one facility which is classified as "upper-tier" establishment under Directive 2012/18/EU of the European Parliament and of the Council of 4 July 2012 on the control of major-accident hazards involving dangerous substances (the "**Seveso Regulation**"). Due to the evolution of the Seveso Regulation, the classification of the Group's facilities may change under the Seveso Regulation. An incident such as an explosion, fire, mechanical failure, pipeline leak or rupture, storage tank leak, chemical spill or transport accident could result in the release of toxic or hazardous substances or gasses. Such events could also occur as a result of improper handling of such substances by Roquette's business partners (such as transporters or operators of storage facilities) or customers, which may seek to shift responsibility to Roquette by alleging a failure to provide appropriate handling and use instructions. Any such event could cause injuries or fatalities, damage to neighboring industrial sites, or harm to the neighboring communities and to the public, and could lead to interruptions or suspensions of activities, liabilities or damage to Roquette's reputation, and could have a material adverse impact on Roquette's results of operations and financial condition.

In addition, Roquette's employees and contractors face risks of workplace injury. Such injuries (including diseases) may result from any number of circumstances, including working with dangerous heavy equipment, chemical, toxic or hazardous substance contact, ignitable liquids and explosive gasses, accidents caused by leaking vessels, pumps or pipes, explosions, fires, exposure to boilers, high voltage transformers and energy sources including electrical shocks, dust and atex environments, powered equipment including cars, forklifts, railcars, falling objects or falls from scaffolding or silos or work at heights, confined space work, lifting weights or heavy parts, driving vehicles. Further, the health effects of any disease may emerge after a long period of latency, which may make it difficult to accurately measure the human and financial impacts of such exposure.

While Roquette has procedures in place to promote the safety of employees and contractors in line with what it believes are best industry practices, which have significantly reduced the number of incidents in recent years, one fatality has occurred early 2026 in India with a contractor.

Other incidents may occur in the future, some of which may be severe including fatality and give rise to liability or impair Roquette's reputation and may have a material adverse effect on its business and results of operations.

Roquette uses some hazardous materials, chemicals and biological and toxic, organic and inorganic compounds, and produces industrial emissions and discharges

Roquette's operations involve the use of hazardous and potentially hazardous substances. These include several substances identified as a substance of very high concern (SVHC) listed in the EU REACH Candidate list and EU REACH Authorization list. As a result, Roquette is subject to a broad range of constantly evolving laws, regulations and standards in each of the jurisdictions where it operates, including those relating to pollution, limitations on emissions of CO₂ and other greenhouse gasses ("GHGs") and industrial emissions, discharges, carbon taxes, protection of human health, protection of the environment, and the generation, storage handling, transportation, treatment, disposal and remediation of hazardous substances and emissions. Under these laws, Roquette could be held liable for any contamination, injury or other damages resulting from these hazardous substances and emissions. Furthermore, if such laws, regulations and standards and their interpretation and application by relevant jurisdictions or administrations evolve, the liabilities faced by Roquette could increase.

In addition, Roquette operations produce waste products (some of which are hazardous) and Roquette's operations emit gasses that can negatively impact air quality, including nitrogen oxide, sulfure oxide and ozone depleting substances, and discharge oxygen-reducing substances (mainly dissolved organic matter) into aqueous receivers, which contribute to industrial waste, including hazardous industrial waste. While Roquette ensures such emissions and discharges are in line and comply with allowable environmental permit limits, if for any reasons Roquette does not comply with the allowable environmental permit limits, it could be subject to penalties or could need to limit or reduce temporarily or permanently its sites production outputs. Roquette could be liable under environmental laws for any required cleanup of sites at which its waste is disposed. Any such liability could have a material adverse impact on Roquette's results of operations or financial condition, and any action against Roquette for its emissions or discharges could negatively affect its reputation.

Roquette's operations may be adversely affected by climate change, natural disasters, severe weather patterns and water scarcity

Increasing concentrations of carbon dioxide and other GHGs in the atmosphere will continue to have an adverse effect on global temperatures, weather patterns, and the frequency and severity of extreme weather events and natural disasters.

Extreme weather and natural disasters that occur around the globe, such as drought, wildfires, storms, changes in ocean currents and flooding, could make it more difficult and costly for the Issuer to manufacture and deliver its products to its customers, obtain raw materials from its suppliers, or perform other critical corporate functions. In particular, if such climate change impacts negatively affect agricultural productivity, the Issuer may be subject to decreased availability or less favorable pricing from certain commodities that are necessary for its products, such as corn, wheat, potato or pea. Adverse weather conditions and natural disasters could reduce crop size and crop quality, which could reduce the Group's supplies of raw materials, lower recoveries of usable raw materials, increase the prices of its raw materials, increase its costs of storing and transporting raw materials, or disrupt production schedules.

If major disasters such as earthquakes, floods, fires, heat waves, high winds, water shortages or other such events occur, Roquette's sites—depending on their location—may be seriously damaged, or it may have to stop or delay development, production and shipment of its products. In 2019, Roquette experienced a production stoppage (i) due to flooding and due to drought in its Gokak plant in Karnataka State in India and (ii) due to flooding in its Keokuk plant in Iowa, USA. In 2023, a storm also resulted in serious damages and activity stoppage at Roquette's grain elevators in La Harpe, Iowa, in the USA which disrupted the supply chain and generated operational and investment costs. Besides, some of Roquette's facilities are located in certain areas where specific administrative orders have been issued by local authorities to regulate the water consumption during drought or normal times, particularly in Lestrem, France, where since 2023 reduction in water consumption has been requested. These administrative orders could result in the temporary or permanent reduction of the production output of its sites.

Roquette may incur expenses or delays relating to the impact of such climate changes, severe weather or water scarcity events, and such events could adversely impact the price and availability of insurance, which could have a material adverse impact on its business, results of operations and financial condition.

Roquette may not be able to meet its sustainability and environmental targets and may be subject to increased scrutiny and changing expectations from stakeholders

To fight climate change, answer its stakeholders' expectations and comply with current and upcoming regulations, Roquette has announced that it plans to reduce its direct CO₂ emissions (Scope 1 and 2) and indirect emissions (Scope 3) by 25% by 2030 compared to 2021. Roquette also announced its target to reduce its water usage by 20% in absolute terms by 2030 compared to 2021. Roquette may announce additional objectives relating to climate change and environmental sustainability in the future.

To achieve its targets, Roquette has invested, and will continue to invest, in transforming its energy mix and investing in cleaner processes and technologies such as renewable energy, water saving processes and technologies. In addition to the capital investments involved, such transformation may have a substantial impact on operations or require Roquette to re-qualify its products with certain suppliers. If Roquette is unable to recover these costs plus a reasonable return, its results of operations, profitability and financial condition may be adversely impacted.

Further, companies across many industries are facing increasing scrutiny related to their climate and environmental practices from investor advocacy groups, investment funds and other influential investors who are placing growing importance on the non-financial impacts of their investments. If Roquette's climate and environmental practices do not meet investor or other industry stakeholder expectations, which continue to evolve, it may incur additional costs, face shareholder actions, and its brand, ability to attract and retain qualified employees and business may be harmed.

The Group relies on information technology systems and networks, which are exposed to cyber-attacks and security breaches

The Group relies on information technology networks and systems, some of which are managed by or are accessible to third parties, to manage crucial parts of its operations, including production, logistics, supply chain management, customer relationship management and other aspects of its business. For example, the Group mainly relies on an ERP system to prepare, plan, transport and deliver the Group's products to customers by ensuring compliance with local regulations in the markets where the Group's products are sold.

Any breaches of security in the Group's information technology systems, such as, for example, attacks by hackers, viruses, breaches due to employee error or sabotage, malfeasance or other actions or disruptions could have an adverse impact on the Group's operations as well as the operations of the Group's customers and suppliers. In particular, this could impact the Group's ability to deliver products to customers and ensure their quality.

The Group and/or its suppliers may fail to effectively prevent, detect, and recover from these or other security breaches and, therefore, such breaches could result in misuse of the Group's assets or loss of property including trade secrets and confidential or personal information, some of which is subject to privacy and security laws, corruption of data and other business disruptions. As a result, the Group may be subject to legal claims, or proceedings, liabilities under privacy laws, reporting errors, processing inefficiencies, negative media attention, loss of sales, interference with regulatory compliance (resulting in sanctions or penalties, including under privacy laws), disruption to its operations, and damage to its reputation. While the Group maintains some insurance coverage against the potential financial impact of a cyberattack, such coverage may not be adequate. If the Group is the subject of a cyberattack that is not adequately covered by insurance, there could be a material adverse effect on the Group's business, result of operations and financial condition, as well as its image with customers.

1.4 Compliance, legal and regulatory risks

Product liability claims could adversely affect Roquette's business, results of operations and financial condition

The Group operates in the pharmaceutical and nutraceutical and the food and nutrition markets which are subject to a constantly changing regulatory environment with increasingly stringent standards. There are numerous regulations which the Group is subject to in particular those related to the manufacture and sale of food and pharmaceutical ingredients. Given the evolving regulatory environment worldwide, the ever-more stringent regulatory requirements applicable to the pharmaceutical and food industry and the more stringent data, quality and supply obligations, the Group may incur liability claims which could adversely affect its business should the Group not be successful in defending these claims. To date, it has not led to significant provision nor significant claims.

To mitigate the risks of product liability claims, Roquette has a global organization in place for ensuring compliance with and changes in laws and regulations applicable to the Group through its Legal, Compliance, Quality, and Regulatory Affairs Department with the support of the Group Executive Committee and the Audit Committee.

Despite these efforts, product liability claims, regardless of their merits or the ultimate success of the Group's defense, are costly, divert management's attention, may harm the Group's reputation and can impact the demand for its products and generate speculative news flows and/or rumors relating to such claims. Substantial product liability claims could materially adversely affect its business, results of operations and financial condition and/or may have an impact on market perception of the Group.

The Group's activities (including its products and manufacturing activities) are subject to significant governmental regulations and regulatory approvals, which are often costly and could result in adverse consequences to its business if the Group fails to anticipate the regulations, comply with them, maintain the required approvals, and/or adapt to changes in applicable regulations

The Group makes plant-based ingredients from raw materials for more than 700 products. The Group operates in the pharmaceutical and nutraceutical and the food and nutrition markets and its activities (including its products and manufacturing activities) are subject to significant government regulations and regulatory approvals.

Some of the Group's business activities, including the operation of industrial facilities, require, among other conditions, to obtain authorizations and licenses. These formalities, which vary from one country to another, must be performed with various national and local authorities; the wide range of competent authorities can make obtaining the authorizations and corresponding permits a long and complex process. The authorizations and licenses may not be obtained for production facilities or units that are currently at the development stage. Furthermore, in connection with existing production facilities, although the Group pays very close attention to their operating conditions, the renewal or retention of the relating operating authorizations could be questioned, in particular if the Group cannot comply with the provisions of such authorizations or if there are any changes on existing laws and regulations. Failure to obtain construction permits or operating authorizations for facilities under development or failure to renew or retain such permits and authorizations obtained by the Group for its existing facilities could have a material adverse effect on the Group's business, financial condition or results of operations, or on its ability to achieve its targets.

Obtaining a regulatory authorization for a food or pharmaceutical product is a long and highly regulated process requiring the Group to present extensive documentation and data to the relevant regulatory authorities either at the time of the filing of the application for a marketing authorization or later during its review. Each regulatory authority may (i) impose its own requirements which can evolve over time or (ii) delay or refuse to grant approval even though a product has already been approved in another country. Regulatory authorities are increasingly strengthening their requirements on product safety and risk/benefit profiles. All these requirements, including post-marketing requirements, have increased the costs associated with maintaining marketing authorizations.

Moreover, to monitor the Group's compliance with applicable regulations, national agencies (which include notably the U.S. Food and Drug Administration (FDA) and the French *Agence nationale de sécurité du médicament et des produits de santé* (ANSM)) routinely conduct inspections of the Group facilities and may identify potential deficiencies which the Group must adequately address. If the Group fails to adequately respond to inspection observations identified during an inspection or fails to comply with applicable regulatory requirements at all or within the targeted timeline, it could be subject to enforcement, remedial and/or punitive actions by the applicable regulatory agency (such as a Warning Letter, injunction, seizure or cease and desist order).

Violation of laws could lead to liabilities and harm to reputation

Roquette is subject to the laws and regulations in the countries and regions in which it does business, in particular France, the European Union, the United States of America and the United Kingdom. Governments and regulatory authorities around the world are strengthening implementation and enforcement activities in recent years, including in relation to anti-bribery, anti-corruption, international sanctions and trade controls, as well as antitrust and human rights.

Roquette has adopted a code of conduct, policies and procedures, risk mapping and analysis, internal controls, and training all of which are designed to help ensure that Roquette, its directors, officers, employees, agents, intermediaries and other third parties comply with applicable laws and regulations (including but not limited to the French anti-corruption law known as Sapin II, the French *Code de commerce*, including the French law for the modernisation of the economy (known as "loi LME") regarding payment terms the US Foreign Corrupt Practices Act, and the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, and other applicable anti-bribery laws and regulations). Likewise Roquette has policies and procedures designed to help ensure Roquette does not violate international sanctions and trade controls, antitrust laws, and principles of human rights. Roquette has also implemented a global alert management system, or hotline, called "SpeakUp" to enable Group employees, partners, customers,

suppliers, and the public to report suspicions or practices that are unethical, fraudulent, against the Code of Conduct and/or current regulations.

Notwithstanding these efforts, failure to comply with laws and regulations may occur and Roquette and certain of its subsidiaries could face audits or become the subject of investigations or proceedings by various government agencies. In such case, an unfavorable outcome could result in liabilities for Roquette and/or its management including harm to its reputation and materially adversely impact Roquette's business activities, financial condition or earnings.

The Group relies on its patents, trademarks and other proprietary rights to provide exclusive rights to market certain of its products. If such patents, trademarks, and other rights were limited, invalidated or circumvented, the Group's financial results could be adversely affected

At the date of this Prospectus, the Group has a global patent portfolio of over 4,000 granted patents or pending applications to protect its innovations across its product portfolio. Through patent and other proprietary rights, the Group holds exclusivity rights for a number of its research-based products. The protection that the Group is able to obtain, however, may vary in its scope due at least to differences in country patent law and patents and other proprietary rights may be challenged and might not provide effective protection. The Group cannot be certain that it will obtain adequate patent or other intellectual property protection for new products and technologies in important markets or that such protections, once granted, will last as long as originally anticipated.

The Group actively protects its intellectual property rights and continuously assesses third party intellectual property rights (otherwise known as freedom to operate (FTO) issues). In the event of an infringement suit against a third-party, the Group may not prevail and the decision rendered may not conclude that its patent or other proprietary rights are valid, enforceable or infringed. Even in cases where the Group ultimately prevails in an infringement claim, legal remedies available for harm caused to the Group by infringing products may be inadequate to cover its losses. Moreover, a successful result against a competing product for a given patent or in a specific country is not necessarily predictive of its future success against another competing product or in another country because of local variations in the patents and patent laws. In addition, if the Group loses patent protection as a result of an adverse court decision or a settlement, it faces the risk of increased competition in the market that may impact financial results. A third party may also bring a patent infringement action against the Group with respect to one of its marketed products and an ultimate determination of infringement could lead to monetary damage claims being assessed against the Group as well as potential injunctive relief prohibiting the continued marketing of any offending product(s).

Claims of intellectual property infringement can be costly and time-consuming to resolve, may delay or prevent product launches, and may result in significant financial liabilities. Furthermore, some countries may consider granting a compulsory license to a third-party to use patents protecting an innovator's product, which limits the value of the patent protection granted to such products.

The Group currently holds more than 1,900 trademark registrations or pending trademark applications, any of which may be the subject of a governmental or third-party objection, which could prevent the maintenance or issuance of the trademark. The Group relies on its brand and its trademarks to differentiate its products from its competitors and, as a result, its business could be adversely affected if it is unable to prevent third parties from adopting, registering or using trademarks that infringe, dilute or otherwise violate its rights.

The Group also relies on unpatented proprietary technology, know-how, trade secrets and other confidential information, which it seeks to protect through various measures, including confidentiality agreements with licensees, employees, third-party collaborators, and consultants who may have access to such information. If these agreements are breached or the Group's other protective measures should fail, then its contractual or other remedies may not be adequate to cover its losses.

If the Group's patents and/or proprietary rights to its products were limited or circumvented, its financial results could be adversely affected.

The Group must comply with complex international tax regimes that are subject to change

The Group determines the amount of taxes it is required to pay in jurisdictions where it operates in Europe, the Asia-Pacific area (including China and India), North America and Latin America based on its interpretation of applicable treaties, laws and regulations. Given the complexity and international nature of its supply chains, the Group may be at

risk for tax claims relating to issues inherent in international operations, such as transfer pricing, VAT and customs duties. The Group relies on the advice of tax advisors in the jurisdictions where it operates and, where appropriate, on interpretative positions taken by competent tax authorities with which the Group or its advisors interact.

However, given its international activity and geographical footprint, the Group is subject to complex and evolving tax legislations that may be subject to different interpretations in the various countries in which it operates. The relevant tax authorities may not agree with its interpretation of the applicable legislation in their jurisdictions. Furthermore, if the tax laws and regulations and their interpretation and application by the jurisdictions or administrations evolve, the tax burden on the Group could increase. This could impact the Group's business, financial conditions and results of operations.

1.5 Financial risks

Foreign exchange risk

The Group is exposed to foreign exchange risks as a result of its international activities, including its geographically diverse production and sales activities, as well as its purchases of raw materials on international markets.

Roquette is subject to the risk of variation in Roquette's euro-denominated consolidated financial statements resulting from subsidiaries operating in currencies other than the euro or from incurring debt in currencies other than the euro (without effective hedging arrangements). In addition, exchange rate fluctuations, particularly of the U.S. dollar, the Great Britain pound and the Japanese yen, can affect Roquette's reported revenues and results of operations.

As of 31 December 2025, a 10% depreciation in currencies compared to the euro would have a negative impact of €200 million on the net turnover forecast.

Roquette's exposure to foreign exchange risk is, to a large extent, covered by hedging agreements. While Roquette seeks to hedge its foreign exchange exposure, its hedging strategy may not be fully effective to address this risk.

Interest rate risk

The Group funding includes fixed and floating rates instruments. The Group is hedging a portion of floating rates instruments through swaps, cross currency swaps or other instruments. As of 31 December 2025, 13% of the gross debt is issued with floating rate instruments. Consequently, this portion is exposed to market interest fluctuation, down from 19% at the end of 2024. This reduction is due to proactive hedging strategies implemented in January 2024, which shifted a significant portion of the debt to fixed rates, thereby reducing exposure to market interest rate fluctuations.

The total interest rates are dependent both on interest rates market and general market conditions as well as on investors' and lenders' perception of the Group's liquidity and growth profile. Any additions to floating rate debt could increase its exposure to movements in both underlying interest rates and the risk premium the Group pays. Any increase in the interest rates the Group pays could have an adverse effect on its business, financial condition and results of operations.

Counterparty risk

The Group has contractual relations with multiple parties and is therefore exposed to the credit standing of its customers, suppliers and financial institutions. While the Group monitors the credit risk of its main customers, suppliers and financial institutions, collaborates with financial institutions having a good credit rating and to the extent possible outsource the credit risk to an investment grade credit insurance company or by using alternative means of security, it cannot be excluded that any of its counterparties would default on their obligations, which could in turn have a material adverse effect on the Group's financial condition and operations.

Liquidity risk

Availability and cost of funding from credit and debt capital markets depend on the Group's creditworthiness. The Group uses bonds, credit facilities from banks and commercial papers to finance its operations. The level and quality of the Group's earnings, operations, business profile and management, among other things, will impact their determination. The management of liquidity within the Group is based on centralising the access to the financing market and the allocation of long-term resource to long-term needs while short term resources are dedicated to short-term needs and secure a minimum liquidity level.

While S&P has assigned Roquette an investment grade rating of BBB with a negative outlook, it may not be able to maintain such rating. A decrease in the ratings assigned to Roquette may negatively impact Roquette's access to debt financing and/or increase its cost of borrowing. In addition, a decrease in ratings may require Roquette to include restrictive covenants in its financing arrangements.

Any actual or anticipated changes or downgrades in any credit rating assigned to Roquette or a decline of its creditworthiness more generally may have a negative impact on its liquidity and capital position.

In addition, adverse market conditions could reduce Roquette's flexibility to finance or refinance existing indebtedness or the ability of Roquette to fulfil its financial obligations or fund its working capital needs. If the Group is unable to obtain financing on sufficiently flexible and cost-efficient terms, this could in turn impact its ability to operate its business or deploy its strategy.

The existing financing arrangements of the Group also contain various undertakings and events of default. An event of default or acceleration under one financing arrangement may trigger an event of default under other financing agreements. In such a case, the Group may be required to repay a number of borrowings before their due date, which could have an adverse impact on the liquidity of the Group.

A substantial increase in new asset charges or a shortfall in the level of previously recorded asset impairment charges in respect of Roquette's assets could have an adverse effect on its results of operations and financial condition

In connection with its investment and acquisitions, Roquette needs to maintain proper outcome and return on its existing assets base, including past acquisitions and fixed assets (factories) investments. Although the Group as a whole is well diversified which allows it to absorb some headwinds in certain businesses, some geographical sectors may experience difficulties which could ultimately lead to impairment of some fixed assets. While it remains unusual and infrequent, most recent impairment on assets includes on annual financial year mainly the Portage asset in Canada for which an impairment of EUR287 million (CAD393 million) was booked for the financial year ended 31 December 2022. This impairment was partly explained by the macroeconomic environment (high generalized inflation and increase in risk-free rates) which leads the Group to revise its assumptions. In 2025, the Group had to take into account the complexity of the Indian market, for which the ethanol manufacturing is putting pressure on the first product selling price while the corn cost is increasing, leading to a structural decrease of profitability and a delay in the rebound in operations of Roquette India, which amounts to an impairment of EUR55 million. In addition, the historical activities in the USA are affected by some headwinds on the commodities market, especially at its Keokuk manufacturing site. The Group has taken an impairment of EUR176 million in the 2025 financial statements.

The assumptions and estimates are made for determining the recoverable value of goodwill, of intangible and tangible fixed assets in particular on the market perspectives required for assessing the cash flow and the discount rates retained. Any modification made to these assumptions can significantly affect the amount of the recoverable value, either at the Cash Generating Unit (CGU) level or at the operating segment level for the acquired intangible assets and the goodwills, especially since the IFF Pharma Acquisition led to a very significant amount of intangible asset and goodwill. The sensitivity to these assumptions and estimates is high given the economic volatility the Group faced in 2025 and the macroeconomic forecasts for the rest of 2026.

Roquette's overall level of such asset impairment charges is based upon Roquette's assessment of prior loss experience, the type of assets, economic conditions and other factors. The Group's management uses its best efforts to establish realistic and appropriate assumptions. Nonetheless, unfavourable changes in market trends in relation to the assumptions used by the Group's management could have a significant adverse impact on impairment tests during the next financial years especially, but not limited to, regarding the assets in Brazil, Canada, India and in the USA.

Any significant increase in charges for losses or a significant change in the estimate of the risk of loss inherent in Roquette's portfolio of non-impaired assets, as well as the occurrence of losses in excess of the charges recorded with respect thereto, could have an adverse effect on Roquette's results of operations and financial condition.

2. RISK FACTORS RELATING TO THE NOTES

The following paragraphs describe the main risk factors that are considered material for prospective investors in order to assess the market risk associated with the Notes. They do not describe all the risks of an investment in the Notes.

2.1 Risks for the Noteholders as creditors of the Issuer

Credit Risk

As contemplated in Condition 2.1 of the Terms and Conditions, the obligations of the Issuer under the Notes in respect of principal and interest (including for the avoidance of doubt, any Arrears of Interest and Additional Interest Amount (as defined below)) constitute direct, unconditional, unsecured and deeply subordinated obligations (*titres subordonnés de dernier rang*) of the Issuer and rank and will rank at all times *pari passu* without any preference among themselves and (i) *pari passu* with all other present and future Parity Securities (as defined below) of the Issuer, (ii) junior to present and future *prêts participatifs* granted to the Issuer and *titres participatifs* issued by the Issuer and to Ordinary Subordinated Obligations and Unsubordinated Obligations of the Issuer and (iii) in priority to any Junior Securities. Credit risk refers to the risk that the Issuer may be unable to meet its financial obligations under the Notes. The value of the Notes will also depend on the creditworthiness and liquidity position of the Issuer which may be impacted by the "*Risk Factors relating to the Issuer*" as described above. If the creditworthiness of the Issuer deteriorates, such deterioration could materially and negatively impact the Noteholders as (i) the Issuer may not be able to fulfil all or part of its payment obligations under the Notes, (ii) the value of the Notes may decrease and (iii) Noteholders may lose all or part of their investment.

French insolvency law

The Issuer is a *société anonyme* incorporated in France. In the event that the Issuer becomes insolvent, insolvency proceedings will be generally governed by the insolvency laws of France to the extent that, where applicable, the "centre of main interests" (as construed under Regulation (EU) 2015/848, as amended) of the Issuer is located in France.

The Directive (EU) 2019/1023 on preventive restructuring frameworks, on discharge of debt and disqualifications, and on measures to increase the efficiency of procedures concerning restructuring, insolvency and discharge of debt, and amending Directive (EU) 2017/1132 has been transposed into French law by the Ordonnance 2021-1193 dated 15 September 2021 (the "**Ordonnance**"). Such Ordonnance amends French insolvency laws notably with regard to the process of adoption of restructuring plans under safeguard (*sauvegarde*), accelerated safeguard (*sauvegarde accélérée*) and reorganisation (*redressement judiciaire*) proceedings. According to this Ordonnance, "affected parties" (including notably creditors, and therefore the Noteholders) shall be treated in separate classes for the purpose of adopting a restructuring plan. Classes shall be formed in such a way that each class comprises claims or interests with rights that reflect a sufficient community of economic interest based on objective and ascertainable criteria. Noteholders will no longer deliberate on the proposed restructuring plan in a separate assembly, meaning that they will no longer benefit from a specific veto power on this plan. Instead, as any other affected parties, the Noteholders will be grouped into one or several classes (with potentially other types of creditors) and their dissenting vote may possibly be overridden by a cross-class cram down.

The decision of each class is taken by a two-third (2/3rd) majority of the voting rights of the participating members, no quorum being required.

If the restructuring plan is not approved by all classes of affected parties, it can still be ratified by the court at the request of the Issuer or the receiver with the Issuer's consent and be imposed on dissenting classes through a cross-class cram down, under certain conditions.

For the avoidance of doubt, the provisions relating to the representation of Noteholders described in Condition 9 "Representation of the Noteholders" of the Terms and Conditions will not be applicable to the extent they are not in compliance with compulsory insolvency law provisions that apply in these circumstances.

The commencement of insolvency proceedings against the Issuer would have a material adverse effect on the market value of Notes. As a consequence, any decision taken by a class of affected parties, could negatively and significantly impact the Noteholders and cause them to lose all or part of their investment, should they not be able to recover all or part of the amounts due to them from the Issuer.

Any decline in the credit rating of the Issuer may affect the market value of the Notes

The Issuer is assigned a rating of BBB with a negative outlook by S&P and the Notes have been rated BB+ by S&P. The credit rating of the Issuer is an assessment of its ability to pay its obligations, including those arising from the Notes. Any such ratings may not continue for any period of time or may not be reviewed, revised, suspended or withdrawn entirely by the relevant rating agency as a result of changes in or unavailability of information or if, in the rating agency's

judgment, circumstances so warrant. Consequently, actual or anticipated declines in the credit rating of the Issuer may affect the market value of the Notes.

S&P may change its methodologies for rating securities with features similar to the Notes in the future. This may include the relationship between ratings assigned to an issuer's senior securities and/or ratings assigned to an issuer on a standalone basis and ratings assigned to securities with features similar to the Notes, sometimes called "notching". If the rating agency were to change its practices for rating such securities in the future and the rating of the Notes were to be subsequently lowered, this may have a negative impact on the trading price of the Notes.

In addition, one or more independent credit rating agencies other than S&P could seek to rate the Notes and if such unsolicited ratings are lower than the comparable rating assigned to the Notes by S&P, as the case may be, such unsolicited ratings could have an adverse effect on the value of the Notes.

2.2 Risks relating to the trading markets of the Notes

Market value of the Notes

Application has been made to admit the Notes to trading on Euronext Paris. Therefore, the market value of the Notes may be affected by the creditworthiness of the Issuer, and/or that of the Group and a number of additional factors, including, but not limited to, the value of the Reference Rate, its volatility, market interest and yield rates or the time remaining to the First Reset Date or subsequent call dates.

The value of the Notes and of the Reference Rate depend on a number of interrelated factors, including economic, financial and political events in France or elsewhere, including factors affecting capital markets generally and Euronext Paris or other stock exchanges on which the Notes or the Reference Rate are traded. The price at which a Noteholder will be able to sell the Notes prior to redemption by the Issuer may be at a discount, which could be substantial, from the issue price or the purchase price paid by such purchaser.

Liquidity Risks/Trading Market for the Notes

Application has been made to Euronext Paris for the Notes to be admitted to trading on Euronext Paris as from the Issue Date. An established trading market in the Notes may never develop or if a secondary market does develop, it may be illiquid. Although the Notes are expected to be admitted to trading on Euronext Paris as from the Issue Date, the Notes may be not so admitted or that an active market will develop. The absence of liquidity may have a significant material adverse effect on the value of the Notes.

The development or continued liquidity of any secondary market for the Notes will be affected by a number of factors such as general economic conditions, the financial condition, the creditworthiness of the Issuer and/or the Group, the value of the Reference Rate, as well as other factors such as the complexity and volatility of the Reference Rate, the interest deferral provisions relating to the Notes (as provided in Condition 4.6(a) "Optional Interest Deferral" of the Terms and Conditions), the method of calculating the return to be paid in respect of such Notes, the outstanding amount of the Notes, any redemption features of the Notes as specified in Condition 5 "Redemption and Purchase" of the Terms and Conditions, the performance of other instruments linked to the Reference Rate and the level, direction and volatility of interest rates generally. Such factors also will affect the market value of the Notes. The price at which a Noteholder will be able to sell the Notes may be at a discount, which could be substantial, from the issue price or the purchase price paid by such Noteholder and accordingly such Noteholder may suffer a significant financial loss.

Noteholders may not be able to sell Notes readily or at prices that will enable Noteholders to realise their anticipated yield. This could have a material adverse impact on the Noteholders and, as a result, Noteholders could lose all or part of their investment in the Notes.

2.3 Risks relating to the structure of the Notes

The Notes are the lowest ranking subordinated obligations of the Issuer

In accordance with Condition 2 "Status of the Notes", the obligations of the Issuer under the Notes in respect of principal and interest (including for the avoidance of doubt, any Arrears of Interest and Additional Interest Amount) constitute direct, unconditional, unsecured and deeply subordinated obligations (*titres subordonnés de dernier rang*) of the Issuer

and rank and will rank at all times *pari passu* without any preference among themselves and (i) *pari passu* with all other present and future Parity Securities (as defined below) of the Issuer, (ii) junior to present and future *prêts participatifs* granted to the Issuer and *titres participatifs* issued by the Issuer and to Ordinary Subordinated Obligations and Unsubordinated Obligations of the Issuer and (iii) in priority to any Junior Securities. In accordance with Condition 2.2 "Payment on the Notes in the event of liquidation of the Issuer", in the event of any judgment is rendered by any competent court declaring the judicial liquidation (*liquidation judiciaire*) of the Issuer, or in the event of a transfer of the whole of the business of the Issuer (*cession totale de l'entreprise*) subsequent to the opening of a judicial recovery procedure (*redressement judiciaire*), or in the event of the voluntary dissolution of the Issuer or if the Issuer is liquidated for any other reason (and in all cases listed above, other than pursuant to a consolidation, amalgamation or merger or other reorganisation outside the context of an insolvency whereby the surviving entity assumes all obligations of the Issuer under the Notes), the rights of Noteholders to payment under the Notes will be subordinated to the full payment of the unsubordinated creditors of the Issuer (including creditors in respect of Unsubordinated Obligations), of the subordinated creditors of the Issuer (including creditors in respect of Ordinary Subordinated Obligations and of subordinated obligations ranking senior to Ordinary Subordinated Obligations) and of lenders in relation to *prêts participatifs* granted to, or *titres participatifs* issued by, the Issuer, if and to the extent that there is still cash available for those payments. The rights of the Noteholders will be calculated on the basis of the principal amount of the Notes together with any accrued interest on such principal amount and any Arrears of Interest (including any Additional Interest Amount thereon). Thus, the Noteholders face a higher recovery risk than holders of unsubordinated and ordinary subordinated obligations of the Issuer. In the event of incomplete payment of unsubordinated creditors and subordinated creditors ranking ahead of the claims of the Noteholders, the obligations of the Issuer in connection with the Notes shall terminate. The claims of the Noteholders under the Notes are intended to be senior only to claims of shareholders. There are, at the Issue Date, no instruments of the Issuer that rank junior to the Notes other than the Junior Securities. Thus, the Noteholders face a significantly higher performance risk than holders of unsubordinated and ordinary subordinated obligations of the Issuer which could result in (i) a loss of all or a part of a Noteholder's investment in the event of a bankruptcy and (ii) more volatility in the market price of the Notes as compared to senior obligations of the Issuer. Please also see "Credit Risk" above.

The Notes are undated securities

In accordance with Condition 5.1 "Final Redemption", the Notes are undated securities, with no specified maturity date. The Issuer is under no obligation to redeem or repurchase the Notes at any time, and the Noteholders have no right to require redemption of the Notes except, in accordance with Condition 8 "Enforcement Events, no Events of Default and no Cross Default", in the event that a judgement is rendered by any competent court declaring the judicial liquidation (*liquidation judiciaire*) of the Issuer, or in the event of a transfer of the whole of the business of the Issuer (*cession totale de l'entreprise*) subsequent to the opening of a judicial recovery procedure (*redressement judiciaire*) or in the event of a voluntary dissolution of the Issuer or if the Issuer is liquidated for any other reason (and in all cases listed above, other than pursuant to a consolidation, amalgamation or merger or other reorganisation outside the context of an insolvency whereby the surviving entity assumes all obligations of the Issuer under the Notes).

As the Notes do not have a fixed maturity, the Noteholders must bear the financial risks of an investment in the Notes for an indefinite period of time and may not recover their investment in a foreseeable future. The Noteholders would only be able to realise value from the Notes prior to an early redemption by selling their Notes at their then market value in an available secondary market. In the absence of a secondary market for the Notes, Noteholders may therefore not recover all or part of their investment in the foreseeable future. Therefore, the principal amount of the Notes may not be repaid and Noteholders may lose the value of their capital investment in the Notes.

Optional deferral of interest payment

In accordance with Condition 4.6 "Interest Deferral", on any applicable Interest Payment Date, the Issuer may elect to defer payment in whole or in part of the interest accrued to that date, and any such failure to pay shall not constitute a default by the Issuer under the Notes or for any other purpose. Any interest in respect of the Notes not paid on an applicable Interest Payment Date will, so long as the same remains outstanding, be deferred and shall constitute Arrears of Interest and, if due for at least a year, bear interest, and may at the option of the Issuer be paid in whole or in part at any time as outlined in Condition 4.6 "Interest Deferral" of the Terms and Conditions.

Arrears of Interest (together with the corresponding Additional Interest Amount) in respect of all Notes for the time being outstanding shall become due and payable in whole, but not in part, on whichever is the earliest of:

- (1) the tenth (10th) Business Day following the date on which a Mandatory Payment Event occurs;

- (2) the next scheduled Interest Payment Date in respect of which the Issuer does not elect to defer all of the interest accrued in respect of the relevant Interest Period;
- (3) the date on which the Notes are redeemed; or
- (4) the date upon which a judgment is made for the judicial liquidation (*liquidation judiciaire*) of the Issuer, or in the event of a transfer of the whole of the business of the Issuer (*cession totale de l'entreprise*) subsequent to the opening of a judicial recovery procedure (*redressement judiciaire*) or in the event of the voluntary dissolution of the Issuer, or in the event the Issuer is liquidated for any other reason (and in all cases listed above, other than pursuant to a consolidation, amalgamation or merger or other reorganisation outside the context of an insolvency whereby the remaining entity assumes all obligations of the Issuer under the Notes).

Any deferral of interest payments or the perception that the Issuer will need to exercise its optional deferral right would have a significant adverse effect on the market price of the Notes. In addition, as a result of the interest deferral provisions of the Notes, the market value of the Notes may be more volatile than the market prices of other debt securities on which interest accrues that are not subject to the above provisions and may be more sensitive generally to adverse changes in the Issuer's financial condition, therefore, investors may lose all or part of their investment. As a result, the value of the Notes or liquidity on the secondary market may be materially and negatively affected.

The Notes may trade, and/or the prices for the Notes may appear, in trading systems with accrued interest. Purchasers of Notes in the secondary market may pay a price which reflects such accrued interest on purchase of the Notes. If one or several interest payments are deferred, a purchaser of Notes in the secondary market may not be entitled to the accrued interest (or part thereof) reflected in the purchase price of the Notes, which would cause the Noteholders to lose all or part of the value of their investment in the Notes.

Early Redemption Risk

In accordance with the provisions of the Condition 5 "Redemption and Purchase", the Issuer may redeem all, but not some only, of the Notes (i) on any day in the period commencing on (and including) the First Call Date and ending on (and including) the First Reset Date, or on any Interest Payment Date thereafter (see Condition 5.2 "Optional Redemption"), (ii) at any time (other than (x) during the period from and including the First Call Date to and including the First Reset Date or (y) on any subsequent Interest Payment Date thereafter) at its option (see Condition 5.3 "Make-whole Redemption by the Issuer") and (iii) at any time, following the occurrence of a Gross-Up Event (see Condition 5.4(i)), a Withholding Tax Event (see Condition 5.4(ii)), a Tax Deduction Event (see Condition 5.4(iii)), an Accounting Event (see Condition 5.5 "Redemption following an Accounting Event"), an Equity Credit Rating Event (see Condition 5.6 "Redemption following an Equity Credit Rating Event") or a Change of Control Event (see Condition 5.8 "Redemption following a Change of Control Event"). The Issuer may also, at its option, redeem all but not some only of the outstanding Notes in the event that at least seventy-five (75) per cent. of the initial aggregate principal amount of the Notes has been purchased or redeemed by the Issuer, in accordance with the provisions set out in Condition 5.7 "Redemption following Substantial Repurchase Event" in the Terms and Conditions.

In the event of an early redemption of the Notes following the occurrence of a Gross-Up Event, a Withholding Tax Event, a Change of Control Event or a Substantial Repurchase Event, such early redemption of the Notes will be made at the principal amount of the Notes together with any accrued interest and Arrears of Interest (including any Additional Interest Amounts thereon), as outlined and defined in Conditions 5.4 "Redemption for Taxation Reason", 5.8 "Redemption following a Change of Control Event" and 5.7 "Redemption following a Substantial Repurchase Event", respectively, of the Terms and Conditions. In the event of an early redemption at the option of the Issuer by exercise of the Make-whole Redemption Option, such early redemption of the Notes will be made at the Make-whole Redemption Amount, as outlined and defined in Condition 5.3 of the Terms and Conditions.

In the event of an early redemption at the option of the Issuer following the occurrence of a Tax Deduction Event, an Accounting Event or an Equity Credit Rating Event, such early redemption of the Notes will be made at (i) 101 per cent. of their principal amount, where such redemption occurs before the First Call Date, or (ii) their principal amount, in each case together with any accrued interest and any Arrears of Interest (including any Additional Interest Amounts thereon) where such redemption occurs on or after the First Call Date, as outlined and defined in Conditions 5.4(iii), 5.5 and 5.6, respectively, of the Terms and Conditions.

Furthermore, the exercise of the Make-whole Redemption by the Issuer, pursuant to Condition 5.3 "Make-whole Redemption by the Issuer" of the Terms and Conditions, may be subject to certain refinancing conditions referred to in

the notice published by the Issuer in connection thereto. Should the refinancing condition, if applicable, not be satisfied, the notice of exercise of the make-whole option by the Issuer will be revoked and the Notes will not be redeemed, which may have a negative impact on the Noteholders as the market price of the Notes is likely to fall below the expected Make-whole Redemption Amount.

The redemption at the option of the Issuer or the perception that the Issuer will exercise its optional redemption right might negatively affect the market value of the Notes. During any period when the Issuer may, or may be perceived to be able to, elect to redeem the Notes, the market value of the Notes generally will not rise substantially above the price at which they can be redeemed. Should the Notes at such time be trading above or well above the price set for redemption, the negative impact on the Noteholders' anticipated returns would be significant. This also may be true prior to the First Reset Date. Since the Issuer may also be expected to redeem the Notes when its cost of borrowing is lower than the interest rate on the Notes, Noteholders might not be able to reinvest the redemption proceeds at an effective interest rate as high as the return that would have been received on such Notes had they not been redeemed.

An exercise of any of the foregoing early redemption options by the Issuer may also result in the materialisation of the risk factor entitled "*Liquidity Risks/Trading Market for the Notes*" for the period starting as of the announcement date to and including the optional redemption date.

There are no events of default or cross default under the Notes

Condition 8 "Enforcement Events, no Events of Default and no Cross Default" provides that there are no events of default or cross default allowing acceleration of the Notes if certain events occur. As a result, if the Issuer fails to meet any obligations under the Notes, including the payment of any interest, or defaults on any of its other outstanding indebtedness, Noteholders will not have the right of acceleration of principal. Upon a payment default, the sole remedy available to Noteholders for recovery of amounts owing in respect of any payment of principal or interest on the Notes will be the institution of proceedings to enforce such payment. Notwithstanding the foregoing, the Issuer will not, by virtue of the institution of any such proceedings, be obliged to pay any sum or sums sooner than the same would otherwise have been payable by it, therefore, investors may lose all or part of their investment. As a result, the value of the Notes or liquidity on the secondary market may be negatively affected.

No limitation on issuing or guaranteeing debt ranking senior to, or pari passu with, the Notes

There is no restriction under the Terms and Conditions on the amount of debt which the Issuer may issue or guarantee, as there is no clause of limitation of indebtedness nor, as per Condition 3 "Negative Pledge", a negative pledge. The Issuer and its subsidiaries and affiliates may incur additional indebtedness or grant guarantees in respect of indebtedness of third parties, including indebtedness or guarantees that rank *pari passu* with, or senior to, the obligations under and in connection with the Notes. An increase of the outstanding amount of such securities or other liabilities may if such outstanding amount were to exceed the assets of the Issuer materially reduce the amount (if any) recoverable by Noteholders on a winding-up of the Issuer and Noteholders could suffer loss of their entire investment if the Issuer were liquidated (whether voluntarily or not). If the amount of interest due under such securities or other liabilities increases, it significantly increases the likelihood of a deferral of interest payments under the Notes and as a result Noteholders could suffer a significant reduction in the return of the Notes.

If the Issuer's financial condition were to deteriorate, the Noteholders could suffer direct and materially adverse consequences, including loss of interest and, if the Issuer were liquidated (whether voluntarily or not), the Noteholders could suffer loss of their entire investment.

The current IFRS accounting classification of financial instruments such as the Notes as equity instruments may change, which may result in the occurrence of an Accounting Event

The current IFRS accounting classification of financial instruments such as the Notes may change, which may result in the occurrence of an Accounting Event in accordance with Condition 5.5 "Redemption following an Accounting Event" of the Terms and Conditions. The classification of the Notes initially as equity may be changed to liability.

In June 2018, the IASB (International Accounting Standards Board) published the discussion paper DP/2018/1 on "Financial Instruments with Characteristics of Equity" (the "**DP/2018/1 Paper**") proposing a new classification approach to articulate more clearly the principles for classifying financial instruments as financial liabilities or equity instruments, and to improve the consistency, completeness and clarity of the classification requirements in IAS 32. In November 2023,

the IASB published a paper titled "Exposure Draft Financial Instruments with Characteristics of Equity" where the IASB has decided not to pursue the proposed classification approach set out in DP/2018/1 Paper and instead aim at, inter alia, clarifying the requirements, including the underlying principles, for classifying a financial instrument as a financial liability or an equity instrument (the "**2023 Exposure Draft**").

The implementation of any of the clarifications regarding the requirements, including the underlying principles, for classifying a financial instrument as a financial liability or an equity instrument set out in the 2023 Exposure Draft or any other proposals that may be made in the future, including the extent and timing of any such implementation, if at all, is uncertain. Accordingly, no assurance can be given as to the future classification of the Notes from an accounting perspective or whether any such change may result in the occurrence of an Accounting Event, thereby providing the Issuer with the option to redeem the Notes (pursuant to Condition 5.5 "Redemption following an Accounting Event").

The redemption of the Notes by the Issuer or the perception that the Issuer will exercise its optional redemption right might negatively affect the market value of the Notes. During any period when the Issuer may elect to redeem the Notes, the market value of the Notes generally will not rise substantially above the price at which they can be redeemed. Should the Notes at such time be trading above or well above the price set for redemption, the negative impact on the Noteholders' anticipated returns would be significant.

For a description of the risks related to the early redemption of the Notes, see the Risk Factor entitled "*Early Redemption Risk*".

The Terms and Conditions contain a prohibition of set-off

In accordance with Condition 2.3 "Prohibition of set-off", no Noteholder may exercise, claim or plead any right of set-off, compensation or retention in respect of any amount owed to it by the Issuer in respect of, or arising under or in connection with the Notes and each Noteholder shall, by virtue of its holding of any Note, be deemed to have waived all such rights of set-off, compensation or retention, subject to applicable law. As a result, a Noteholder which is also a debtor of the Issuer cannot set-off its payment obligation against any sum due to it by the Issuer under the Notes. This prohibition of set-off could therefore have an adverse impact on the counterparty risk for a Noteholder in the event that the Issuer were to become insolvent.

Fixed Interest Rate Notes

Pursuant to Condition 4.1 "General", the Notes bear interest at a rate of 6.000 per cent. *per annum* from, and including, the Issue Date to but excluding the First Reset Date.

A holder of a fixed interest rate note is exposed to the risk that the price of such note may fall because of changes in the market interest rate. While the nominal interest rate of a fixed interest rate note is fixed during the life of such note or during a certain period of time, the current interest rate on the capital market ("**Market Interest Rate**") typically changes on a daily basis. If the Market Interest Rate increases, the price of such note typically falls, until the yield of such note is approximately equal to the Market Interest Rate. If the Market Interest Rate falls, the price of a fixed interest rate note typically increases, until the yield of such note is approximately equal to the Market Interest Rate. Holders of Notes should be aware that movements of the Market Interest Rate are uncertain and can adversely affect the market price of the Notes and can lead to losses for the holders if they sell their Notes.

Reset of Interest Rate linked to the Euro 5-Year Swap Rate

From and including the First Reset Date to, but excluding, the final redemption of the Notes, the Notes bear interest at a resettable rate which shall be equal to the relevant Reference Rate plus the Relevant Margin for each Interest Period subject to any applicable margin pursuant to Condition 4.2 and provided that each of the First Reset Rate, the First Step-up Interest Rate and the Second Step-up Interest Rate shall never be less than zero (notwithstanding the use of any Alternative Rate or Successor Rate and the application of any Adjustment Spread).

The performance of the Euro 5-Year Swap Rate and the interest income on the Notes cannot be anticipated and neither the current nor the historical level of the Euro 5-Year Swap Rate is an indication of the future development of the Euro 5-Year Swap Rate. Due to varying interest income, Noteholders are not able to determine a definite yield of the Notes at the time they purchase them, so that their return on investment cannot be compared with that of investments having longer fixed interest periods. In addition, after interest payment dates, Noteholders are exposed to the reinvestment risk if market

interest rates decline. That is, Noteholders may reinvest the interest income paid to them only at the relevant lower interest rates then prevailing.

Furthermore, it cannot be ruled out that the price of the Notes may fall as a result of changes in the Market Interest Rate, as the Market Interest Rate fluctuates. The Noteholder is exposed to the risk "*Fixed Interest Rate Notes*" described above.

Reform and regulation of "benchmarks"

From and including the First Reset Date to but excluding the date on which the Issuer redeems the Notes, the Notes bear interest at a rate *per annum* which shall be subject to a reset every five years and shall be equal to the sum of the relevant Euro 5-Year Swap Rate for the relevant Interest Period plus the Relevant Margin for each Interest Period, subject to any applicable margin pursuant to Condition 4.2 and provided that each of the First Reset Rate, the First Step-up Interest Rate and the Second Step-up Interest Rate shall never be less than zero (notwithstanding the use of any Alternative Rate or Successor Rate and the application of any Adjustment Spread). The Euro 5-Year Swap Rate and the 6-month EURIBOR rate (on which the floating leg of the Euro 5-Year Swap Rate is based) constitute benchmarks for the purposes of Regulation (EU) 2016/2011 of 8 June 2016 on indices used as benchmarks in financial instruments and financial contracts or to measure the performance of investment funds (as amended, the "**Benchmarks Regulation**").

The Benchmarks Regulation applies to "contributors", "administrators" and "users" of "benchmarks" in the EU, and, among other things, (i) requires benchmark administrators to be authorised or registered (or, if non-EU-based, to be subject to an equivalent regime or otherwise recognised or endorsed) and to comply with extensive requirements in relation to the administration of "benchmarks" (or, if non-EU based, to be subject to equivalent requirements) and (ii) prevents certain uses by EU supervised entities of "benchmarks" of administrators that are not authorised/registered (or, if non EU based, deemed equivalent or recognised or endorsed).

Notwithstanding the provisions of Condition 4.7 "Benchmark Event" which seek to offset any adverse effects for the Noteholders, the Benchmarks Regulation could have an adverse effect on their market value and return if the methodology or other terms of the Euro 5-Year Swap Rate or the EURIBOR as "benchmarks" are changed in order to comply with the requirements of the Benchmarks Regulation. Such changes could, among other things, have the effect of reducing, increasing or otherwise affecting the volatility of the published rate or level of such "benchmarks".

In the event of the occurrence of a Benchmark Event, the rate of interest on Notes will be determined for the relevant period by the fallback provisions applicable to the Notes - please refer to the risk factor entitled "*Risks Relating to Benchmark Event*" below. This may in certain circumstances result (i) in the modifications of the Terms and Conditions to implement the changes required by determining a Successor Rate or Alternative Rate and, if applicable, Adjustment Spread, without the consent of the Noteholders or (ii) where no Independent Adviser has been appointed or no Successor Rate or Alternative Rate (as applicable) is determined, in the effective application of a fixed rate based on the rate which applied in the previous period when the benchmark was available. Accordingly, the application of such fallbacks may result in the Notes performing differently (which may include payment of a lower interest rate) than they would do if the Euro 5-Year Swap Rate were to continue to apply in its current form.

More broadly, any of the international, national or other proposals for reform or the general increased regulatory scrutiny of "benchmarks" could increase the costs and risks of administering or otherwise participating in the setting of a "benchmark" and complying with any such regulations or requirements.

Such factors may have the effect of discouraging market participants from continuing to administer or contribute to certain "benchmarks", trigger changes in the rules or methodologies used in certain "benchmarks" or lead to the disappearance of certain "benchmarks".

Any of the foregoing changes and their potential consequences, as a result of international, national or other reforms, or investigations, could have a material adverse effect on the market value of, and return on, the Notes.

The Benchmarks Regulation was (i) amended by Regulation (EU) 2019/2089 of the European Parliament and of the Council of 27 November 2019 and (ii) further amended by Regulation (EU) 2021/168 of the European Parliament and of the Council of 10 February 2021 which introduces a harmonised approach to deal with the cessation or wind-down of certain benchmarks (such as EURIBOR) by conferring the power to designate a statutory replacement for certain benchmarks on the European Commission or the relevant national authority, such replacement being limited to contracts and financial instruments which contain no fallback provision or no suitable fallback provisions before the date of

cessation of the benchmark concerned. This replacement could have a negative impact on the value or liquidity of, and return on, the Notes. However, there are still some uncertainties as to the application of these regulatory provisions as implementing acts must still be adopted. In addition, the transitional provisions applicable to third-country benchmarks are extended until the end of 2025.

The Benchmarks Regulation has been further amended. The final text was published in the Official Journal of the European Union on 19 May 2025 and is applicable since 1 January 2026. One of the key changes to the regime is that only benchmarks defined as critical or significant (determined based on quantitative or qualitative criteria), EU Paris-aligned benchmarks, EU Climate Transition benchmarks, and certain commodity benchmarks remain in scope of the mandatory application of the Benchmarks Regulation. An exemption applies for certain foreign exchange benchmarks. Other benchmarks have fallen out of mandatory Benchmarks Regulation scope (other than certain limited provisions in relation to statutory replacement of a benchmark, connected with cessation and/or non-representativeness).

Risks Relating to Benchmark Event

Pursuant to Condition 4.7 "Benchmark Event", in the event of a Benchmark Event, the Issuer shall use its reasonable endeavours to appoint an Independent Adviser. The Independent Adviser shall, acting in good faith and in a commercially reasonable manner as an independent expert in the performance of its duties, advise the Issuer as to whether a Successor Rate or Alternative Rate to be used in place of the Original Reference Rate and determine the Benchmark Amendments (including, without limitation, to the business day convention, the definition of business day, the determination date, the day count fraction and any method for obtaining the Successor Rate or Alternative Rate, including any adjustment factor needed to make such Successor Rate or Alternative Rate comparable to the Euro 5-Year Swap Rate (including any Adjustment Spread)).

Such Successor Rate or Alternative Rate will (in the absence of manifest error) be binding, and no consent of the Noteholders shall be required in connection with effecting the Successor Rate or Alternative Rate or any other changes pursuant to Condition 4.7.

In addition, if a Benchmark Event occurs pursuant to Condition 4.7 "Benchmark Event", no Successor Rate or Alternative Rate will be adopted and no Adjustment Spread shall apply, nor will any other related adjustments and/or amendments to the Terms and Conditions be made, if and to the extent that, in the determination of the Issuer, the same could reasonably be expected to (i) result in a reduction of the amount of "equity credit" (or such other nomenclature that the relevant Rating Agency may then use to describe the degree to which an instrument exhibits the characteristics of an ordinary share) assigned to the Notes by any Rating Agency when compared to the "equity credit" assigned to the Notes immediately prior to the occurrence of the relevant Benchmark Event from such Rating Agency or (ii) otherwise prejudice the eligibility of the Notes for "equity credit" from any Rating Agency.

The Successor Rate or Alternative Rate may have no or very limited trading history and accordingly its general evolution and/or interaction with other relevant market forces or elements may be difficult to determine or measure. In addition, the Successor Rate or Alternative Rate may perform differently from the discontinued benchmark. This could affect the performance of an alternative rate compared to the historical and expected performance of the relevant benchmark, although the adjustment factor applied to the Notes is supposed to adequately compensate for this impact. This could in turn impact the rate of interest on, and market value of, the Notes and Noteholders may receive lower return on the Notes than anticipated at the time of the issue.

In certain circumstances, including where no Independent Adviser has been appointed or no Successor Rate or Alternative Rate (as applicable) is determined or applied or due to the uncertainty concerning the availability of Successor Rates and Alternative Rates and the involvement of an Independent Adviser, the relevant fallback provisions may not operate as intended at the relevant time. In all these circumstances, other fallback rules might apply if the Original Reference Rate is discontinued or otherwise unavailable, which consist in the last 5-year Swap Rate available on the Screen Page, as determined by the Calculation Agent, to be used for the next succeeding Interest Period. This may result in the effective application of a fixed rate. In a rising interest rate environment, Noteholders will not benefit from any increase in rates. Any such consequences could have a material adverse effect on the value of and return on any Notes and as a consequence, Noteholders may lose part of their investment.

Modification of the Terms and Conditions

Condition 9 "Representation of the Noteholders" of the Terms and Conditions contains provisions for calling meetings of Noteholders or taking written decisions to consider matters affecting the Noteholders' interests generally. These

provisions permit defined majorities to bind all Noteholders including Noteholders who did not attend and vote at the relevant meeting, and Noteholders who voted in a manner contrary to the majority, Noteholders may through Collective Decisions (as such term is defined in Condition 9 "Representation of the Noteholders" of the Terms and Conditions) adopt any proposal relating to the modification of the Terms and Conditions including any proposal, whether for arbitration or settlement, relating to rights in controversy or which were the subject of judicial decisions, as more fully described in Condition 9 "Representation of the Noteholders" of the Terms and Conditions. This may have a negative impact on the market value of the Notes and hence investors may lose part of their investment.

By exception to the above provisions, Condition 9 "Representation of the Noteholders" of the Terms and Conditions provides that (i) the provisions of Article L.228-65 I. 1° and 4° of the French *Code de commerce* respectively providing for a prior approval by the General Meeting of the Noteholders of any change in corporate purpose or form of the Issuer or of an issue of Notes benefiting from a security (*sûreté réelle*) (without prejudice to Condition 3) and the related provisions of the French *Code de commerce* shall not apply to the Notes and (ii) the provisions of Article L.228-65 I. 3° of the French *Code de commerce* providing for a prior approval of the Noteholders in relation to any proposal to merge or demerge the Issuer in the cases referred to in Articles L.236-14 and L.236-23 of the French *Code de commerce* shall not apply to the Notes to the extent that such proposal relates to a merger or demerger within the Group.

As a result of these exclusions, the prior approval of the Noteholders will not have to be obtained on any such matter which may affect their interests generally.

GENERAL DESCRIPTION OF THE NOTES

This overview is a general description of the Notes and is qualified in its entirety by the remainder of this Prospectus. For a more complete description of the Notes, including definitions of capitalised terms used but not defined in this section, please see "Terms and Conditions of the Notes".

This General Description of the Notes constitutes a general description of the Notes and it does not, and is not intended to, constitute a summary of this Prospectus within the meaning of Article 7 of the Prospectus Regulation or any implementing regulation thereof.

"Issuer"	Roquette Frères S.A.
"Legal Entity Identifier (LEI)"	969500FO141C5967KC72
"Securities"	€600,000,000 Undated Deeply Subordinated Fixed to Reset Rate Non-Call 6 Notes (the "Notes").
"Maturity"	Undated.
"Joint Global Coordinators and Joint Bookrunners"	Crédit Agricole Corporate and Investment Bank, Goldman Sachs Bank Europe SE, Natixis and Société Générale
"Joint Bookrunners"	BNP PARIBAS, Crédit Industriel et Commercial S.A. and J.P. Morgan SE
"Form and Denomination"	The Notes will be issued in dematerialised bearer form (<i>au porteur</i>) in the denomination of €100,000 each.
"Issue Date"	21 April 2026
"Status" / "Ranking"	The Notes (which constitute <i>obligations</i>) are deeply subordinated notes. The subordination provisions of the Notes are governed by the provisions of Article L. 228-97 of the French <i>Code de commerce</i> . The obligations of the Issuer under the Notes in respect of principal and interest (including for the avoidance of doubt, any Arrears of Interest and Additional Interest Amount (as defined below)) constitute direct, unconditional, unsecured and deeply subordinated obligations (<i>titres subordonnés de dernier rang</i>) of the Issuer and rank and will rank at all times <i>pari passu</i> without any preference among themselves and (i) <i>pari passu</i> with all other present and future Parity Securities (as defined below) of the Issuer, (ii) junior to present and future <i>prêts participatifs</i> granted to the Issuer and <i>titres participatifs</i> issued by the Issuer and to Ordinary Subordinated Obligations (as defined below) and Unsubordinated Obligations (as defined below) of the Issuer and (iii) in priority to any Junior Securities (as defined below).

"Existing Notes" means the €600,000,000 Undated Deeply Subordinated Fixed to Reset Rate Non-Call 5.25 Notes issued on 25 November 2024 (FR001400U3Q9).

"Junior Securities" means (a) the ordinary shares (*actions ordinaires*) of the Issuer and (b) any other class of the Issuer's share capital (including preference shares (*actions de préférence*)).

"obligations" means, in respect of any person, any financial obligation expressed to be assumed by or imposed on such person under or arising as a result of any contract, agreement, guarantee, document, instrument, conduct or relationship or directly by law.

"Ordinary Subordinated Obligations" means obligations, whether in the form of notes or otherwise, the principal and interest of which constitute direct, unconditional, unsecured and subordinated obligations of the Issuer and rank and will rank or are expressed to rank *pari passu* among themselves and (i) *pari passu* with all other present or future Ordinary Subordinated Obligations, (ii) junior to any subordinated obligations of the Issuer ranking or expressed to rank senior to Ordinary Subordinated Obligations and Unsubordinated Obligations and (iii) in priority to *prêts participatifs* and *titres*

participatifs, if any, deeply subordinated obligations of the Issuer, including the Notes and Junior Securities.

"Parity Securities" means (a) any securities or other similar instruments issued by the Issuer which rank, or are expressed to rank, *pari passu* with (i) the Issuer's obligations under the Notes and (ii) any deeply subordinated securities or other similar instruments or deeply subordinated obligations of the Issuer, (b) any securities or other similar instruments issued by a Subsidiary of the Issuer which have the benefit of a guarantee (or similar instrument) from the Issuer, which rank or are expressed to rank *pari passu* with the Issuer's obligations under the Notes and (c) the Existing Notes.

"Subsidiary" means any entity controlled by the Issuer within the meaning of Article L.233-3 of the French *Code de commerce*.

"Unsubordinated Obligations" means obligations, whether in the form of notes or otherwise, the principal and interest of which constitute direct, unconditional, unsecured and unsubordinated obligations of the Issuer and rank and will rank *pari passu* without preference or priority among themselves and (save for certain obligations required to be preferred by French law) (i) *pari passu* with all other present or future unsecured and unsubordinated obligations of the Issuer and (ii) in priority to Ordinary Subordinated Obligations, subordinated obligations expressed to rank senior to Ordinary Subordinated Obligations, *prêts participatifs* and *titres participatifs*, if any, and deeply subordinated obligations of the Issuer, including the Notes and Junior Securities.

"Interest"

The Notes shall bear interest on their principal amount:

- (i) from (and including) the Issue Date to (but excluding) 21 April 2032 (the "**First Reset Date**"), at an interest rate per annum of 6.000 per cent. (the "**Fixed Interest Rate**"), payable annually in arrear on each Interest Payment Date, commencing on 21 April 2027 (the "**First Interest Payment Date**") and ending on the Interest Payment Date falling on the First Reset Date;
- (ii) from (and including) the First Reset Date to (but excluding) 21 April 2037 (the "**First Step-up Date**"), at an interest rate per annum which shall be equal to the sum of the Reference Rate in respect of the relevant Reset Period and the Relevant Margin (the "**First Reset Rate**"), payable annually in arrear on each Interest Payment Date, commencing on the Interest Payment Date immediately following the First Reset Date and ending on the Interest Payment Date falling on the First Step-up Date;
- (iii) from (and including) the First Step-up Date to (but excluding) 21 April 2052 (the "**Second Step-up Date**"), at an interest rate per annum which will be subject to a reset every five years and shall be equal to the sum of the Reference Rate in respect of the relevant Reset Period and the Relevant Margin (the "**First Step-up Interest Rate**"), payable annually in arrear on each Interest Payment Date, commencing on the Interest Payment Date immediately following the First Step-up Date and ending on the Interest Payment Date falling on the Second Step-up Date; and
- (iv) from (and including) the Second Step-up Date, at an interest rate per annum which will be subject to a reset every five years and shall be equal to the sum of the Reference Rate in respect of the relevant Reset Period and the Relevant Margin (the "**Second Step-up Interest Rate**"), payable annually in arrear on each Interest Payment Date, commencing on the Interest Payment Date immediately following the Second Step-up Date;

where the "**Relevant Margin**" means, (i) from (and including) the First Reset Date to (but excluding) the First Step-up Date, 3.098 per cent. per annum, (ii) from (and including) the First Step-up Date to (but excluding) the Second Step-up Date, 3.348 per cent. per annum and (iii) from (and including) the Second Step-up Date, 4.098 per cent. per annum and provided that each of the First Reset Rate, the First Step-up Interest Rate and the Second Step-up Interest Rate shall never be less than zero (notwithstanding the

use of any Alternative Rate or Successor Rate and the application of any Adjustment Spread pursuant to Condition 4.7).

For the purpose hereof:

"Business Day" means any calendar day (other than a Saturday or a Sunday) which is (i) a T2 Business Day and (ii) a day on which commercial banks and foreign exchange markets settle payments and are open for general business (including dealing in foreign exchange and foreign currency deposits) in Paris and (solely for purposes of determining the Calculation Date as provided in Condition 5.3) Frankfurt.

"Euro 5-Year Swap Rate" means, on any Reset Interest Determination Date, the mid swap rate in euros for a term of five (5) years as displayed on Reuters screen ICESWAP2/EURSFIXA (or such other page or service as may replace it for the purposes of displaying European swap rates of leading reference banks for swaps in euro) (the **"Screen Page"**) as at 11:00 a.m. (Central European time) on such Reset Interest Determination Date. In the event that the Euro 5-Year Swap Rate does not appear on the Screen Page on such Reset Interest Determination Date, the Euro 5-Year Swap Rate on such Reset Interest Determination Date will be the Reference Bank Rate on the Business Day immediately following such Reset Interest Determination Date.

"Euro 5-Year Swap Rate Quotation" means the arithmetic mean of the bid and offered rates for the annual fixed leg (calculated on a 30/360 day count basis) of a fixed for floating euro interest rate swap which (i) has a term of five (5) years commencing on the first calendar day of the relevant Reset Period, (ii) is in an amount that is representative of a single transaction in the relevant market at the relevant time with an acknowledged dealer of good credit in the swap market and (iii) has a floating leg based on the 6 month EURIBOR rate (calculated on an Actual/360 day count basis).

"Interest Payment Date" means 21 April of each year, commencing on the First Interest Payment Date.

"Interest Rate" means, subject to Condition 4.2, any of the Fixed Interest Rate, First Reset Rate, First Step-up Interest Rate or Second Step-up Interest Rate, as applicable.

"Reference Bank Rate" means, on any date, the percentage rate (rounded, if not an integral multiple of 0.001%, to the nearest integral multiple of 0.001%, with 0.0005% being rounded upwards) determined on the basis of the Euro 5-Year Swap Rate Quotations provided by the Reference Banks to the Calculation Agent at its request at approximately 11:00 a.m. (Central European time), on such date. If one (1) Euro 5-Year Swap Rate Quotation is provided, the Reference Bank Rate will be such Euro 5-Year Swap Rate Quotation. If two (2) or more Euro 5-Year Swap Rate Quotations are provided, the Reference Bank Rate will be the arithmetic mean of such Euro 5-Year Swap Rate Quotations, eliminating, if at least three Euro 5-Year Swap Rate Quotations are provided, the highest Euro 5-Year Swap Rate Quotation (or, in the event of equality one of the highest) and the lowest Euro 5-Year Swap Rate Quotation (or, in the event of equality, one of the lowest). If the Reference Bank Rate on such date cannot be determined in accordance with the foregoing provisions of this paragraph, the Reference Bank Rate on such date shall be equal to the Euro 5-Year Swap Rate last quoted on the Screen Page as obtained by the Calculation Agent.

"Reference Banks" means five (5) leading swap dealers in the interbank market selected from time to time by the Calculation Agent, in consultation with the Issuer.

"Reference Rate" means, in respect of any Reset Period, the Euro 5-Year Swap Rate on the Reset Interest Determination Date in respect of such Reset Period, as determined by the Calculation Agent.

"Reset Date" means the First Reset Date, the First Step-up Date and every fifth (5th) Interest Payment Date thereafter.

"Reset Interest Determination Date" means, in respect of any Reset Period, the day falling two (2) Business Days prior to the first calendar day of such Reset Period.

"**Reset Period**" means each period from (and including) a Reset Date to (but excluding) the next succeeding Reset Date.

"**T2**" means the real time gross settlement system operated by the Eurosystem or any successor or replacement for that system.

"**T2 Business Day**" means any calendar day on which T2 is operating.

"Benchmark Event"

If a Benchmark Event occurs then the Issuer may appoint an Independent Adviser in accordance with Condition 4.7 (*Benchmark Event*), to advise the Issuer in determining a Successor Rate, failing which an Alternative Rate and, in either case, an Adjustment Spread if any and any Benchmark Amendments.

"Rate of Interest following a Change of Control"

Further to the occurrence of a Change of Control Event, if a Change of Control Notice specifies that the Issuer has elected not to exercise the Change of Control Call Option, the interest rate payable on the Notes will be increased by an additional margin of 5 per cent. *per annum* as from (and including) the earlier of (i) the date of the Change of Control Notice or (ii) the thirtieth (30th) calendar day following the occurrence of a Change of Control Event, to (but excluding) the redemption of the Notes.

Where more than one Change of Control Event occurs during the life of the Notes, the increase in Interest Rate as referred to in the paragraph above shall only apply once, upon the occurrence of the first Change of Control Event.

"Optional Interest Deferral"

Optional Interest Payment

The Issuer may, at any time and at its sole discretion, by giving notice to the Noteholders in accordance with sub paragraph (d) below, elect to defer all or part of the payment of interest accrued on the Notes in respect of any Interest Period, except in relation to a payment of interest to be made on an Interest Payment Date falling on the date of redemption of the Notes. If the Issuer makes such an election, the Issuer shall have no obligation to make such payment and any such non-payment or partial payment of interest shall not constitute a default of the Issuer or any other breach of obligations under the Notes.

Any interest in respect of the Notes which has not been paid at the election of the Issuer in accordance with this paragraph will be deferred and shall constitute "**Arrears of Interest**" and shall be payable as outlined below.

Payment of Arrears of Interest

Arrears of Interest (together with any Additional Interest Amount (as defined below)) may at the option of the Issuer be paid in whole or in part, at any time, provided that all Arrears of Interest (together with any Additional Interest Amounts thereon) in respect of all Notes for the time being outstanding shall become due and payable in whole, but not in part, on the date (the "**Mandatory Settlement Date**") which is the earliest of:

- (i) the tenth (10th) Business Day following the date on which a Mandatory Payment Event occurs;
- (ii) the next scheduled Interest Payment Date in respect of which the Issuer does not elect to defer all of the interest accrued in respect of the relevant Interest Period;
- (iii) the date on which the Notes are redeemed; or
- (iv) the date upon which a judgment is made for the judicial liquidation (*liquidation judiciaire*) of the Issuer, or in the event of a transfer of the whole of the business of the Issuer (*cession totale de l'entreprise*) subsequent to the opening of a judicial recovery procedure (*redressement judiciaire*) or in the event of the voluntary dissolution of the Issuer, or in the event the Issuer is liquidated for any other reason (and in all cases listed above, other than pursuant to a consolidation, amalgamation or merger or other reorganisation outside the context of an insolvency whereby the remaining entity assumes all obligations of the Issuer under the Notes).

Each amount of Arrears of Interest shall bear interest, in accordance with Article 1343-2 of the French Code civil, as if it constituted the principal of the Notes at a rate which corresponds to the Interest Rate from time to time applicable to such Notes (the "**Arrears Interest Rate**") and the amount of such interest (the "**Additional Interest Amount**") with respect to Arrears of Interest shall be due and payable pursuant to this paragraph (b) and shall be calculated by the Calculation Agent applying the Arrears Interest Rate to the amount of the Arrears of Interest and otherwise mutatis mutandis as provided in the foregoing provisions of this Condition.

The Additional Interest Amount accrued up to any Interest Payment Date shall be added in accordance with and to the extent permitted by applicable law to the amount of Arrears of Interest remaining unpaid on such Interest Payment Date so that it will itself become Arrears of Interest, for the purpose only of calculating the Additional Interest Amount accruing thereafter.

Optional Partial Payment of Arrears of Interest and Additional Interest Amounts:

If amounts in respect of Arrears of Interest and Additional Interest Amounts are paid in part:

- (i) all unpaid amounts of Arrears of Interest shall be payable before any Additional Interest Amounts;
- (ii) Arrears of Interest accrued for any period shall not be payable until full payment has been made of all Arrears of Interest that have accrued during any earlier period and the order of payment of Additional Interest Amounts shall follow that of the Arrears of Interest to which they relate; and
- (iii) the amount of Arrears of Interest or Additional Interest Amounts payable in respect of any of the Notes in respect of any period, shall be pro rata to the total amount of all unpaid Arrears of Interest or, as the case may be, Additional Interest Amounts accrued on the Notes in respect of that period to the date of payment.

"Taxation"

All payments of principal, interest or other revenues by or on behalf of the Issuer in respect of the Notes shall be made free and clear of, and without withholding or deduction for, any taxes, or duties of whatever nature imposed, levied or collected by or on behalf of France or any authority therein or thereof having power to tax, unless such withholding or deduction is required by law.

"Additional Amounts"

If, pursuant to French laws or regulations, payments of principal, interest or other revenues in respect of any Note become subject to deduction or withholding in respect of any present or future taxes, duties, assessments or other governmental charges of whatever nature imposed, levied, collected, withheld or assessed by or on behalf of the Republic of France or any authority therein or thereof having power to tax, the Issuer shall, to the fullest extent then permitted by law, pay such additional amounts (the "**Additional Amounts**") as may be necessary in order that the holder of each Note, after such deduction or withholding, will receive the full amount then due and payable thereon in the absence of such deduction or withholding; provided, however, that the Issuer shall not be liable to pay any such Additional Amounts in respect of any Note to, or to a third party on behalf of, a Noteholder who is liable to such taxes, duties, assessments or governmental charges in respect of such Note by reason of his having some connection with the Republic of France other than the mere holding of such Note.

"Final Redemption"

Subject to any early redemption described below, the Notes are undated securities with no specified maturity date.

"Optional Redemption at the option of the Issuer"

The Issuer will have the right to redeem the Notes in whole, but not in part, on any day in the period commencing on (and including) 21 January 2032 (being the date falling three months prior to the First Reset Date (the "**First Call Date**")) and ending on (and including) the First Reset Date, and on any Interest Payment Date thereafter. Such early redemption of the Notes will be made at their principal amount together with any accrued interest and Arrears of Interest (including any Additional Interest Amounts thereon).

"Make-whole Redemption by the Issuer"

The Issuer may redeem in whole, but not in part, the Notes then outstanding at any time (other than (i) during the period from (and including) the First Call Date to (and including) the First Reset Date or (ii) on any subsequent Interest Payment Date) at the Make-whole Redemption Amount.

"Early Redemption following a Gross-Up Event"

If, by reason of a change in French law or regulation, or any change in the official application or interpretation of such law or regulation, becoming effective after the Issue Date, the Issuer would, on the occasion of the next payment due in respect of the Notes, not be able to make such payment without having to pay Additional Amounts (a "**Gross-Up Event**"), the Issuer may, at its sole discretion, at any time, redeem the Notes then outstanding in whole, but not in part, at 100 per cent. of their principal amount together with any accrued interest to the date set for redemption and any Arrears of Interest (including any Additional Interest Amounts thereon) provided that the due date for redemption of which notice hereunder may be given shall be no earlier than the latest practicable Interest Payment Date on which the Issuer could make payment of principal and interest without withholding or deduction for French taxes or, if such date has passed, as soon as practicable thereafter.

"Early Redemption following a Withholding Tax Event"

If the Issuer would, on the occasion of the next payment in respect of the Notes, be prevented by French law or regulation from making payment to the Noteholders of the full amount then due and payable, notwithstanding the undertaking to pay additional amounts contained in Condition 7 below (a "**Withholding Tax Event**"), then the Issuer may, at its sole discretion, at any time, redeem the Notes then outstanding in whole, but not in part, at 100 per cent. of their principal amount together with any accrued interest to the date set for redemption and any Arrears of Interest (including any Additional Interest Amounts thereon) on the latest practicable date on which the Issuer could make payment of the full amount payable in respect of the Notes without withholding or deduction for French taxes, or, if such date has passed, as soon as practicable thereafter.

"Early Redemption following a Tax Deduction Event"

If an opinion of a recognised law firm of international standing has been delivered to the Issuer and the Fiscal Agent, stating that by reason of a change in French law or regulation, or any change in the official application or interpretation of such law or regulation, becoming effective after the Issue Date, the tax regime of any payments under the Notes is modified and such modification results in the part of the interest payable by the Issuer in respect of the Notes that is tax deductible being reduced (a "**Tax Deduction Event**"), the Issuer may, at its option, at any time, redeem the Notes then outstanding, in whole, but not in part, at (i) 101 per cent. of their principal amount where such redemption occurs prior to the First Call Date, or (ii) 100 per cent. of their principal amount where such redemption occurs on or after the First Call Date, in each case together with any accrued interest and any Arrears of Interest (including any Additional Interest Amounts thereon), provided that the effective date of redemption of which notice hereunder may be given shall be no earlier than the latest practicable date preceding the effective date on which the tax regime of interest payments under the Notes is modified.

"Early Redemption following an Accounting Event"

If an Accounting Event (as defined below) has occurred, the Issuer may, at its sole discretion, redeem the Notes in whole, but not in part, at any time, at (i) 101 per cent. of their principal amount where such redemption occurs prior to the First Call Date, or (ii) 100 per cent. of their principal amount where such redemption occurs on or after the First Call Date, in each case together with any accrued interest and any Arrears of Interest (including any Additional Interest Amounts thereon).

"**Accounting Event**" is deemed to have occurred if, on the earlier of:

- (i) the delivery of an opinion of a recognised accountancy firm of international standing to the Issuer and the Fiscal Agent, or
- (ii) the official announcement or adoption or implementation by the relevant body of IFRS, (the earlier to occur of (i) or (ii) above being the "**Accounting Event Adoption Date**"),

a change in the accounting rules or methodology (or the application thereof) has occurred after the Issue Date, as a result of which the Notes may not or may no longer, from the implementation date of the relevant new International Financial Reporting Standards, as

adopted in the European Union ("**IFRS**") or any other accounting standards that may replace IFRS, be recorded as "equity" in full pursuant to IFRS or any other accounting standards that may replace IFRS for the purposes of the annual, semi-annual or quarterly consolidated financial statements of the Issuer.

For the avoidance of doubt, the Accounting Event shall be deemed to have occurred on the Accounting Event Adoption Date, notwithstanding any later effective date and notwithstanding any transitional period between the Accounting Event Adoption Date and the date on which it comes into effect.

"Early Redemption following an Equity Credit Rating Event"

If an Equity Credit Rating Event has occurred, then the Issuer may, at its option, redeem the Notes in whole, but not in part, at any time, at (i) 101 per cent. of their principal amount where such redemption occurs prior to the First Call Date, or (ii) 100 per cent. of their principal amount where such redemption occurs on or after the First Call Date, in each case together with any accrued interest and any Arrears of Interest (including any Additional Interest Amounts thereon), provided that the due date for redemption of which notice hereunder may be given shall be no earlier than the last calendar day before the date on which the Notes are assigned a level of equity credit that is lower than the level or equivalent level of equity credit assigned to the Notes by the relevant Rating Agency on the Issue Date, or if such equity credit was not assigned on the Issue Date, at the date when the equity credit was assigned for the first time.

"Equity Credit Rating Event" means that the Issuer has received written confirmation from any Rating Agency from whom the Issuer is assigned solicited ratings either directly or via a publication by such agency, that an amendment, clarification or change has occurred in the "equity credit" criteria (or such other nomenclature that the relevant Rating Agency may then use to describe the degree to which an instrument exhibits the characteristics of an ordinary share) of such Rating Agency (as defined below) or the application thereof, effective after the Issue Date (or effective after the date when the equity credit is assigned for the first time, as applicable), which amendment, clarification or change or the application thereof results in (a) a lower equity credit for all or any of the Notes than the then respective equity credit assigned on the Issue Date, or if equity credit is not assigned on the Issue Date, at the date when the equity credit is assigned for the first time (or if the Notes have been partially or fully re-financed after the Issue Date and are no longer eligible for equity credit in part or in full as a result, the Notes would no longer have been eligible as a result of such change in the assessment criteria had they not been re-financed), or (b) the period of time during which the relevant Rating Agency has assigned to the Notes a particular level of "equity credit" being shortened as compared to the period of time for which such Rating Agency did assign to the Notes that level of "equity credit" on the Issue Date, or if such "equity credit" was not assigned on the Issue Date, at the date when the "equity credit" was assigned for the first time.

"Early Redemption following a Change of Control Event"

If at any time while any Note remains outstanding, (A) there occurs a Change of Control or a Potential Change of Control (as defined below), and (B) within the Restructuring Period, a Rating Event (as defined below) occurs as a result of that Change of Control or, as the case may be, Potential Change of Control (such Rating Event as a result of a Change of Control or a Potential Change of Control, as the case may be, not having been cured prior to the expiry of the Restructuring Period, together, a "**Change of Control Event**"), the Issuer may, at its sole discretion, redeem or procure the purchase of, all but not some only, of the Notes, on the Change of Control Call Date at their principal amount together with (or where purchased, together with an amount equal to) interest accrued (and any Arrears of Interest (including any Additional Interest Amounts thereon)) to, but excluding, the Change of Control Call Date.

Promptly upon the Issuer becoming aware that a Change of Control Event has occurred, the Issuer shall give notice (a "**Change of Control Notice**") to the Noteholders in accordance with Condition 10 specifying the nature of the Change of Control Event and the circumstances giving rise to it and either (i) the date on which redemption or purchase of the Notes (the "**Change of Control Call Date**") will take place or, as the case may be, (ii) the Issuer's election not to redeem, or procure purchase of, the Notes, in which

case the Interest Step-Up following a Change of Control Event will apply in accordance with Condition 4.2.

If the Issuer elects to redeem, or to procure purchase of, the Notes, such redemption or purchase will take place not less than ten (10) nor more than sixty (60) calendar days after a Change of Control Notice is given.

Where:

A "**Change of Control**" means descendants of Germain Roquette and Dominique Roquette ceasing, for any reason whatsoever:

(A) to own, directly or indirectly at least fifty point one per cent. (50.1%) of the issued share capital of the Issuer (excluding any part of that issued share capital that carries no right to participate beyond a specified amount in a distribution of either profits of capital);

(B) to hold the power to cast or control the casting of more than 50 per cent. of the maximum number of votes capable of being cast at a general meeting of the Issuer; or

(C) to have the power to appoint or remove more than half of the directors or other equivalent officers of the Issuer.

A "**Potential Change of Control**" means any public announcement or statement by the Issuer, or by any actual or potential bidder(s) relating to any potential Change of Control of the Issuer.

"**Rating Agency**" means S&P Global Ratings Europe Limited and its successors or any other rating agency of equivalent standing notified by the Issuer to the Noteholders in accordance with Condition 10.

A "**Rating Event**" shall be deemed to have occurred in respect of a Change of Control or a Potential Change of Control, as the case may be, if, within the Restructuring Period, (A) the rating previously assigned to the Notes or to the Issuer by any Rating Agency solicited by the Issuer is (x) withdrawn or (y) changed from an investment grade rating (BBB- or its equivalent for the time being, or better) to a non-investment grade rating (BB+ or its equivalent for the time being, or worse) or (z) (if the rating previously assigned to the Notes or to the Issuer by any Rating Agency solicited by the Issuer was below an investment grade rating (as described above)), lowered by at least one full rating notch (for example, from BB+ to BB, or their respective equivalents) and (B) such rating is not within the Restructuring Period subsequently upgraded (in the case of a downgrade) or reinstated (in the case of a withdrawal) either to an investment grade credit rating (in the case of (x) and (y)) or to its earlier credit rating or better (in the case of (z)) by such Rating Agency, provided that the Rating Agency making the reduction in rating shall announce or publicly confirm or, having been so requested by the Issuer, inform the Issuer and the Fiscal Agent in writing that the lowering was the result, in whole or in part, of the applicable Change of Control or Potential Change of Control.

If the Notes are rated by more than one Rating Agency and such rating has been solicited by the Issuer, the rating to be taken into account to determine whether a Rating Downgrade has occurred shall be the lower rating assigned by any such Rating Agency.

If the Notes cease at any time to have a rating assigned to them by at least one Rating Agency, the Issuer shall use its best endeavours to obtain a rating of the Notes from another Rating Agency as soon as practicable. For the avoidance of doubt, if at the time of the occurrence of a Change of Control or a Potential Change of Control the Notes are not rated by a Rating Agency, and no Rating Agency assigns within the Restructuring Period an investment grade rating to the Notes, a Change of Control Event will be deemed to have occurred.

"**Restructuring Period**" means the period beginning one hundred and twenty (120) days prior to, and ending, one hundred and twenty (120) days after the date of the public announcement by the Issuer, any bidder or any designated advisor, of the completion of the relevant Change of Control (or such longer period for which the Notes or the senior unsecured long term debt of the Issuer are under consideration (such consideration

having been announced publicly within the period ending one hundred twenty (120) days after the occurrence of the relevant Change of Control) for rating review or, as the case may be, for rating by, a Rating Agency, such period not to exceed sixty (60) days after the public announcement of such consideration).

"Purchases"

The Issuer may, at any time, purchase the Notes together with rights to interest and any other amounts relating thereto in the open market or otherwise (including by way of tender or exchange offers) at any price, subject to applicable laws and regulations.

All Notes so purchased by, or for the account of, the Issuer, may, at its sole discretion, be held and resold or cancelled in accordance with applicable laws and regulations.

"Redemption following Substantial Repurchase Event"

If a Substantial Repurchase Event has occurred, the Issuer may at its option, at any time, redeem the outstanding Notes in whole, but not in part, at 100 per cent. of their principal amount.

"Substantial Repurchase Event" means that prior to the giving of the relevant notice of redemption, at least 75 per cent. of the initial aggregate principal amount of the Notes issued on the Issue Date has been purchased by or on behalf of the Issuer or a Subsidiary of the Issuer and has been cancelled.

"Prohibition of set-off"

Subject to applicable law, no Noteholder may exercise, claim or plead any right of set-off, compensation or retention in respect of any amount owed to it by the Issuer in respect of, or arising under or in connection with the Notes and each Noteholder shall, by virtue of its holding of any Note, be deemed to have waived all such rights of set-off, compensation or retention.

"No Negative Pledge"

There will be no negative pledge in respect of the Notes.

"Enforcement Events, no Events of Default and no Cross Default"

There are no events of default in respect of the Notes. There is no cross default under the Notes.

However, each Note shall become immediately due and payable at its principal amount, together with accrued interest thereon, if any, to the date of payment and any Arrears of Interest (including any Additional Interest Amounts thereon), in the event that a judgement is rendered by any competent court declaring the judicial liquidation (*liquidation judiciaire*) of the Issuer, or in the event of a transfer of the whole of the business of the Issuer (*cession totale de l'entreprise*) subsequent to the opening of a judicial recovery procedure (*redressement judiciaire*) or in the event of a voluntary dissolution of the Issuer or if the Issuer is liquidated for any other reason (and in all cases listed above, other than pursuant to a consolidation, amalgamation or merger or other reorganisation outside the context of an insolvency whereby the surviving entity assumes all obligations of the Issuer under the Notes). No payments will be made to holders of Junior Securities before all amounts due, but unpaid, to all Noteholders have been paid by the Issuer.

"Representation of the Noteholders"

The Noteholders will be grouped automatically for the defense of their respective common interests in a single masse (hereinafter referred to as the "**Masse**") which will be governed by the provisions of the French *Code de commerce* subject to certain exceptions and provisions. The *Masse* will be a separate legal entity and will act in part through a representative and in part through a General Meeting of Noteholders. The Issuer is entitled in lieu of holding a General Meeting to seek approval of a resolution from the Noteholders by way of a Written Decision.

"Admission to trading"

Application has been made for the Notes to be admitted to trading on Euronext Paris. Such admission to trading are expected to occur as of the Issue Date or as soon as practicable thereafter.

"Selling Restrictions"

There are restrictions on the offer and sale of the Notes and the distribution of offering material, including in the United States of America, the United Kingdom, France and the European Economic Area.

"Use of Proceeds"

The estimated net proceeds of the issue of the Notes are expected to amount to €596,640,000. The Issuer intends to use the net proceeds for general corporate purposes.

"Governing law"	The Notes will be governed by, and construed in accordance with, French law.
"Settlement"	Euroclear France.
"Fiscal Agent", "Principal Paying Agent", "Make-whole Calculation Agent" and "Calculation Agent"	BNP PARIBAS (acting through its Securities Services business)

DOCUMENTS INCORPORATED BY REFERENCE

This Prospectus should be read and construed in conjunction with the following documents and the information referred to in the cross-reference list below which are incorporated by reference in, and shall be deemed to form part of, this Prospectus:

- 1) the sections referred to in the table below of the 2025 annual report (the "[2025 Annual Report](#)") of the Group including the audited consolidated annual financial statements of the Group for the financial year ended 31 December 2025 and the notes related thereto (the "**2025 Consolidated Financial Statements**") and the related statutory auditors' report in French language; and
- 2) the sections referred to in the table below of the 2024 annual report (the "[2024 Annual Report](#)") of the Group including the audited consolidated annual financial statements of the Group for the financial year ended 31 December 2024 and the notes related thereto (the "**2024 Consolidated Financial Statements**") and the related statutory auditors' report in French language;

save that any statement contained in this Prospectus or in a document which is incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this Prospectus to the extent that a statement contained in any document which is subsequently incorporated by reference herein by way of a supplement prepared in accordance with Article 23 of the Prospectus Regulation herein modifies or supersedes such earlier statement (whether expressly, by implication or otherwise). Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Prospectus.

Any reference in the Prospectus to the 2024 Annual Report and the 2025 Annual Report shall be deemed to include only the sections mentioned in the table below.

Any document incorporated by reference may be obtained, free of charge, at the registered office of the Issuer during normal business hours so long as any of the Notes is outstanding, as described in the section entitled "General Information" below. Such documents are also available on the website of the Issuer (<https://www.roquette.com>). Free translations in the English language of the 2024 Annual Report and 2025 Annual Report are available on the Issuer's website (<https://www.roquette.com>), provided that only the French language versions of these documents are binding. These documents are available for information purposes only and are not incorporated by reference in this Prospectus.

Any information not listed in the cross-reference list below but included in the documents incorporated by reference is either not relevant for investors or covered elsewhere in the Prospectus.

Other than in relation to the documents which are deemed to be incorporated by reference, the information on the websites to which this Prospectus (including, for the avoidance of doubt, any information on the websites which appear in the documents incorporated by reference) refers does not form part of this Prospectus and has not been scrutinised or approved by the AMF.

Cross-reference list for information incorporated by reference

Annex 7 of the Commission Delegated Regulation 2019/980, as amended		Page/Ref No.
11	Financial Information concerning the Issuer’s Assets and Liabilities, Financial Position and Profits and Losses	
11.1	Historical Financial Information	
11.1.1	Historical financial information covering the latest two financial years (at least 24 months) or such shorter period as the issuer has been in operation and the audit report in respect of each year.	2024 Annual Report pages 145 to 196 2025 Annual Report pages 145 to 199
11.1.3	Accounting standards The financial information must be prepared according to International Financial Reporting Standards as endorsed in the Union based on Regulation (EC) No 1606/2002. If Regulation (EC) No 1606/2002 is not applicable the financial statements must be prepared according to: (a) a Member State’s national accounting standards for issuers from the EEA as required by Directive 2013/34/ EU; (b) a third country’s national accounting standards equivalent to Regulation (EC) No 1606/2002 for third country issuers. Otherwise the following information must be included in the registration document: (a) a prominent statement that the financial information included in the registration document has not been prepared in accordance with International Financial Reporting Standards as endorsed in the Union based on Regulation (EC) No 1606/2002 and that there may be material differences in the financial information had Regulation (EC) No 1606/2002 been applied to the historical financial information; (b) immediately following the historical financial information a narrative description of the differences between Regulation (EC) No 1606/2002 as adopted by the Union and the accounting principles adopted by the issuer in preparing its annual financial statements.	2024 Annual Report page 149 2025 Annual Report page 150
11.1.5	Consolidated financial statements If the issuer prepares both stand-alone and consolidated financial statements, include at least the consolidated financial statements in the registration document.	
	(a) consolidated balance sheet;	2024 Annual Report page 147 2025 Annual Report page 147
	(b) consolidated income statement;	2024 Annual Report page 146 2025 Annual Report page 146
	(c) consolidated cash flow statement; and	2024 Annual Report page 148 2025 Annual Report page 148
	(d) accounting policies and explanatory notes.	2024 Annual Report pages 149 to 192 2025 Annual Report pages 149 to 195
11.1.6	Age of financial information The balance sheet date of the last year of audited financial information may not be older than 18 months from the date of the registration document	2025 Annual Report page 147
11.2	Auditing of historical annual financial information	

Annex 7 of the Commission Delegated Regulation 2019/980, as amended		Page/Ref No.
11.2.1	The historical annual financial information must be independently audited. The audit report shall be prepared in accordance with Directive 2006/43/EC and Regulation (EU) No 537/2014.	2024 Annual Report pages 193 to 196 2025 Annual Report pages 196 to 199
11.2.1a	Where audit reports on the historical financial information have been refused by the statutory auditors or where they contain qualifications, modifications of opinion, disclaimers or an emphasis of matter, the reason must be given, and such qualifications, modifications, disclaimers or emphasis of matter must be reproduced in full.	N/A

TERMS AND CONDITIONS OF THE NOTES

The terms and conditions of the Notes (the "Terms and Conditions") will be as follows:

The issue of the €600,000,000 Undated Deeply Subordinated Fixed to Reset Rate Non-Call 6 Notes (the "**Notes**") of Roquette Frères SA (the "**Issuer**") was authorised by a resolution of the Board of Directors (*Conseil d'administration*) of the Issuer held on 11 February 2026, and decided pursuant to a decision of the Chief Financial Officer of the Issuer dated 14 April 2026.

The Issuer has entered into a fiscal agency agreement (the "**Fiscal Agency Agreement**") dated 17 April 2026 with BNP PARIBAS (acting through its Securities Services business) as fiscal agent, principal paying agent, make-whole calculation agent and calculation agent for the purposes of the Conditions. The fiscal agent, the principal paying agent, the make-whole calculation agent, the calculation agent and the paying agents for the time being are respectively referred to in these Conditions as the "**Fiscal Agent**", the "**Principal Paying Agent**", the "**Make-whole Calculation Agent**", the "**Calculation Agent**" and the "**Paying Agents**" (which expression shall include the Principal Paying Agent and the Fiscal Agent), each of which expression shall include the successors from time to time of the relevant persons, in such capacities, under the Fiscal Agency Agreement, and are collectively referred to as the "**Agents**". Copies of the Fiscal Agency Agreement are available for inspection at the specified offices of the Paying Agents.

References below to "**Conditions**" are, unless the context otherwise requires, to the numbered paragraphs below.

In these Conditions, references to "**day**" or "**days**" are to calendar days unless the context otherwise specifies.

1. **Form, Denomination and Title**

The Notes will be issued on 21 April 2026 (the "**Issue Date**") in dematerialised bearer form (*au porteur*) in the denomination of €100,000 each. Title to the Notes will be evidenced in accordance with Articles L.211-3 *et seq.* and R.211-1 *et seq.* of the French *Code monétaire et financier* in the books of the Account Holders. No physical document of title (including *certificats représentatifs* pursuant to Article R.211-7 of the French *Code monétaire et financier*) will be issued in respect of the Notes.

The Notes will, upon issue, be inscribed in the books of Euroclear France, which shall credit the accounts of the Account Holders. For the purpose of these Conditions, "**Account Holder**" shall mean any authorised financial intermediary institution entitled to hold accounts, directly or indirectly, with Euroclear France, and includes Euroclear Bank SA/NV ("**Euroclear**") and the depositary bank for Clearstream Banking, SA ("**Clearstream**").

Title to the Notes shall be evidenced by entries in the books of Account Holders and will pass upon, and transfer of the Notes may only be effected through, registration of the transfer in such books.

2. **Status of the Notes**

2.1 **Deeply Subordinated Notes**

The Notes (which constitute *obligations*) are deeply subordinated notes. The subordination provisions of the Notes are governed by the provisions of Article L. 228-97 of the French *Code de commerce*. The obligations of the Issuer under the Notes in respect of principal and interest (including for the avoidance of doubt, any Arrears of Interest and Additional Interest Amount (as defined below)) constitute direct, unconditional, unsecured and deeply subordinated obligations (*titres subordonnés de dernier rang*) of the Issuer and rank and will rank at all times *pari passu* without any preference among themselves and (i) *pari passu* with all other present and future Parity Securities (as defined below) of the Issuer, (ii) junior to present and future *prêts participatifs* granted to the Issuer and *titres participatifs* issued by the Issuer and to Ordinary Subordinated Obligations (as defined below) and Unsubordinated Obligations (as defined below) of the Issuer and (iii) in priority to any Junior Securities (as defined below).

"**Existing Notes**" means the €600,000,000 Undated Deeply Subordinated Fixed to Reset Rate Non-Call 5.25 Notes issued on 25 November 2024 (FR001400U3Q9).

"**Junior Securities**" means (a) the ordinary shares (*actions ordinaires*) of the Issuer and (b) any other class of the Issuer's share capital (including preference shares (*actions de préférence*)).

"**obligations**" means, in respect of any person, any financial obligation expressed to be assumed by or imposed on such person under or arising as a result of any contract, agreement, guarantee, document, instrument, conduct or relationship or directly by law.

"**Ordinary Subordinated Obligations**" means obligations, whether in the form of notes or otherwise, the principal and interest of which constitute direct, unconditional, unsecured and subordinated obligations of the Issuer and rank and will rank or are expressed to rank *pari passu* among themselves and (i) *pari passu* with all other present or future Ordinary Subordinated Obligations, (ii) junior to any subordinated obligations of the Issuer ranking or expressed to rank senior to Ordinary Subordinated Obligations and Unsubordinated Obligations and (iii) in priority to *prêts participatifs* and *titres participatifs*, if any, deeply subordinated obligations of the Issuer, including the Notes and Junior Securities.

"**Parity Securities**" means (a) any securities or other similar instruments issued by the Issuer which rank, or are expressed to rank, *pari passu* with (i) the Issuer's obligations under the Notes and (ii) any deeply subordinated securities or other similar instruments or deeply subordinated obligations of the Issuer, (b) any securities or other similar instruments issued by a Subsidiary of the Issuer which have the benefit of a guarantee (or similar instrument) from the Issuer, which rank or are expressed to rank *pari passu* with the Issuer's obligations under the Notes and (c) the Existing Notes.

"**Subsidiary**" means any entity controlled by the Issuer within the meaning of Article L.233-3 of the French *Code de commerce*.

"**Unsubordinated Obligations**" means obligations, whether in the form of notes or otherwise, the principal and interest of which constitute direct, unconditional, unsecured and unsubordinated obligations of the Issuer and rank and will rank *pari passu* without preference or priority among themselves and (save for certain obligations required to be preferred by French law) (i) *pari passu* with all other present or future unsecured and unsubordinated obligations of the Issuer and (ii) in priority to Ordinary Subordinated Obligations, subordinated obligations expressed to rank senior to Ordinary Subordinated Obligations, *prêts participatifs* and *titres participatifs*, if any, and deeply subordinated obligations of the Issuer, including the Notes and Junior Securities.

2.2 Payment on the Notes in the event of the liquidation of the Issuer

If any judgment is rendered by any competent court declaring the judicial liquidation (*liquidation judiciaire*) of the Issuer, or in the event of a transfer of the whole of the business of the Issuer (*cession totale de l'entreprise*) subsequent to the opening of a judicial recovery procedure (*redressement judiciaire*), or in the event of the voluntary dissolution of the Issuer or if the Issuer is liquidated for any other reason (and in all cases listed above, other than pursuant to a consolidation, amalgamation or merger or other reorganisation outside the context of an insolvency whereby the surviving entity assumes all obligations of the Issuer under the Notes), each Note shall become immediately due and payable and the rights of the Noteholders will be calculated on the basis of the principal amount of the Notes together with any accrued interest on such principal amount and any Arrears of Interest (including any Additional Interest Amount thereon), and the payments of the creditors of the Issuer shall be made in the following order of priority (in each case subject to the payment in full of priority creditors):

- (i) unsubordinated creditors of the Issuer (including creditors in respect of Unsubordinated Obligations);
- (ii) subordinated creditors of the Issuer (including creditors in respect of Ordinary Subordinated Obligations and of subordinated obligations ranking senior to Ordinary Subordinated Obligations);
- (iii) lenders in relation to *prêts participatifs* granted to, or *titres participatifs* issued by, the Issuer (if any);
- (iv) deeply subordinated creditors of the Issuer (including holders of Notes and creditors in respect of Parity Securities) and

- (v) holders in respect of Junior Securities.

2.3 Prohibition of set-off

Subject to applicable law, no Noteholder may exercise, claim or plead any right of set-off, compensation or retention in respect of any amount owed to it by the Issuer in respect of, or arising under or in connection with the Notes and each Noteholder shall, by virtue of its holding of any Note, be deemed to have waived all such rights of set-off, compensation or retention.

3. Negative pledge

There will be no negative pledge in respect of the Notes.

4. Interest and deferral of interest

4.1 General

Unless previously redeemed in accordance with Condition 5 and subject to the further provisions of this Condition (in particular, but not limited to Conditions 4.2 and 4.6), the Notes shall bear interest on their principal amount:

- (i) from (and including) the Issue Date to (but excluding) 21 April 2032 (the "**First Reset Date**"), at an interest rate *per annum* of 6.000 per cent. (the "**Fixed Interest Rate**"), payable annually in arrear on each Interest Payment Date, commencing on 21 April 2027 (the "**First Interest Payment Date**") and ending on the Interest Payment Date falling on the First Reset Date;
- (ii) from (and including) the First Reset Date to (but excluding) 21 April 2037 (the "**First Step-up Date**"), at an interest rate *per annum* which shall be equal to the sum of the Reference Rate in respect of the relevant Reset Period and the Relevant Margin (the "**First Reset Rate**"), payable annually in arrear on each Interest Payment Date, commencing on the Interest Payment Date immediately following the First Reset Date and ending on the Interest Payment Date falling on the First Step-up Date;
- (iii) from (and including) the First Step-up Date to (but excluding) 21 April 2052 (the "**Second Step-up Date**"), at an interest rate *per annum* which will be subject to a reset every five years and shall be equal to the sum of the Reference Rate in respect of the relevant Reset Period and the Relevant Margin (the "**First Step-up Interest Rate**"), payable annually in arrear on each Interest Payment Date, commencing on the Interest Payment Date immediately following the First Step-up Date and ending on the Interest Payment Date falling on the Second Step-up Date; and
- (iv) from (and including) the Second Step-up Date, at an interest rate *per annum* which will be subject to a reset every five years and shall be equal to the sum of the Reference Rate in respect of the relevant Reset Period and the Relevant Margin (the "**Second Step-up Interest Rate**"), payable annually in arrear on each Interest Payment Date, commencing on the Interest Payment Date immediately following the Second Step-up Date;

where the "**Relevant Margin**" means, (i) from (and including) the First Reset Date to (but excluding) the First Step-up Date, 3.098 per cent. *per annum*, (ii) from (and including) the First Step-up Date to (but excluding) the Second Step-up Date, 3.348 per cent. *per annum* and (iii) from (and including) the Second Step-up Date, 4.098 per cent. *per annum* and provided that each of the First Reset Rate, the First Step-up Interest Rate and the Second Step-up Interest Rate shall never be less than zero (notwithstanding the use of any Alternative Rate or Successor Rate and the application of any Adjustment Spread pursuant to Condition 4.7).

For the purpose hereof:

"**Business Day**" means any calendar day (other than a Saturday or a Sunday) which is (i) a T2 Business Day and (ii) a day on which commercial banks and foreign exchange markets settle payments and are open for general business (including dealing in foreign exchange and foreign currency deposits) in Paris and (solely for purposes of determining the Calculation Date as provided in Condition 5.3) Frankfurt.

"Euro 5-Year Swap Rate" means, on any Reset Interest Determination Date, the mid-swap rate in euros for a term of five (5) years as displayed on Reuters screen ICESWAP2/EURSFIXA (or such other page or service as may replace it for the purposes of displaying European swap rates of leading reference banks for swaps in euro) (the **"Screen Page"**) as at 11:00 a.m. (Central European time) on such Reset Interest Determination Date. In the event that the Euro 5-Year Swap Rate does not appear on the Screen Page on such Reset Interest Determination Date, the Euro 5-Year Swap Rate on such Reset Interest Determination Date will be the Reference Bank Rate on the Business Day immediately following such Reset Interest Determination Date.

"Euro 5-Year Swap Rate Quotation" means the arithmetic mean of the bid and offered rates for the annual fixed leg (calculated on a 30/360 day count basis) of a fixed-for-floating euro interest rate swap which (i) has a term of five (5) years commencing on the first calendar day of the relevant Reset Period, (ii) is in an amount that is representative of a single transaction in the relevant market at the relevant time with an acknowledged dealer of good credit in the swap market and (iii) has a floating leg based on the 6-month EURIBOR rate (calculated on an Actual/360 day count basis).

"Interest Payment Date" means 21 April of each year, commencing on the First Interest Payment Date.

"Interest Rate" means, subject to Condition 4.2, any of the Fixed Interest Rate, First Reset Rate, First Step-up Interest Rate or Second Step-up Interest Rate, as applicable.

"Reference Bank Rate" means, on any date, the percentage rate (rounded, if not an integral multiple of 0.001%, to the nearest integral multiple of 0.001%, with 0.0005% being rounded upwards) determined on the basis of the Euro 5-Year Swap Rate Quotations provided by the Reference Banks to the Calculation Agent at its request at approximately 11:00 a.m. (Central European time), on such date. If one (1) Euro 5-Year Swap Rate Quotation is provided, the Reference Bank Rate will be such Euro 5-Year Swap Rate Quotation. If two (2) or more Euro 5-Year Swap Rate Quotations are provided, the Reference Bank Rate will be the arithmetic mean of such Euro 5-Year Swap Rate Quotations, eliminating, if at least three Euro 5-Year Swap Rate Quotations are provided, the highest Euro 5-Year Swap Rate Quotation (or, in the event of equality one of the highest) and the lowest Euro 5-Year Swap Rate Quotation (or, in the event of equality, one of the lowest). If the Reference Bank Rate on such date cannot be determined in accordance with the foregoing provisions of this paragraph, the Reference Bank Rate on such date shall be equal to the Euro 5-Year Swap Rate last quoted on the Screen Page as obtained by the Calculation Agent.

"Reference Banks" means five (5) leading swap dealers in the interbank market selected from time to time by the Calculation Agent, in consultation with the Issuer.

"Reference Rate" means, in respect of any Reset Period, the Euro 5-Year Swap Rate on the Reset Interest Determination Date in respect of such Reset Period, as determined by the Calculation Agent.

"Reset Interest Determination Date" means, in respect of any Reset Period, the day falling two (2) Business Days prior to the first calendar day of such Reset Period.

"Reset Date" means the First Reset Date, the First Step-up Date and every fifth (5th) Interest Payment Date thereafter.

"Reset Period" means each period from (and including) a Reset Date to (but excluding) the next succeeding Reset Date.

"T2" means the real time gross settlement system operated by the Eurosystem or any successor or replacement for that system.

"T2 Business Day" means any calendar day on which T2 is operating.

Promptly after the determination of the Reference Rate by it, the Calculation Agent shall determine the Interest Rate for each Note and calculate the relevant Interest Amount (as defined in Condition 4.3 below).

The Calculation Agent will cause the Interest Rate and the relevant Interest Amount (as defined below) payable per Note to be notified to the Issuer, each of the Paying Agents and, if required by the rules of Euronext Paris or

any other stock exchange on which the Notes are listed or admitted to trading from time to time, to such stock exchange, and to holders of Notes (the "Noteholders" and each a "Noteholder") in accordance with Condition 10 without undue delay, but, in any case, not later than on the fourth (4th) Business Day after its determination.

4.2 Interest Step-up following a Change of Control Event

Further to the occurrence of a Change of Control Event as defined in Condition 5.8 below, (i) if a Change of Control Notice (as defined in Condition 5.8 below) specifies that the Issuer has elected not to exercise the Change of Control Call Option, the interest rate payable on the Notes will be increased by an additional margin of 5 per cent. *per annum* as from (and including) the earlier of (i) the date of the Change of Control Notice (as defined in Condition 5.8 below) or (ii) the thirtieth (30th) calendar day following the occurrence of a Change of Control Event, to (but excluding) the date of the redemption of the Notes.

Where more than one Change of Control Event occurs during the life of the Notes, the increase in Interest Rate as referred to in the paragraph above shall only apply once, upon the occurrence of the first Change of Control Event.

4.3 Calculation of interest

The amount of interest payable on each Note and on the relevant date in respect of any period (including without limitation any Interest Period) (an "Accrual Period") in accordance with the Conditions will be the product of (i) the principal amount of such Note, (ii) the applicable Interest Rate and (iii) the Actual/Actual (ICMA) Day Count Fraction in respect of such Accrual Period, and rounding the resulting figure, if necessary, to the nearest cent (half a cent being rounded upwards).

"Actual"/"Actual (ICMA) Day Count Fraction" means, in respect of any Accrual Period:

- (i) if such Accrual Period is equal to or shorter than the Determination Period during which it falls, the number of calendar days in such Accrual Period divided by the number of calendar days in such Determination Period;
- (ii) if such Accrual Period is longer than the Determination Period in which it begins, the sum of (a) the number of calendar days in such Accrual Period falling in the Determination Period in which it begins divided by the number of calendar days in such Determination Period and (b) the number of calendar days in such Accrual Period falling in the next Determination Period divided by the number of calendar days in such next Determination Period.

"Determination Date" means 21 April of each year.

"Determination Period" means the period from (and including) a Determination Date to (but excluding) the next Determination Date.

"Interest Amount" means the amount of interest payable pursuant to Condition 4.1 for each Note outstanding on any Interest Payment Date in respect of the Interest Period ending on (but excluding) such Interest Payment Date.

"Interest Period" means the period from (and including) an Interest Payment Date (or the Issue Date as the case may be) to (but excluding) the next Interest Payment Date (or the First Interest Payment Date, as the case may be).

4.4 Notifications, etc. to be final

All notifications, opinions, determinations, certificates, calculations, quotations and decisions given, expressed, made or obtained for the purposes of the provisions of this Condition 4, whether by the Reference Banks (or any of them), the Calculation Agent or the Independent Adviser, as the case may be, will (in the absence of wilful default, bad faith or manifest error) be binding on the Issuer, the Calculation Agent, the Independent Adviser, the Fiscal Agent and all Noteholders.

4.5 Calculation Agent

Calculations and determinations performed by the Calculation Agent pursuant to these Conditions shall be so made upon request by the Issuer and shall be final and binding (in the absence of manifest error) on the Issuer, the Noteholders, the Representative and the Paying Agent. The Calculation Agent may, subject to the provisions of the Fiscal Agency Agreement, consult, at the expense of the Issuer, on any matter (including but not limited to, any legal matter), with any legal or other professional adviser and it shall be able to rely upon, and it shall not be liable and shall incur no liability as against the Noteholders, the Representative and the Paying Agent in respect of anything done, or omitted to be done, relating to that matter in good faith in accordance with that adviser's opinion.

The Calculation Agent is acting exclusively as an agent for and upon request from the Issuer. The Calculation Agent (acting in such capacity) shall not have any relationship of agency or trust with, and shall incur no liability as against, the Noteholders, the Representative and any other Agent.

The Fiscal Agency Agreement provides that the Issuer may at any time terminate the appointment of the Calculation Agent and appoint a substitute Calculation Agent, provided that so long as any of the Notes remain outstanding, there shall at all times be a Calculation Agent for the purposes of the Notes having a specified office in a major European city. In the event of the appointed office of any bank being unable or unwilling to continue to act as the Calculation Agent or failing duly to determine the Interest Amount for any Interest Period, the Issuer shall appoint the European office of another leading bank engaged in the Euro-zone or London interbank market to act in its place. The Calculation Agent may not resign its duties or be removed without a successor having been appointed. The Calculation Agent shall act as an independent expert and not as agent for the Issuer or the Noteholders.

Notice of any change of Calculation Agent or any change of specified office shall promptly be given as soon as reasonably practicable to the Noteholders in accordance with Condition 10 and, so long as the Notes are admitted to trading on Euronext Paris and if the rules applicable to such stock exchange so require, to such stock exchange.

4.6 Interest Deferral

Interest payments shall only be due and payable if the Issuer so elects, in accordance with the provisions of the following paragraphs.

(a) Optional Interest Payment

The Issuer may, at any time and at its sole discretion, by giving notice to the Noteholders in accordance with sub-paragraph (d) below, elect to defer all or part of the payment of interest accrued on the Notes in respect of any Interest Period, except in relation to a payment of interest to be made on an Interest Payment Date falling on the date of redemption of the Notes. If the Issuer makes such an election, the Issuer shall have no obligation to make such payment and any such non-payment or partial payment of interest shall not constitute a default of the Issuer or any other breach of obligations under the Notes.

Any interest in respect of the Notes which has not been paid at the election of the Issuer in accordance with this paragraph will be deferred and shall constitute "**Arrears of Interest**" and shall be payable as outlined below.

(b) Payment of Arrears of Interest

Arrears of Interest (together with any Additional Interest Amount (as defined below)) may at the option of the Issuer be paid in whole or in part, at any time, provided that all Arrears of Interest (together with any Additional Interest Amounts thereon) in respect of all Notes for the time being outstanding shall become due and payable in whole, but not in part, on the date (the "**Mandatory Settlement Date**") which is the earliest of:

- (i) the tenth (10th) Business Day following the date on which a Mandatory Payment Event occurs;
- (ii) the next scheduled Interest Payment Date in respect of which the Issuer does not elect to defer all of the interest accrued in respect of the relevant Interest Period;

- (iii) the date on which the Notes are redeemed; or
- (iv) the date upon which a judgment is made for the judicial liquidation (*liquidation judiciaire*) of the Issuer, or in the event of a transfer of the whole of the business of the Issuer (*cession totale de l'entreprise*) subsequent to the opening of a judicial recovery procedure (*redressement judiciaire*) or in the event of the voluntary dissolution of the Issuer, or in the event the Issuer is liquidated for any other reason (and in all cases listed above, other than pursuant to a consolidation, amalgamation or merger or other reorganisation outside the context of an insolvency whereby the remaining entity assumes all obligations of the Issuer under the Notes).

Each amount of Arrears of Interest shall bear interest, in accordance with Article 1343-2 of the French *Code civil*, as if it constituted the principal of the Notes at a rate which corresponds to the Interest Rate from time to time applicable to such Notes (the "**Arrears Interest Rate**") and the amount of such interest (the "**Additional Interest Amount**") with respect to Arrears of Interest shall be due and payable pursuant to this paragraph (b) and shall be calculated by the Calculation Agent applying the Arrears Interest Rate to the amount of the Arrears of Interest and otherwise *mutatis mutandis* as provided in the foregoing provisions of this Condition.

The Additional Interest Amount accrued up to any Interest Payment Date shall be added in accordance with and to the extent permitted by applicable law to the amount of Arrears of Interest remaining unpaid on such Interest Payment Date so that it will itself become Arrears of Interest, for the purpose only of calculating the Additional Interest Amount accruing thereafter.

(c) Optional Partial Payment of Arrears of Interest and Additional Interest Amounts

If amounts in respect of Arrears of Interest and Additional Interest Amounts are paid in part:

- (i) all unpaid amounts of Arrears of Interest shall be payable before any Additional Interest Amounts;
- (ii) Arrears of Interest accrued for any period shall not be payable until full payment has been made of all Arrears of Interest that have accrued during any earlier period and the order of payment of Additional Interest Amounts shall follow that of the Arrears of Interest to which they relate; and
- (iii) the amount of Arrears of Interest or Additional Interest Amounts payable in respect of any of the Notes in respect of any period, shall be pro rata to the total amount of all unpaid Arrears of Interest or, as the case may be, Additional Interest Amounts accrued on the Notes in respect of that period to the date of payment.

(d) Notice of Deferral and Payment of Arrears of Interest

Notice of (i) deferral of any interest under the Notes on any Interest Payment Date and (ii) any date upon which amounts in respect of Arrears of Interest and/or Additional Interest Amounts shall become due and payable shall be given to the Noteholders in accordance with Condition 10, and the Paying Agents and the Calculation Agent at least five (5) business days in Paris, but no more than thirty (30) business days in Paris, prior to such Interest Payment Date (in the case of (i) above) or date (in the case of (ii) above) which notice shall be irrevocable. So long as the Notes are listed on Euronext Paris and the rules applicable to such stock exchange so require, notice of any such deferral shall also be given as soon as reasonably practicable to such stock exchange.

For the purpose hereof:

A "**Mandatory Payment Event**" means any one or more of the following events:

- (i) a dividend (either interim or final), or any other distribution or payment (whether or not in cash) was validly resolved on, declared, paid or made in respect of any Junior Securities or Parity Securities, except (i) where such dividend, distribution or payment was contractually required to be declared, paid or made under the terms of such Junior Securities or Parity Securities and (ii) in the case of Parity Securities, any partial payment of arrears of interest at the option of the Issuer (provided that such partial payment is made, on a pro-rata basis, concurrently in respect of Arrears of Interest on the Notes), or

- (ii) the Issuer, or any Subsidiary of the Issuer, has repurchased, purchased, redeemed, or otherwise acquired any Junior Securities, except where (x) such repurchase, purchase, redemption or acquisition was undertaken in connection with the satisfaction by the Issuer or any Subsidiary of the Issuer of its obligations under any share buyback programme in force and duly approved by its shareholder's general meeting or any stock option plan or free share allocation plan in each case reserved for directors, officers, and/or employees of the Issuer's group, any existing or future liquidity agreement (*contrat de liquidité*) or any associated hedging transaction or the hedging of convertible securities or hedging of other equity-linked securities or (y) such repurchase, purchase, redemption or acquisition is contractually required to be made under the terms of such Junior Securities; or
- (iii) the Issuer, or any Subsidiary of the Issuer, has repurchased, purchased, redeemed, or otherwise acquired any Parity Securities or any Notes, except where (x) such repurchase, purchase, redemption or acquisition is contractually required to be made under the terms of such Parity Securities or (y) such repurchase, purchase, redemption or acquisition is effected as a public tender offer or public exchange offer at a purchase price per security which is below its par value.

4.7 Benchmark Event

If the Issuer (in consultation with the Calculation Agent) determines that a Benchmark Event occurs in relation to the Original Reference Rate when any Interest Rate (or any component part thereof) remains to be determined by reference to the Original Reference Rate, then the following provisions shall apply and shall prevail over other fallbacks specified in the definition of "Euro 5-Year Swap Rate" in Condition 4.1.

(a) Independent Adviser

The Issuer shall use its reasonable endeavours to appoint an Independent Adviser, as soon as reasonably practicable, to determine a Successor Rate, failing which an Alternative Rate (in accordance with Condition 4.7(b)) and, in either case, an Adjustment Spread if any (in accordance with Condition 4.7(c)) and any Benchmark Amendments (in accordance with Condition 4.7(d)).

An Independent Adviser appointed pursuant to this Condition 4.7 shall act in good faith and in a commercially reasonable manner as an independent expert. In the absence of manifest error, bad faith or fraud, the Independent Adviser shall have no liability whatsoever to the Issuer, the Agents or the Noteholders for any determination made by it, pursuant to this Condition 4.7.

(b) Successor Rate or Alternative Rate

If the Independent Adviser determines in good faith and in a commercially reasonable manner that:

- (i) there is a Successor Rate, then such Successor Rate shall (subject to adjustment as provided in Condition 4.7(c)) subsequently be used in place of the Original Reference Rate to determine the Interest Rate (or the relevant component part thereof) for all relevant future payments of interest on the Notes (subject to the further operation of this Condition 4.7); or
- (ii) there is no Successor Rate but that there is an Alternative Rate, then such Alternative Rate shall (subject to adjustment as provided in Condition 4.7(c)) subsequently be used in place of the Original Reference Rate to determine the Interest Rate (or the relevant component part thereof) for all relevant future payments of interest on the Notes (subject to the further operation of this Condition 4.7).

(c) Adjustment Spread

If the Independent Adviser determines in good faith and in a commercially reasonable manner (i) that an Adjustment Spread is required to be applied to the Successor Rate or the Alternative Rate (as the case may be) and (ii) the quantum of, or a formula or methodology for determining, such Adjustment Spread, then such Adjustment Spread shall be applied to the Successor Rate or the Alternative Rate (as the case may be) for each subsequent determination of the Interest Rate (or a relevant component part thereof) by reference to such Successor Rate or Alternative Rate, as applicable.

(d) Benchmark Amendments

If any Successor Rate, Alternative Rate or Adjustment Spread is determined in accordance with this Condition 4.7 and the Independent Adviser, determines in good faith and in a commercially reasonable manner (i) that amendments to these Conditions (including, without limitation, amendments to the definitions of Actual/Actual (ICMA) Day Count Fraction, Business Day or Screen Page) are necessary to ensure the proper operation of such Successor Rate, Alternative Rate and/or Adjustment Spread (such amendments, the "**Benchmark Amendments**") and (ii) the terms of the Benchmark Amendments, then the Issuer shall, subject to giving notice thereof in accordance with Condition 4.7(e), without any requirement for the consent or approval of the Noteholders, vary these Conditions to give effect to such Benchmark Amendments with effect from the date specified in such notice.

For the avoidance of doubt, and in connection with any such variation in accordance with this Condition 4.7(d), the Issuer shall comply with the rules of any stock exchange on which the Notes are for the time being listed or admitted to trading.

(e) Notices

Any Successor Rate, Alternative Rate, Adjustment Spread and the specific terms of any Benchmark Amendments determined under this Condition 4.7 will be notified promptly by the Issuer, after receiving such information from the Independent Adviser, to the Agents and, in accordance with Condition 10, the Noteholders. Such notice shall be irrevocable and shall specify the effective date of the Benchmark Amendments, if any.

The Successor Rate or Alternative Rate and the Adjustment Spread (if any) and the Benchmark Amendments (if any) specified in such notice will (in the absence of manifest error, bad faith or fraud in the determination of the Successor Rate or Alternative Rate and the Adjustment Spread (if any) and the Benchmark Amendments (if any)) be binding on the Issuer, the Agents and the Noteholders.

(f) Survival of Original Reference Rate

If (i) the Issuer is unable to appoint an Independent Adviser; or (ii) the Independent Adviser appointed by it fails to determine a Successor Rate or, failing which, an Alternative Rate in accordance with this Condition 4.7 prior to the relevant Reset Interest Determination Date, the Euro 5-Year Swap Rate applicable to the next succeeding Reset Period shall be equal to the last Euro 5-Year Swap Rate available on the Screen Page as determined by the Calculation Agent.

For the avoidance of doubt, this Condition 4.7 shall apply to the relevant next succeeding Reset Period only and any subsequent Reset Periods are subject to the subsequent operation of, and to adjustment as provided in, this Condition 4.7.

Without prejudice to the obligations of the Issuer under this Condition 4.7, the Original Reference Rate and the fallback provisions provided for in Condition 4.1 will continue to apply unless and until a Benchmark Event has occurred.

Notwithstanding any other provision of this Condition, no Successor Rate or Alternative Rate will be adopted, nor will the applicable Adjustment Spread be applied, nor will any other related Benchmark Amendments be made, if and to the extent that, in the determination of the Issuer, the same could reasonably be expected to (i) result in a reduction of the amount of "equity credit" assigned to the Notes by a Rating Agency when compared to the "equity credit" assigned to the Notes immediately prior to the occurrence of the relevant Benchmark Event from such Rating Agency or (ii) otherwise prejudice the eligibility of the Notes for "equity credit" from a Rating Agency.

(g) New Benchmark Event in respect of the Successor Rate or Alternative Rate

If Benchmark Amendments have been implemented pursuant to this Condition 4.7 and a new Benchmark Event occurs in respect of the then applicable Successor Rate or Alternative Rate, the Issuer shall use its reasonable endeavours to appoint an Independent Adviser and ensure that the provisions of this Condition 4.7 shall apply as if the Successor Rate or Alternative Rate were the Original Reference Rate.

(h) Definitions

As used in this Condition 4.7:

"Adjustment Spread" means either a spread (which may be positive or negative), or the formula or the methodology for calculating a spread, in either case, which the Independent Adviser, acting in good faith and in a commercially reasonable manner, determines in accordance with customary market usage in the international debt capital market for such Successor Rate or Alternative Rate and which is required to be applied to the Successor Rate or the Alternative Rate as the case may be to reduce or eliminate, to the fullest extent reasonably practicable in the circumstances, any economic prejudice or benefit as the case may be to Noteholders as a result of the replacement of the Original Reference Rate with the Successor Rate or the Alternative Rate as the case may be and is the spread, formula or methodology which:

- (i) in the case of a Successor Rate, is formally recommended or formally provided as an option for parties to adopt in relation to the replacement of the Original Reference Rate with the Successor Rate by any Relevant Nominating Body; or
- (ii) if no recommendation required under (i) above has been made or in the case of an Alternative Rate, the Independent Adviser determines and which is recognised or acknowledged as being the industry standard for over-the-counter derivative transactions which reference the Original Reference Rate, where such rate has been replaced by the Successor Rate or the Alternative Rate as the case may be; or
- (iii) if the Independent Adviser determines that no such industry standard is recognised or acknowledged, the spread, formula or methodology which the Independent Adviser (acting in good faith) determines to be appropriate;

"Alternative Rate" means an alternative benchmark or screen rate which the Independent Adviser determines in accordance with Condition 4.7(b) and which is recognised or acknowledged as being the industry standard for over-the-counter derivative transactions for the purposes of determining rates of interest (or the relevant component part thereof) for a determined interest period in euro;

"Benchmark Amendments" has the meaning given to it in Condition 4.7(d);

"Benchmark Event" means:

- (i) the Original Reference Rate ceasing to be published for a period of at least 10 Business Days or ceasing to exist; or
- (ii) the later of (a) the making of a public statement by the administrator of the Original Reference Rate that it will, on or before a specified date, cease publishing the Original Reference Rate permanently or indefinitely (in circumstances where no successor administrator has been appointed that will continue publication of the Original Reference Rate) and (b) the date falling six (6) months prior to the specified date referred to in (a) above; or
- (iii) the later of (a) the making of a public statement by the supervisor of the administrator of the Original Reference Rate that the Original Reference Rate will, on or before a specified date, be permanently or indefinitely discontinued and (b) the date falling six (6) months prior to the specified date referred to in (a) above; or
- (iv) (i) the making of a public statement by the supervisor of the administrator of the Original Reference Rate or by any relevant competent authority or other relevant official body pursuant to the Benchmarks Regulation, or (ii) the effect of the application of the Benchmarks Regulation otherwise being, that: (1) the Original Reference Rate will be prohibited from being used; (2) the Original Reference Rate is no longer (or will no longer be) representative of an underlying market; (3) the use of the Original Reference Rate will be subject to restrictions or adverse consequences; or (4) adding a new reference to the Original Reference Rate will be prohibited; or

provided that the Benchmark Event shall occur on the date on which: (A) the Original Reference Rate is prohibited from use (assuming, in the case of a public statement by any relevant competent authority or other relevant official body pursuant to the Benchmarks Regulation, that the Issuer has not published (within six months of the date of the relevant public statement) a statement on its website providing a reasoned explanation for not being able to replace the Original Reference Rate); (B) the Original Reference Rate is deemed no longer to be representative; (C) the Original Reference Rate becomes subject to restrictions or adverse consequences; or (D) adding a new reference to the Original Reference Rate is prohibited, and not (in any such case) the date of the relevant public statement, unless the date of the relevant public statement coincides with the relevant date in (1), (2), (3) or (4) above (as applicable); or

- (v) the making of a public statement by the supervisor of the administrator of the Original Reference Rate that, in the opinion of such supervisor, the methodology to calculate such Original Reference Rate has materially changed; or
- (vi) it is or will become unlawful for the Fiscal Agent, the Calculation Agent or the Issuer to calculate any payments due to be made to any Noteholder using the Original Reference Rate; or
- (vii) that a decision to withdraw the authorisation or registration pursuant to Article 35 of the Benchmarks Regulation of any benchmark administrator previously authorised to publish such Original Reference Rate has been adopted.

For the avoidance of doubt, in respect of paragraphs (b), (c) and (d) above, such public statement will not constitute a Benchmark Event before the date falling six months prior the date specified in the relevant public announcement on which the Original Reference Rate is permanently or indefinitely discontinued or prohibited.

"Benchmarks Regulation" means Regulation (EU) 2016/1011 of 8 June 2016, as amended or supplemented;

"Independent Adviser" means an independent financial institution of international repute or an independent financial adviser of recognised standing with appropriate expertise, at all times acting in good faith and in a commercially reasonable manner, appointed by the Issuer at its own expense under Condition 4.7(a);

"Original Reference Rate" means the Euro 5-Year Swap Rate;

"Relevant Nominating Body" means, in respect of a benchmark or screen rate, as applicable:

- (i) the central bank for the currency to which the benchmark or screen rate, as applicable, relates, or any central bank or other supervisory authority which is responsible for supervising the administrator of the benchmark or screen rate, as applicable; or
- (ii) any working group or committee sponsored by, chaired or co-chaired by or constituted at the request of (a) the central bank for the currency to which the benchmark or screen rate, as applicable, relates, (b) any central bank or other supervisory authority which is responsible for supervising the administrator of the benchmark or screen rate, as applicable, (c) a group of the aforementioned central banks or other supervisory authorities or (d) the Financial Stability Board or any part thereof; and

"Successor Rate" means a successor to or replacement of the Original Reference Rate which is formally recommended by any Relevant Nominating Body, and if, following a Benchmark Event, two (2) or more successor or replacement rates are recommended by any Relevant Nominating Body, the Independent Adviser, shall determine which of those successor or replacement rates is most appropriate, having regard to, *inter alia*, the particular features of the Notes and the nature of the Issuer.

5. Redemption and Purchase

The Notes may not be redeemed otherwise than in accordance with this Condition.

5.1 Final Redemption

Subject to any early redemption described below, the Notes are undated securities with no specified maturity date.

5.2 Optional Redemption

The Issuer will have the right to redeem the Notes in whole, but not in part, on any day in the period commencing on (and including) 21 January 2032 (being the date falling three months prior to the First Reset Date (the "**First Call Date**")) and ending on (and including) the First Reset Date, and on any Interest Payment Date thereafter, subject to having given not more than seventy-five (75) nor less than ten (10) calendar days' prior notice to the Noteholders (which notice shall be irrevocable) in accordance with Condition 10. Such early redemption of the Notes will be made at their principal amount together with any accrued interest and Arrears of Interest (including any Additional Interest Amounts thereon).

5.3 Make-whole Redemption by the Issuer

The Issuer may, subject to the satisfaction of any refinancing conditions to which the redemption is subject and having given not less than ten (10) nor more than seventy-five (75) calendar days' prior notice to the Noteholders in accordance with Condition 10 (*Notices*) (which notice shall (i) specify the date fixed for redemption (such date, the "**Make-whole Redemption Date**")), (ii) specify the refinancing conditions to which the redemption is subject (if any) or (iii) be otherwise irrevocable) redeem in whole, but not in part, the Notes then outstanding at any time (other than (i) during the period from (and including) the First Call Date to (and including) the First Reset Date or (ii) on any subsequent Interest Payment Date) at the Make-whole Redemption Amount (the "**Make-whole Redemption Option**"). The Issuer shall, not less than ten (10) calendar days before the giving of any notice referred to above, notify the Fiscal Agent and the Make-whole Calculation Agent of its decision to exercise the Make-whole Redemption Option. The Make-whole Calculation Agent shall notify the Issuer and the Fiscal Agent, and the Issuer shall notify the Noteholders, of the Make-whole Redemption Amount promptly after the determination thereof. All Notes shall be redeemed on the Make-whole Redemption Date in accordance with this Condition.

The Make-whole Calculation Agent shall act solely as agent of the Issuer and shall not assume any obligation or relationship of agency for, and shall not incur any liability as against, any Noteholder or the Representative. The Issuer will procure that, so long as any Note is outstanding, there shall at all times be a Make-whole Calculation Agent for the purposes of the Notes. If the then prevailing Make-whole Calculation Agent is unable to act (including without limitation in circumstances where limb (C) of the definition of "Reference Price" applies and no quotation of the mid-market price of the Reference Security is capable of being obtained by the Make-whole Calculation Agent from the Reference Dealers) or is unwilling to continue to act as the Make-whole Calculation Agent or if the Make-whole Calculation Agent fails duly to establish the amount due in relation to this Condition 5.3, the Issuer shall appoint some other party (which shall be a leading bank engaged in the Euro interbank market (acting through its principal Eurozone office)) to act as Make-whole Calculation Agent in its place.

All notifications, opinions, determinations, certifications, calculations, quotations and decisions given, expressed, made or obtained for the purposes of this Condition 5.3 by the Make-whole Calculation Agent shall (in the absence of wilful misconduct, fraud, gross negligence or manifest error) be binding on the Issuer, the Noteholders, the Fiscal Agent or the Paying Agent and the Representative.

For the purposes of this Condition, unless the context otherwise requires, the following defined terms shall have the meanings set out below:

"**Benchmark Rate**" means the annual yield to maturity (rounded to the nearest integral multiple of 0.001%, with 0.0005% rounded upwards) of the Reference Security based on the Reference Price, such yield being calculated by the Make-whole Calculation Agent in accordance with applicable market conventions.

"**Calculation Date**" means the third Business Day prior to the Make-whole Redemption Date.

"**Make-whole Margin**" means 0.45 per cent. *per annum*.

"Make-whole Redemption Amount" means, in respect of each Note, an amount in Euro, determined by the Make-whole Calculation Agent, equal to the sum of:

- (i) the greater of (x) the principal amount of such Note (being €100,000) and (y) the sum (rounding the resulting figure, if necessary, to the nearest cent (half a cent being rounded upwards)) of the present values as at the Make-whole Redemption Date of the remaining scheduled payments of principal and interest on such Note (excluding any Arrears of Interest and Additional Interest Amount thereon and any interest accruing on such Note from (and including) the last Interest Payment Date or, as the case may be, the Issue Date, immediately preceding such Make-whole Redemption Date to (but excluding) the Make-whole Redemption Date) up to (and including) the Relevant Date (assuming for this purpose that such Note would otherwise be scheduled to be redeemed on the Relevant Date at 100 per cent. of its principal amount together with any accrued interest), discounted to the Relevant Date on an annual basis (in accordance with applicable market conventions and on a basis which is consistent with the calculation of interest as set out in Condition 4 and, in particular, the Actual/Actual (ICMA) Day Count Fraction) at a rate equal to the Make-whole Redemption Rate; and
- (ii) any interest accrued and any Arrears of Interest (and Additional Interest Amount thereon) but not paid on such Note from (and including) the last Interest Payment Date immediately preceding such Make-whole Redemption Date or, as the case may be, the Issue Date, to (but excluding) the Make-whole Redemption Date.

"Make-whole Redemption Rate" means the sum, as calculated by the Make-whole Calculation Agent, of the Benchmark Rate and the Make-whole Margin.

"Reference Bond" means Obligation Assimilable du Trésor (OAT) of the French Republic (or any other relevant related entity) bearing interest at a rate of 0 per cent. per annum due 25 November 2031, with ISIN FR0014002WK3 or if applicable the relevant Similar Security.

"Reference Dealers" means four banks selected from time to time by the Make-whole Calculation Agent, at its sole discretion, which are primary European government security dealers or market makers in pricing corporate bond issues.

"Reference Dealers Price" means, in respect of any Reference Bond, the average of the four quotations (or such lesser number of quotations (if any) the Make-whole Calculation Agent is capable of obtaining from such Reference Dealers, provided that where the Make-whole Calculation Agent is capable of obtaining only one such quotation from the Reference Dealers, the Reference Dealers Price shall be such quotation) provided by the Reference Dealers for the mid-market price of such Reference Bond as at 11:00 a.m. (Central European Time) on the Business Day immediately following the Calculation Date.

"Reference Price" means the mid-market price (using the pricing source "Bloomberg Generic Price" ("BGN") (or any successor thereto)) for the Reference Security at 11:00 a.m. (Central European Time) on the Calculation Date as appearing on the Calculation Date on Bloomberg page QR (or any successor thereto) in respect of the Reference Security, or (C) if the Reference Price cannot be so determined, the Reference Dealers Price in respect of the Reference Security.

"Reference Security" means (i) if the Make-whole Redemption Date occurs prior to the First Call Date, the euro-denominated Reference Bond (or, if such note is no longer outstanding on the Calculation Date, the Similar Security), or (ii) if the Make-whole Redemption Date occurs after the First Reset Date, the Similar Security.

"Relevant Date" means:

- (i) if the Make-whole Redemption Date occurs prior to the First Call Date: the First Call Date; or
- (ii) if the Make-whole Redemption Date occurs after the First Reset Date: the Interest Payment Date immediately following the Make-whole Redemption Date.

"Similar Security" means any euro-denominated (OAT) of the French Republic outstanding on the Calculation Date that (i) (if there is any relevant market for new issues of corporate debt securities of comparable maturity

to the Relevant Date) would be used, at the time of selection and in accordance with customary financial practice, in pricing new issues of corporate debt securities of comparable maturity to the Relevant Date as aforesaid, or (ii) (where (i) does not apply) has the maturity date falling nearest to the Relevant Date (or, if there is more than one such Reference Bond, the Reference Bond with the shortest maturity date, or if there is more than one such Reference Bond, the Reference Bond which Reference Dealers Price is closest to par), all as determined by the Make-whole Calculation Agent and notified (promptly following such determination) by the Issuer in accordance with Condition 10.

5.4 Redemption for Taxation Reasons

- (i) If, by reason of a change in French law or regulation, or any change in the official application or interpretation of such law or regulation, becoming effective after the Issue Date, the Issuer would, on the occasion of the next payment due in respect of the Notes, not be able to make such payment without having to pay Additional Amounts (as defined in Condition 7 below) (a "**Gross-Up Event**"), the Issuer may, at its sole discretion, at any time, subject to having given not more than seventy-five (75) nor less than ten (10) calendar days' prior notice to the Noteholders (which notice shall be irrevocable), in accordance with Condition 10, redeem the Notes then outstanding in whole, but not in part, at 100 per cent. of their principal amount together with any accrued interest to the date set for redemption and any Arrears of Interest (including any Additional Interest Amounts thereon) provided that the due date for redemption of which notice hereunder may be given shall be no earlier than the latest practicable Interest Payment Date on which the Issuer could make payment of principal and interest without withholding or deduction for French taxes or, if such date has passed, as soon as practicable thereafter.
- (ii) If the Issuer would, on the occasion of the next payment in respect of the Notes, be prevented by French law or regulation from making payment to the Noteholders of the full amount then due and payable, notwithstanding the undertaking to pay additional amounts contained in Condition 7 below (a "**Withholding Tax Event**"), then the Issuer may, at its sole discretion, at any time, subject to having given not less than seven (7) calendar days' prior notice to the Noteholders (which notice shall be irrevocable) in accordance with Condition 10, redeem the Notes then outstanding in whole, but not in part, at 100 per cent. of their principal amount together with any accrued interest to the date set for redemption and any Arrears of Interest (including any Additional Interest Amounts thereon) on the latest practicable date on which the Issuer could make payment of the full amount payable in respect of the Notes without withholding or deduction for French taxes, or, if such date has passed, as soon as practicable thereafter.
- (iii) If an opinion of a recognised law firm of international standing has been delivered to the Issuer and the Fiscal Agent, stating that by reason of a change in French law or regulation, or any change in the official application or interpretation of such law or regulation, becoming effective after the Issue Date, the tax regime of any payments under the Notes is modified and such modification results in the part of the interest payable by the Issuer in respect of the Notes that is tax-deductible being reduced (a "**Tax Deduction Event**"), the Issuer may, at its option, at any time (subject to having given not more than seventy-five (75) nor less than ten (10) calendar days' notice to Noteholders (which notice shall be irrevocable) in accordance with Condition 10), redeem the Notes then outstanding, in whole, but not in part, at (i) 101 per cent. of their principal amount where such redemption occurs prior to the First Call Date, or (ii) 100 per cent. of their principal amount where such redemption occurs on or after the First Call Date, in each case together with any accrued interest and any Arrears of Interest (including any Additional Interest Amounts thereon), provided that the effective date of redemption of which notice hereunder may be given shall be no earlier than the latest practicable date preceding the effective date on which the tax regime of interest payments under the Notes is modified.

5.5 Redemption following an Accounting Event

If an Accounting Event (as defined below) has occurred, the Issuer may, at its sole discretion, redeem the Notes in whole, but not in part, at any time, subject to the Issuer having given the Noteholders not less than ten (10), or more than seventy-five (75), calendar days' prior notice (which notice shall be irrevocable) in accordance with Condition 10, at (i) 101 per cent. of their principal amount where such redemption occurs prior to the First Call Date, or (ii) 100 per cent. of their principal amount where such redemption occurs on or after the First Call Date, in each case together with any accrued interest and any Arrears of Interest (including any Additional Interest Amounts thereon).

"**Accounting Event**" is deemed to have occurred if, on the earlier of:

- (i) the delivery of an opinion of a recognised accountancy firm of international standing to the Issuer and the Fiscal Agent, or
- (ii) the official announcement or adoption or implementation by the relevant body of IFRS (as defined below), (the earlier to occur of (i) or (ii) above being the "**Accounting Event Adoption Date**"),

a change in the accounting rules or methodology (or the application thereof) has occurred after the Issue Date, as a result of which the Notes may not or may no longer, from the implementation date of the relevant new International Financial Reporting Standards, as adopted in the European Union ("**IFRS**") or any other accounting standards that may replace IFRS, be recorded as "equity" in full pursuant to IFRS or any other accounting standards that may replace IFRS for the purposes of the annual, semi-annual or quarterly consolidated financial statements of the Issuer.

For the avoidance of doubt, the Accounting Event shall be deemed to have occurred on the Accounting Event Adoption Date, notwithstanding any later effective date and notwithstanding any transitional period between the Accounting Event Adoption Date and the date on which it comes into effect.

5.6 Redemption following an Equity Credit Rating Event

If an Equity Credit Rating Event has occurred, then the Issuer may, at its option, subject to having given not less than ten (10) nor more than seventy-five (75) calendar days' notice to the Fiscal Agent and, in accordance with Condition 10, the Noteholders (which notice shall be irrevocable), redeem the Notes in whole, but not in part, at any time, at (i) 101 per cent. of their principal amount where such redemption occurs prior to the First Call Date, or (ii) 100 per cent. of their principal amount where such redemption occurs on or after the First Call Date, in each case together with any accrued interest and any Arrears of Interest (including any Additional Interest Amounts thereon), provided that the due date for redemption of which notice hereunder may be given shall be no earlier than the last calendar day before the date on which the Notes are assigned a level of equity credit that is lower than the level or equivalent level of equity credit assigned to the Notes by the relevant Rating Agency on the Issue Date, or if such equity credit was not assigned on the Issue Date, at the date when the equity credit was assigned for the first time.

Equity Credit Rating Event means that the Issuer has received written confirmation from any Rating Agency from whom the Issuer is assigned solicited ratings either directly or via a publication by such agency, that an amendment, clarification or change has occurred in the "equity credit" criteria (or such other nomenclature that the relevant Rating Agency may then use to describe the degree to which an instrument exhibits the characteristics of an ordinary share) of such Rating Agency (as defined below) or the application thereof, effective after the Issue Date (or effective after the date when the equity credit is assigned for the first time, as applicable), which amendment, clarification or change or the application thereof results in (a) a lower equity credit for all or any of the Notes than the then respective equity credit assigned on the Issue Date, or if equity credit is not assigned on the Issue Date, at the date when the equity credit is assigned for the first time (or if the Notes have been partially or fully re-financed after the Issue Date and are no longer eligible for equity credit in part or in full as a result, the Notes would no longer have been eligible as a result of such change in the assessment criteria had they not been re-financed), or (b) the period of time during which the relevant Rating Agency has assigned to the Notes a particular level of "equity credit" being shortened as compared to the period of time for which such Rating Agency did assign to the Notes that level of "equity credit" on the Issue Date, or if such "equity credit" was not assigned on the Issue Date, at the date when the "equity credit" was assigned for the first time.

5.7 Redemption following Substantial Repurchase Event

If a Substantial Repurchase Event has occurred, the Issuer may at its option, at any time, redeem the outstanding Notes in whole, but not in part, at 100 per cent. of their principal amount, subject to the Issuer having given the Noteholders not less than ten (10), or more than seventy-five (75), calendar days' prior notice (which notice shall be irrevocable) in accordance with Condition 10.

Substantial Repurchase Event means that prior to the giving of the relevant notice of redemption, at least 75 per cent. of the initial aggregate principal amount of the Notes issued on the Issue Date has been purchased by or on behalf of the Issuer or a Subsidiary of the Issuer and has been cancelled.

5.8 Redemption following a Change of Control Event

If at any time while any Note remains outstanding, (A) there occurs a Change of Control or a Potential Change of Control (as defined below), and (B) within the Restructuring Period (as defined below), a Rating Event (as defined below) occurs as a result of that Change of Control or, as the case may be, Potential Change of Control (such Rating Event as a result of a Change of Control, or Potential Change of Control, as the case may be, not having been cured prior to the expiry of the Restructuring Period, together, a "**Change of Control Event**"), the Issuer may, at its sole discretion, redeem or procure the purchase of, all but not some only, of the Notes, on the Change of Control Call Date (as defined below) at their principal amount together with (or where purchased, together with an amount equal to) interest accrued (and any Arrears of Interest (including any Additional Interest Amounts thereon)) to, but excluding, the Change of Control Call Date.

Promptly upon the Issuer becoming aware that a Change of Control Event has occurred, the Issuer shall give notice (a "**Change of Control Notice**") to the Noteholders in accordance with Condition 10 specifying the nature of the Change of Control Event and the circumstances giving rise to it and either (i) the date on which redemption or purchase of the Notes (the "**Change of Control Call Date**") will take place or, as the case may be, (ii) the Issuer's election not to redeem, or procure purchase of, the Notes, in which case the Interest Step-Up following a Change of Control Event will apply in accordance with Condition 4.2.

If the Issuer elects to redeem, or to procure purchase of, the Notes, such redemption or purchase will take place not less than ten (10) nor more than sixty (60) calendar days after a Change of Control Notice is given.

Where:

A "**Change of Control**" means descendants of Germain Roquette and Dominique Roquette ceasing, for any reason whatsoever:

- (A) to own, directly or indirectly at least fifty point one per cent. (50.1%) of the issued share capital of the Issuer (excluding any part of that issued share capital that carries no right to participate beyond a specified amount in a distribution of either profits of capital);
- (B) to hold the power to cast or control the casting of more than 50 per cent. of the maximum number of votes capable of being cast at a general meeting of the Issuer; or
- (C) to have the power to appoint or remove more than half of the directors or other equivalent officers of the Issuer.

A "**Potential Change of Control**" means any public announcement or statement by the Issuer, or by any actual or potential bidder(s) relating to any potential Change of Control of the Issuer.

"**Rating Agency**" means S&P Global Ratings Europe Limited and its successors or any other rating agency of equivalent standing notified by the Issuer to the Noteholders in accordance with Condition 10.

A "**Rating Event**" shall be deemed to have occurred in respect of a Change of Control or a Potential Change of Control, as the case may be, if, within the Restructuring Period, (A) the rating previously assigned to the Notes or to the Issuer by any Rating Agency solicited by the Issuer is (x) withdrawn or (y) changed from an investment grade rating (BBB- or its equivalent for the time being, or better) to a non-investment grade rating (BB+ or its equivalent for the time being, or worse) or (z) (if the rating previously assigned to the Notes or to the Issuer by any Rating Agency solicited by the Issuer was below an investment grade rating (as described above)), lowered by at least one full rating notch (for example, from BB+ to BB, or their respective equivalents) and (B) such rating is not within the Restructuring Period subsequently upgraded (in the case of a downgrade) or reinstated (in the case of a withdrawal) either to an investment grade credit rating (in the case of (x) and (y)) or to its earlier credit rating or better (in the case of (z)) by such Rating Agency, provided that the Rating Agency making the reduction in rating shall announce or publicly confirm or, having been so requested by the Issuer, inform the

Issuer and the Fiscal Agent in writing that the lowering was the result, in whole or in part, of the applicable Change of Control or Potential Change of Control.

If the Notes are rated by more than one Rating Agency and such rating has been solicited by the Issuer, the rating to be taken into account to determine whether a Rating Downgrade has occurred shall be the lower rating assigned by any such Rating Agency.

If the Notes cease at any time to have a rating assigned to them by at least one Rating Agency, the Issuer shall use its best endeavours to obtain a rating of the Notes from another Rating Agency as soon as practicable. For the avoidance of doubt, if at the time of the occurrence of a Change of Control or a Potential Change of Control the Notes are not rated by a Rating Agency, and no Rating Agency assigns within the Restructuring Period an investment grade rating to the Notes, a Change of Control Event will be deemed to have occurred.

"Restructuring Period" means the period beginning one hundred and twenty (120) days prior to, and ending, one hundred and twenty (120) days after the date of the public announcement by the Issuer, any bidder or any designated advisor, of the completion of the relevant Change of Control (or such longer period for which the Notes or the senior unsecured long term debt of the Issuer are under consideration (such consideration having been announced publicly within the period ending one hundred twenty (120) days after the occurrence of the relevant Change of Control) for rating review or, as the case may be, for rating by, a Rating Agency, such period not to exceed sixty (60) days after the public announcement of such consideration).

5.9 Purchases

The Issuer may, at any time, purchase the Notes together with rights to interest and any other amounts relating thereto in the open market or otherwise (including by way of tender or exchange offers) at any price, subject to applicable laws and regulations.

All Notes so purchased by, or for the account of, the Issuer, may, at its sole discretion, be held and resold or cancelled in accordance with applicable laws and regulations.

5.10 Cancellation

All Notes which are purchased by the Issuer pursuant to this Condition 5 may be cancelled or held (together with rights to interest and any other amounts relating thereto) in accordance with applicable laws and regulations. Any Notes so cancelled may not be reissued or resold and the obligations of the Issuer in respect of any such Notes shall be discharged.

6. Payments

6.1 Method of Payment

Payments of principal and interest (including, for the avoidance of doubt, any Arrears of Interest and Additional Interest Amounts) in respect of the Notes will be made in euro by credit or transfer to a euro-denominated account (or any other account to which euro may be credited or transferred) specified by the payee in a city in which banks have access to T2.

Where:

"T2" means the real time gross settlement system operated by the Eurosystem or any successor or replacement for that system.

Such payments shall be made for the benefit of the Noteholders to the Account Holders and all payments validly made to such Account Holders in favour of the Noteholders will be an effective discharge of the liability of the Issuer and the Paying Agents, as the case may be, in respect of such payments.

Payments of principal and interest on the Notes will, in all cases, be subject to any fiscal or other laws and regulations applicable thereto in the place of payment but without prejudice to the provisions of Condition 7.

6.2 Payments on Business Days

If any due date for payment of principal or interest in respect of any Note is not a Business Day (as defined below), then the Noteholder thereof shall not be entitled to payment of the amount due until the next following day which is a Business Day and the Noteholder shall not be entitled to any interest or other sums in respect of such postponed payment. No commission or expenses shall be charged to the Noteholders in respect of such payments.

"**Business Day**" means any day, not being a Saturday or a Sunday, on which the T2 is operating and on which Euroclear France is open for general business.

6.3 Fiscal Agent, Paying Agent, Calculation Agent and Make-whole Calculation Agent

The names of the initial Agents and their specified offices are set out below:

BNP PARIBAS
(acting through its Securities Services business)
9, rue du Débarcadère
93500 Pantin
France

The Issuer reserves the right at any time to vary or terminate the appointment of the Fiscal Agent, Principal Paying Agent, Paying Agent or the Make-whole Calculation Agent and/or appoint additional or other Paying Agents or the Make-whole Calculation Agent or approve any change in the office through which any such Agent acts, provided that there will at all times be a Fiscal Agent, a Principal Paying Agent, a Calculation Agent and a Make-whole Calculation Agent having a specified office in a European city.

Notice of any termination or appointment and of any changes in specified offices shall be given to the Noteholders promptly by or on behalf of the Issuer in accordance with Condition 10 (*Notices*).

7. Taxation

(a) Withholding Tax

All payments of principal, interest or other revenues by or on behalf of the Issuer in respect of the Notes shall be made free and clear of, and without withholding or deduction for, any taxes, or duties of whatever nature imposed, levied or collected by or on behalf of France or any authority therein or thereof having power to tax, unless such withholding or deduction is required by law.

(b) Additional Amounts

If, pursuant to French laws or regulations, payments of principal, interest or other revenues in respect of any Note become subject to deduction or withholding in respect of any present or future taxes, duties, assessments or other governmental charges of whatever nature imposed, levied, collected, withheld or assessed by or on behalf of the Republic of France or any authority therein or thereof having power to tax, the Issuer shall, to the fullest extent then permitted by law, pay such additional amounts (the "**Additional Amounts**") as may be necessary in order that the holder of each Note, after such deduction or withholding, will receive the full amount then due and payable thereon in the absence of such deduction or withholding; provided, however, that the Issuer shall not be liable to pay any such Additional Amounts in respect of any Note to, or to a third party on behalf of, a Noteholder who is liable to such taxes, duties, assessments or governmental charges in respect of such Note by reason of his having some connection with the Republic of France other than the mere holding of such Note.

Any references in these Conditions to principal, interest and other revenues shall be deemed also to refer to any Additional Amounts which may be payable under the provisions of this Condition 7.

8. Enforcement events, no events of default and no cross default

There are no events of default in respect of the Notes. There is no cross default under the Notes.

However, each Note shall become immediately due and payable at its principal amount, together with accrued interest thereon, if any, to the date of payment and any Arrears of Interest (including any Additional Interest Amounts thereon), in the event that a judgement is rendered by any competent court declaring the judicial liquidation (*liquidation judiciaire*) of the Issuer, or in the event of a transfer of the whole of the business of the Issuer (*cession totale de l'entreprise*) subsequent to the opening of a judicial recovery procedure (*redressement judiciaire*) or in the event of a voluntary dissolution of the Issuer or if the Issuer is liquidated for any other reason (and in all cases listed above, other than pursuant to a consolidation, amalgamation or merger or other reorganisation outside the context of an insolvency whereby the surviving entity assumes all obligations of the Issuer under the Notes). No payments will be made to holders of Junior Securities before all amounts due, but unpaid, to all Noteholders have been paid by the Issuer.

9. Representation of the Noteholders

The Noteholders will be grouped automatically for the defense of their respective common interests in a *masse* (hereinafter referred to as the "**Masse**").

The *Masse* will be governed by the provisions of the French *Code de commerce* applicable to the *Masse*, and with the exception of Articles L.228-48, L.228-59, L.228-65 I 1°, 3° and 4°, L.228-71, R.228-63, R.228-67 and R.228-69 of the French *Code de commerce* subject to the following provisions:

(a) Legal Personality:

The *Masse* will be a separate legal entity and will act in part through a representative (the "**Representative**") and in part through collective decisions of the Noteholders (the "**Collective Decisions**").

The *Masse* alone, to the exclusion of all individual Noteholders, shall exercise the common rights, actions and benefits which now or in the future may accrue respectively with respect to the Notes.

(b) Representative of the Masse

The following person is designated as Representative of the *Masse*:

DIIS Group
12 rue Vivienne
75002 Paris
France
Email: rmo@diisgroup.com

The Representative shall be entitled to an annual remuneration of €400 (excluding taxes) payable upfront at the Issue Date.

In the event of liquidation, dissolution, death, retirement, resignation or revocation of appointment of the Representative, another Representative will be elected by a Collective Decision of Noteholders.

(c) Powers of the Representative

The Representative shall (in the absence of any Collective Decision to the contrary) have the power to take all acts of management necessary in order to defend the common interests of the Noteholders.

All legal proceedings against the Noteholders or initiated by them, must be brought by or against the Representative, and any legal proceedings which shall not be brought in accordance with this provision shall not be legally valid.

The Representative may not interfere in the management of the affairs of the Issuer.

(d) Collective Decisions

Collective Decisions are adopted either in a general meeting (a "**General Meeting**") or by consent following a written consultation (the "**Written Resolution**").

In accordance with Article R.228-71 of the French *Code de commerce*, the rights of each Noteholder to participate in Collective Decisions will be evidenced by the entries in the books of the relevant Account Holder of the name of such Noteholder on the second business day in Paris preceding the date set for the Collective Decision at 0:00, Paris time.

The Issuer shall hold a register of the Collective Decisions and shall make it available, upon request, to any subsequent Noteholder.

(i) General Meeting

A General Meeting may be held at any time, on convocation either by the Issuer or by the Representative. One or more Noteholders, holding together at least one-thirtieth (1/3) of the principal amount of the Notes outstanding, may address to the Issuer and the Representative a demand for convocation of the General Meeting, together with the proposed agenda for such General Meeting. If such General Meeting has not been convened within two (2) months after such demand, the Noteholders may commission one of their members to petition a competent court in Paris to appoint an agent (*mandataire*) who will call the General Meeting.

Notice of the date, time, place and agenda of any General Meeting will be published as provided under Condition 10 (*Notices*) not less than fifteen (15) days prior to the date of such General Meeting on first convocation, and five (5) days on second convocation.

(ii) Powers of the General Meetings

The General Meeting is empowered to deliberate on the dismissal and replacement of the Representative and may also act with respect to any other matter that relates to the common rights, actions and benefits which now or in the future may accrue with respect to the Notes, including authorising the Representative to act at law as plaintiff or defendant.

General Meetings may deliberate validly on first convocation only if Noteholders present or represented hold at least a fifth of the principal amount of the Notes then outstanding. On second convocation, no quorum shall be required. Decisions of the General Meetings shall be taken by a two-third (2/3) majority of votes cast by Noteholders attending such General Meetings or represented thereat. The votes cast shall not include votes attaching to notes in respect of which the holders of Notes have not taken part in the vote or have abstained or have returned a blank or spoilt ballot paper.

(iii) Written Resolutions

Pursuant to Article L.228-46-1 of the French *Code de commerce*, the Issuer shall be entitled in lieu of the holding of a General Meeting to seek approval of a resolution from the Noteholders by way of a Written Resolution. Subject to the following sentence a Written Resolution may be contained in one document or in several documents in like form, each signed by or on behalf of one or more of the Noteholders. Pursuant to Articles L.228-46-1 and R.225-97 of the French *Code de commerce* approval of a Written Resolution may also be given by way of electronic communication allowing the identification of Noteholders ("**Electronic Consent**").

Notice seeking the approval of a Written Resolution (including by way of Electronic Consent) will be published as provided under Condition 10 (*Notices*) not less than 15 calendar days prior to the date fixed for the passing of such Written Resolution (the "**Written Resolution Date**"). Notices seeking the approval of a Written Resolution will contain the conditions of form and time-limits to be complied with by the Noteholders who wish to express their approval or rejection of such proposed Written Resolution. Noteholders expressing their approval or rejection before the Written Resolution Date will undertake not to dispose of their Notes until after the Written Resolution Date.

For the purpose hereof, a "**Written Resolution**" means a resolution in writing signed by the Noteholders of not less than 75 per cent. in nominal amount of the Notes outstanding.

(e) Exclusion of certain provisions of the French *Code de commerce*

The provisions of Article L.228-65 I. 1° and 4° of the French *Code de commerce* respectively providing for a prior approval by the General Meeting of the Noteholders of any change in corporate purpose or form of the Issuer or of an issue of Notes benefiting from a security (*sûreté réelle*) and the related provisions of the French *Code de commerce* shall not apply to the Notes.

The provisions of Article L.228-65 I. 3° of the French *Code de commerce* providing for a prior approval of the Noteholders in relation to any proposal to merge or demerge the Issuer in the cases referred to in Articles L.236-14 and L.236-23 of the French *Code de commerce* shall not apply to the Notes to the extent that such proposal relates to a merger or demerger within the Group.

(f) Information to Noteholders

Each Noteholder or Representative thereof will have the right, during the 15-day period preceding the General Meeting on first convocation or the Written Resolution Date and during the 5-day period preceding the holding of the General Meeting on second convocation, to consult or make a copy of the text of the resolutions which will be proposed and of the reports which will be prepared in connection with such resolutions, all of which will be available for inspection by the relevant Noteholders at the registered office of the Issuer, at the specified offices of any of the Paying Agents and at any other place specified in the notice of the Collective Decision.

(g) Expenses

The Issuer will pay all reasonable expenses relating to the operation of the *Masse*, including expenses relating to the calling and holding of General Meetings and seeking of a Written Resolution and, more generally, all administrative expenses resolved upon by the General Meeting or in writing by the Noteholders, it being expressly stipulated that no expenses may be imputed against interest payable under the Notes.

(h) Notice of Decisions

Collective Decisions shall be published in accordance with the provisions set out in Condition 10 (*Notices*) not more than 90 calendar days from the date thereof.

For the avoidance of doubt, "**outstanding**" shall not include those Notes subscribed or purchased by the Issuer that are held and not cancelled pursuant to Article L.213-0-1 of the French *Code monétaire et financier*.

10. Notices

Any notice to the Noteholders will be valid if delivered to the Noteholders through Euroclear France, Euroclear or Clearstream, for so long as the Notes are cleared through such clearing systems and published on the website of the Issuer (<https://www.roquette.com>); and so long as the Notes are admitted to trading on Euronext Paris and the rules of Euronext Paris so require, on the website of Euronext Paris (www.euronext.fr). Any such notice shall be deemed to have been given on the date of delivery of such notice to Euroclear France, Euroclear or Clearstream or, if delivered more than once or on different dates, on the first date on which such delivery is made, and if later, on the date of such publication on the website of the Issuer.

11. Prescription

Claims against the Issuer for the payment of principal and interest in respect of the Notes shall be prescribed and become void unless made within ten (10) years (in the case of principal) and five (5) years (in the case of interest) from the due date for payment thereof.

12. Further issues

The Issuer may, from time to time without the consent of the Noteholders, issue further notes to be assimilated (*assimilables*) with the Notes as regards their financial service, provided that such further notes and the Notes shall carry rights identical in all respects (or in all respects except for the issue price and the first payment of interest thereon) and that the terms of such further notes shall provide for such assimilation. In the event of such assimilation, the Noteholders and the holders of any assimilated notes will, for the defense of their common interests, be grouped in a single Masse having legal personality. References in these Conditions to the Notes include any other notes issued pursuant to this Condition and assimilated with the Notes.

13. Governing law and jurisdiction

The Notes are governed by, and shall be construed in accordance with, the laws of France.

Any claim against the Issuer in connection with any Notes shall be brought (subject to mandatory provisions relating to territorial jurisdiction of French courts) before the *Tribunal des Activités Economiques (Tribunal de commerce) de Paris*.

The following paragraphs in italics do not form part of the Terms and Conditions of the Notes.

The Issuer intends (without thereby assuming a legal or contractual obligation), that it will redeem or repurchase the Notes (or any part thereof) only to the extent that such part of the aggregate principal amount of the Notes (or any part thereof) to be redeemed or repurchased which was assigned "equity credit" (or such similar nomenclature used by a Rating Agency from time to time) at the time of the issuance of the Notes does not exceed such part of the net proceeds received by the Issuer or any Subsidiary of the Issuer on or prior to the date of such redemption or repurchase from the sale or issuance of securities by the Issuer or such Subsidiary to third party purchasers (other than group entities of the Issuer) which are assigned by a Rating Agency, as the case may be, an aggregate "equity credit" (or such similar nomenclature used by a Rating Agency from time to time) that is equal to or greater than the "equity credit" assigned to the relevant Notes (or any part thereof) to be redeemed or repurchased at the time of the sale or issuance of such securities (but taking into account any changes in hybrid capital methodology or another relevant methodology or the interpretation thereof since the issuance of the Notes), unless:

- (i) the long-term corporate credit rating (or such similar nomenclature then used by S&P) assigned by S&P to the Issuer is the same as or higher than the long-term corporate credit rating assigned to the Issuer on the date of the last additional hybrid issuance (excluding refinancing without net new issuance) and the Issuer is of the view that such a rating would not fall below this level as a result of such redemption or repurchase; or*
- (ii) in the case of repurchase or redemption, taken together with other relevant repurchases or redemptions of hybrid securities of the Issuer, such repurchase or redemption is of less than (i) 10 per cent. of the aggregate hybrid capital outstanding in any period of 12 consecutive months or (ii) 25 per cent. of the aggregate hybrid capital outstanding in any period of 10 consecutive years; or*
- (iii) if, in the case of a repurchase or a redemption, such repurchase or redemption is in an amount necessary to allow the Issuer's aggregate amount of hybrid capital remaining outstanding after such repurchase or redemption to remain below the maximum aggregate principal amount of hybrid capital to which a Rating Agency would assign equity content under its prevailing methodology; or*
- (iv) the Notes are redeemed pursuant to an Equity Credit Rating Event, an Accounting Event, a Tax Deduction Event, a Withholding Tax Event, a Gross-Up Event, a Change of Control Event or a Substantial Repurchase Event; or*
- (v) the Notes are not assigned an "equity credit" by S&P (or such similar nomenclature then used by S&P) at the time of such redemption or repurchase; or*
- (vi) such redemption or repurchase occurs on or after the Second Step-Up Date.*

Terms used but not defined in the above paragraphs shall have the same meaning as that in the Conditions.

USE OF PROCEEDS

The estimated net proceeds of the issue of the Notes are expected to amount to €596,640,000. The Issuer intends to use the net proceeds for general corporate purposes.

DESCRIPTION OF THE ISSUER

1. GENERAL INFORMATION ABOUT THE ISSUER

1.1 LEGAL INFORMATION

The legal and commercial name of the Issuer is Roquette Frères (referred to herein as "**Roquette**" or the "**Issuer**").

The Issuer is a French limited liability company (*société anonyme*) governed by laws and regulations applicable to commercial companies in France.

The Issuer was formed on 1 November 1933 for a period of 99 years, i.e. until 31 October 2032, except in the event of extension or early dissolution. The fiscal year of the Issuer begins on 1 January and ends on 31 December of each year.

The Issuer is registered with the Arras Register of Commerce and Companies under reference number 357 200 054. The Issuer's registered office is located 1, rue de la Haute Loge, 62136 Lestrem, France. The telephone number of its registered office is: +33 3 21 63 36 00. The legal entity identifier ("**LEI**") of the Issuer is 969500FO141C5967KC72.

The information available on the website of the Issuer (<https://www.roquette.com>) does not form part of this Prospectus unless that information is incorporated by reference into the Prospectus and it has not been scrutinised or approved by the AMF.

1.2 HISTORY AND DEVELOPMENT

Roquette is the ultimate holding company of the Group, a privately held, family-owned, French based, world-class manufacturer of plant-based ingredients and pharmaceutical excipients for the health and nutrition sectors.

Founded in 1933, by two brothers, Dominique and Germain Roquette, the Group currently serves clients in over 150 countries, through more than 40 industrial sites across Europe, the Americas, and Asia and processes more than six million tonnes each year of agricultural raw materials (including corn, wheat, potato, pea, seaweed and cellulose) to craft high-performance ingredients used in everyday foods, oral medications, advanced biopharmaceuticals, and a range of bio-based products.

1.2.1 Key dates in Roquette's history


1933	Dominique and Germain Roquette opened the Issuer's first potato starch factory, for application on textile and in breweries.
1946	Roquette started the production of corn starch for applications including paper and board.
1954	Roquette started producing sorbitol, a sugar-free sweetener which we continue to find in everyday products including chewing gum and toothpaste.
1956	Construction of a potato starch factory in Vecquemont, France.
1957	Roquette started its expansion in Europe and became a shareholder of Levantina Agrícola Industrial, S.A. (LAISA) in Benifaió, Spain, eventually becoming the majority shareholder in 1970.

1962	Roquette inaugurated its site in Cassano, Italy.
1967	Roquette started the production of maltodextrins, notably for sports drinks and for infant milk.
1970s	Roquette enters the pharmaceutical market with its Lycadex PF (apyrogenic dextrose monohydrate) for excipients.
1978	Roquette enters the United States of America with the opening of its first American office in New York City.
1986	Roquette started the production of wheat starch for bakery and snacks.
2001	Roquette enters Asia with the creation of its site in Lianyungang, China.
2005	Inauguration of the first pea protein plant in Vic-sur-Aisne, France, opening its doors to plant-based meat and fish alternatives, enabling a whole new plant-based cuisine.
2006	Roquette expands in Asia with a 14.9% shareholding in Riddhi Siddhi Gluco Biols Ltd, eventually becoming the sole shareholder in 2014.
2017	Roquette reinforced its cellulose-based excipients offering to customers through sites in India and Brazil dedicated to cellulose, thanks to its acquisition of Itacel.
2021	Roquette opened a brand-new pea-protein manufacturing site in Portage la Prairie, Canada. This manufacturing site gives Roquette the largest pea protein supply in the world.
2023	Roquette acquired Qualicaps, allowing Roquette's Pharma offering to be expanded to include hard capsules.
2025	Roquette acquired IFF Pharma Solutions from International Flavors and Fragrances, Inc. ("IFF") to strengthen its position in the pharmaceutical excipients market.

1.2.2 Evolution and development of Roquette's manufacturing and R&D sites

The Group operates more than 40 industrial sites and 20 R&D sites and Innovation centres.

The recent acquisition of IFF Pharma Solutions from International Flavors and Fragrances, Inc. is a strategic expansion made by Roquette to become the pharmaceutical industry's go-to partner for the development of drug delivery solutions that contribute to improving, sustaining, and saving patients' lives.



1.2.2.1 Europe

Lestrem, France

Roquette was founded in 1933 in Lestrem in the north of France by Dominique and Germain Roquette. Its only initial raw material was potato, with wheat and corn added in the 1940s. The factory discontinued the use of potato as a raw material in 1956 with the opening of its site in Vecquemont, France.

Between 2020 and 2023, the Group undertook works in the water treatment plant in Lestrem, France, to improve its operational efficiency (it has a treatment capacity equivalent to that of a city of 700,000 inhabitants) and to reduce its environmental impact.

In 2022 and 2023, Roquette invested in its site in Lestrem, France, to (i) strengthen its position in the polyols market and (ii) open a Food Innovation Centre to provide formulators with a large range of capabilities, including technical and R&D support, cutting-edge equipment, labs and scale-up testing. The goal of this Centre is to foster innovation and accelerate the go-to-market of new products. With an investment of €4.5 million, the new Centre is a key part of the Group's R&D global network.

Today, the site covers 150 hectares, two departments and three towns. It employs approximately 2,800 employees in 57 production workshops and 50 packaging facilities. The site produces starches, dextrin, maltodextrins, dextrose, glucose syrups, polyols, proteins, fibres and corn oil for all Roquette's markets.

Vecquemont, France

In 1956, Roquette constructed a potato starch factory in Vecquemont, in the north of France.

Today the site is the Group's sole potato starch factory, and it employs around 125 permanent employees. The site produces starches, proteins and fibres for many of Roquette's markets.

Benifaió, Spain

In 1957, Roquette started its international expansion and became a shareholder of Levantina Agrícola Industrial, S.A. (LAISA), eventually becoming the majority shareholder in 1970.

Today, the site employs approximately 245 employees, and from its corn raw material, it produces starches, dextrose, glucose and isoglucose for the Spanish and Portuguese markets.

Cassano, Italy

Roquette's site in Cassano, Italy was inaugurated in 1962.

Today, the site employs approximately 450 employees and transforms corn into starches, dextrose, glucose syrups, fibres, proteins, and oils for health and nutrition markets. It also produces fermentation products (gluconates and biosuccinic acid).

Beinheim, France

The site in Beinheim, in the east of France, was constructed in 1975, and today employs approximately 250 employees. From its corn and wheat raw materials, it produces starches, glucose syrups, proteins, fibres and gluten, as well as bioethanol, for several of the company's end markets.

Since 2016, the Beinheim site has been operated by a geothermal power unit and a biomass boiler, which provide more than two-thirds of its heating needs.

Vic-Sur-Aisne, France

In 1989, Roquette acquired its facility in Vic-Sur-Aisne, France.

This site became in 2005 the first pea protein plant of Roquette, opening the way to plant-based meat and fish alternatives, enabling a whole new plant-based cuisine.

In 2017, Roquette announced a significant investment of €40 million in its Vic-sur-Aisne facility to increase its pea processing capacity and respond to a fast-growing global demand for pea protein. These investments add to a €40 million invested in the Vic-sur-Aisne's facility in 2015, and they mark a strong acceleration of the Group's pea business line to serve an increasing global demand.

In 2023, Roquette launched a flagship project in Vic-sur-Aisne, France to reuse evaporation condensate in the steam production system. The heat recovered reduces both the water and natural gas consumption at this site.

Today, the site employs around 130 employees and produces pea starch, proteins and fibres for nutrition markets. The site also has a plant-based protein R&D centre.

Panevėžys, Lithuania

In 2011, Roquette started a partnership with Lithuanian manufacturer Amilina, which became part of the Group in 2014.

In 2019, Roquette, guided by its drive for innovation and its long-term vision, opened a new R&D laboratory in Panevezys, Lithuania, strengthening its position in Northern Europe to better address industrial, nutrition and health challenges. Three times as big as the previous premises, the state-of-the-art facilities guarantee highest-quality goods and

services for the clients, along with improved productivity, sustainability and working conditions for its employees, thus creating a safe and ethical working environment.

The labs in Panevezys provide benefits for customers, academia, the local economy and society and consumers at large.

Today, this site produces starches, glucose syrups proteins and fibres from wheat and has an R&D centre of analytical and pilot labs. It employs around 340 employees.

Horst, the Netherlands

In 2018, Roquette announced the acquisition of an extrusion unit from Texpall B.V. in The Netherlands. With this acquisition, the Group wants to expand its range of premium textured plant-based ingredients for the global meat alternatives market.

Located in the Netherlands, the facility acquired from Texpall B.V. benefits from a significant expertise in extrusion of plant-based proteins, especially pulse proteins. The site employs around 30 employees.

This facility reinforces Roquette's position as a pioneer in specialty plant-based proteins for nutrition and health markets.

Merville, France

After enjoying two successful joint ventures in France and in China with Sethness Products Company, a family business founded in the United States in 1880, Roquette completed the acquisition of Sethness Products Company (Roquette Sethness) in 2018. Operations and businesses of Roquette and Roquette Sethness are run independently.

Sethness Roquette is a global leader in caramels, and it employs around 280 employees in four sites. One of them is in Merville, France.

Saint-Denis, France

In 2020, Roquette opened a 'Roquette Beauté Expertise Centre' in Saint-Denis, near Paris, in France. The site employs around 10 people.

Madrid, Spain

In October 2023, Roquette announced the completion of the acquisition of Qualicaps from the Mitsubishi Chemical Group. The Qualicaps site in Madrid produces gelatine and hydroxypropyl methylcellulose (HPMC) capsules for pharmaceutical uses. The site employs around 260 employees.

Odorheiu / Bucharest / Cornu, Romania

As part of the mentioned acquisition of Qualicaps, three Qualicaps sites in Romania were added to Roquette's global footprint; these plants produce equipment for hard gel capsules (Odorheiu, around 60 employees), gelatine capsules (Bucharest, around 200 employees) and equipment for soft get capsules (Cornu, around 130 employees), the three of them serving pharmaceutical markets. The following European sites are part of the IFF Pharma Solutions acquisition, completed in May 2025:

Bomlitz, Germany

This site is also an innovation center and pilot plant for cellulose and alginates. It employs around 150 people.

Stade, Germany

Producing Methocel™ from Pulp, Caustic, Propylene Oxide, Methyl Chloride, this site employs around 100 people.

Cork, Ireland

With around 100 employees, this site produces Avicel® Microcrystalline Cellulose and Ac-Di-Sol® Croscarmellose Sodium

Sandvika, Norway

This site produces ultra-pure medical grade sodium alginate. It employs around 15 people.

Haugesund, Norway

This site produces alginates for pharma and food from fresh and dry seaweed. It employs around 120 people.

Reykholar, Iceland

A joint venture with Thorverk, this site produces dried seaweed.

1.2.2.2 Americas

Gurnee, USA

After establishing an office in New York City in 1978, Roquette rapidly expanded its footprint in the United States of America with the construction of a sorbitol plant in Gurnee, Illinois, in 1982.

Today, the Gurnee site employs approximately 40 employees and produces polyols (sorbitol, maltitol and xylitol) from the glucose delivered from Roquette's Keokuk, Iowa, site.

Keokuk, USA

In 1991, Roquette acquired a Hubinger Co. Corn wet-milling plant in Keokuk, Iowa.

Today, the site employs around 450 employees and produces starches, glucose syrups, polyols (sorbitol, mannitol and maltitol), proteins and fibres from corn. All these ingredients serve many of the Roquette's end markets.

Geneva, Illinois, USA

In 2011, Roquette opened an Innovation Centre in Geneva, Illinois, to further support its clients by developing and offering adapted solutions to their needs. The site employs today around 100 people, including office staff and remote sales teams. In September 2025, Roquette opened a Customer Technical Services (CTS) Application Lab in Geneva, Illinois, USA dedicated to agriscience.

Itapevi, Brazil

In 2017, Roquette announced the completion of the acquisition of Itacel, a leading player in the pharmaceutical excipients market in Brazil and Latin America. Today, its Itapevi site employs approximately 300 employees and produces microcrystalline cellulose, croscarmellose sodium and sodium starch glycolate from cellulose, corn starch and potato starch.

Clinton, Iowa, USA

After enjoying two successful joint ventures in France and in China with Sethness Products Company, a family business founded in the United States in 1880, Roquette completed the acquisition of Sethness Products Company (**Roquette Sethness**) in 2018. Operations and businesses of Roquette and Roquette Sethness are run independently.

Sethness Roquette is a global leader in caramels, and it employs around 280 employees in four sites. One of them is in Clinton, Iowa, USA.

Portage la Prairie, Canada

In 2021, Roquette opened a brand-new pea protein manufacturing site. This manufacturing site is the largest pea protein production facility in the world and is located alongside some of the world's best experts in developing new plant-based foods.

Today, the site employs around 120 people and produces starches, proteins and fibres.

In June 2024, to reinforce Roquette's world class capabilities in plant protein solutions the Group announced the introduction of the fava bean as a new botanical, non-allergen raw material for its plant protein solutions.

Lower Gwynedd Township, Pennsylvania, USA (Philadelphia)

In April 2023, Roquette opened its new Pharmaceutical Innovation Centre, located near Philadelphia, Pennsylvania, right in the heart of the United States' Northeastern pharmaceutical corridor. Staffed with a team of highly skilled research, application and formulation experts, the new centre is an advanced training and collaboration hub for pharmaceutical and nutraceutical manufacturers around the world. With a focus on optimising patient experience with next-generation oral dosage forms, the US facility complements the cutting-edge research activities of Roquette's existing pharma innovation centres in France and Singapore. This site employs around 25 employees, including office staff.

Windsor, Canada

In October 2023, Roquette announced the completion of the acquisition of Qualicaps from the Mitsubishi Chemical Group. The Qualicaps site in Windsor, Canada assembles capsule equipment. The site employs around 25 employees.

Whitsett, USA

In October 2023, Roquette announced the completion of the acquisition of Qualicaps from the Mitsubishi Chemical Group. The Qualicaps site in Whitsett, USA, produces capsules from gelatine. The site employs around 110 employees. At the end of 2025, it was announced that the Group had taken the decision to close this site in 2026. It will gradually ramp-down activity through 2026 and the plant will cease operations by end of 2026.

Anapolis, Goias, Brazil

In October 2023, Roquette announced the completion of the acquisition of Qualicaps from the Mitsubishi Chemical Group. The Qualicaps site in Anapolis, Brazil, produces capsules from gelatine. The site employs around 260 employees.

The following Americas sites are part of the IFF Pharma Solutions acquisition, completed in May 2025:

Castelo Branco, Brazil

This site currently employs 25 people. In October 2025, Roquette announced the opening of a Pharmaceutical Innovation Center to strengthen Latin America as a collaborative hub for health and pharma solutions.

Newark, Delaware, USA

Producing Avicel®, Ac-Di-Sol®, Aquacoat® from a variety of raw materials, this site employs around 125 people.

Wilmington, Delaware, USA

Employing around 90 people, including office and remote staff, this is the North American Application and Development Centre.

Plaquemine, Louisiana, USA

This site of around 50 people produces METHOCEL™ Hydroxypropyl Methylcellulose (HPMC) from Cellulose Pulp, Methyl Chloride, Propylene Oxide and Caustic.

Institute, West Virginia, USA

A site of around 50 people, producing POLYOX™ Polyethylene Oxide.

Midland/Larkin, Michigan, USA

From cellulose pulp, these sites employ around 260 people and they produce METHOCEL™ - Methylcellulose (MC) and Hydroxypropyl Methylcellulose (HPMC) and ETHOCEL™ - Ethylcellulose

They are also R&D and Innovation centres.

1.2.2.3 Asia

Lianyungang, China

Roquette's expansion into Asia began in the early 21st century, with the creation of its site in Lianyungang, China in 2001, which has constantly evolved to get closer to markets and customers. As such, it transitioned from being a product manufacturer to a high-quality solution provider, making Roquette in China a reference in the food and nutrition market.

In 2019, the plant was selected as the leading pilot for upgrading traditional manufacturers to "Intelligent and green enterprises" by both the Ministry of Industry and Information Technology of the People Republic of China and the Ministry of Economics and Finance of France.

In 2020, the site was certified as "Green Manufacturer" by the China Starch Industry Association, to recognise Roquette's project for power and centralized heating.

Today, the site employs approximately 500 employees, and it produces starches, maltodextrins, dextrose, glucose syrups, polyols (sorbitol and maltitol), proteins and fibres from corn.

Wuhan and Nanning, China

Additionally, Roquette has two other manufacturing sites in China, in Wuhan and Nanning, each employing around 120 employees.

Gokak (Karnataka), Pantnagar (Uttarakhand), Viramgam (Gujarat) and Ahmedabad (Gujarat), India

In 2006, Roquette took a 14.9% shareholding in Riddhi Siddhi Gluco Biols Ltd and established a strategic alliance with this family-owned company.

In June 2012, Roquette announced the acquisition of the three starch production sites of Riddhi Siddhi Gluco Biols Ltd by taking the majority share in the new company called "Roquette - Riddhi Siddhi", headquartered in Ahmedabad (Gujarat).

In 2014, Roquette acquired 100% of Roquette - Riddhi Siddhi.

In 2018, the country headquarters relocated to Mumbai, India, where it currently employs around 100 people, including the staff of a Food Innovation Centre.

These three Roquette's production sites in India produce starches, maltodextrins, glucose syrups, dextrose, proteins and fibres from corn. Gokak and Pantnagar's sites each employ around 400 employees, with Viramgam's site employing approximately 200 employees.

Roquette presence remains in Ahmedabad, through its activities with Sethness Roquette. Acquired in 2018, Sethness Roquette is a global leader in caramels, and it employs around 280 employees in four sites. One of them is in Ahmedabad, India.

Singapore

In 2017, Roquette opened new offices and an innovation centre in Singapore, increasing its focus on Asia's nutrition and health challenges. In 2019, the site was expanded to include a Food Customer Technical Service (CTS) Centre. The Singapore site employs around 80 people, including office staff.

In June 2023, Roquette opened its new Customer Experience Centre in Singapore. This facility aims at further advancing Roquette's position as a strategic partner to its customers for more exciting food innovations that suit the Asian palate. In addition, the brand-new centre is a testament to Roquette's rich 90-year history of excellence and strong commitment towards serving its customers.

The state-of-the-art facilities, which include a research laboratory, customer technical services as well as the new regional headquarters, allow Roquette to tailor its products and address the specific health and dietary challenges of the region such as obesity or diabetes. Singapore is an international research and development hub for fast-growing areas in Asia Pacific such as biomedical sciences, bioengineering, medical technology (MedTech), personal care, food and nutrition. Roquette's capabilities include the development of new products and new applications for existing products as well as pre-clinical research. Additionally, this facility is equipped for physical and chemical characterization of materials, support for pharmaceutical customers with prototypes, and formulation and process development.

Tokyo, Japan

In 2018, Roquette announced the expansion of its Food Customer Technical Service (CTS) Centre in Tokyo to respond to a local increasing demand in personalized nutrition, with ingredients such as plant-based proteins, fibres and healthy carbohydrates.

The expansion of the facility has increased its size by 50%, and it now includes new pilot-scale capabilities that will enable Roquette food application experts to bring value to Japanese and Asian customers in specialized nutrition (baby food, maternal nutrition, sports nutrition, weight management, senior and clinical nutrition), dairy as well as beverages. The Group sees the Japanese market as a pioneer market for trends that are expected to grow worldwide.

Shanghai, China

In 2019, the opening of a new Food Innovation Centre, including R&D and customer technical service, in Shanghai was a key milestone for Roquette to enhance closer partnerships with customers and further develop tailored nutritional solutions for the Asian market.

It employs approximately 130 employees.

Nellore, India

In 2022, Roquette completed the acquisition of India-based excipient manufacturer, Crest Cellulose. This acquisition allowed Roquette to continue realising its strong growth ambitions and meet rising global demand for high-quality plant-based excipients. Thanks to this wholly owned subsidiary, Roquette's international customer base can benefit from its ability to provide pharmacopoeia-compliant, premium quality, fully traceable solutions to help solve the toughest challenges in drug delivery.

The production site in Nellore employs around 80 employees and produces modified cellulose products from starch and cellulose.

Nara, Japan

In October 2023, Roquette announced the completion of the acquisition of Qualicaps from the Mitsubishi Chemical Group.

The Qualicaps Nara site is a world class facility producing capsules for pharmaceutical markets, and it employs around 400 employees.

1.2.2.4 Oceania


King Island, Australia

With the acquisition of IFF Pharma Solutions, Roquette now has a small presence in King Island, where 5 employees work to produce dried seaweed.

1.2.3 Group's Strategy

1.2.3.1 Strengthening Roquette position in health and pharma solutions

As a leading drug delivery solutions partner, Roquette provides comprehensive and technically differentiated solutions to its clients. Over the years, Roquette has transitioned from an excipient supplier to comprehensive drug delivery solutions provider.



(1) Majority share in the company in 2018, complete acquisition in 2022

The ambition of Roquette is to strengthen its pharmaceutical activities to achieve balanced distribution and benefit from a growing market, reinforcing its presence in the US. With the acquisition of Qualicaps in 2023, Roquette enhanced its customer proposition through portfolio complementarity, maximizing coverage of key pharma players. In addition, Roquette completed the acquisition of the IFF Pharma Solutions from IFF in May 2025, further solidifying its position as a major partner in the pharmaceutical industry. This strategic acquisition allows Roquette to expand its excipients for oral dosage solutions, aligning with the company's goal of comprehensive drug delivery solutions.

1.2.3.2 R&D and Innovation

Since its creation, Roquette has constantly been innovating to develop new solutions, adapted to customers' and consumers' needs. Since the 1950s, Roquette relies on its own R&D department to accompany these developments and today the Group reinvests around 10% of its turnover per year in R&D and large investment projects.

Today, Roquette's renowned R&D continues to be key to the Group's strategy by deploying the state-of-the-art science and technology essential to create the applications, ingredients and formulations that best support its customer's ambitions. R&D priorities are driven by the needs of the market, which are increasingly focusing on nutrition, health and selected industrial applications.

Today, the Group's R&D teams continue to support existing activity by improving Roquette's ingredients' properties or by helping internal and external customers through advice or through the development of new solutions (ingredients, technologies, analytical methods and all related scientific proofs) to answer customers' and markets' needs expressed by the Business Units. They are also responsible for proposing technology modifications to operations and product line managers to improve the profitability of industrial processes. They explore long-term research fields, driven by societal trends, scientific advances, and technological developments, to anticipate and prepare future areas of innovation and ultimately create value for sustainable growth of the Group. Roquette's innovative ingredients and formulations for products makes it a natural strategic partner for its customers.

Roquette boasts 20 R&D and Innovation centers, in Europe, America and Asia. At these centres, the relationship with local sales teams and customers allows for incremental innovation and meeting the needs of the local markets. Thanks to

its global network of Customer Technical Services (CTS), combined with an intensively customer-oriented approach, Roquette is also able to continuously create new products, processes and solutions needs, wherever the customer may be located.

Roquette employs a global patent strategy with a goal to protect its R&D innovations and commercial products as well as to strengthen the Group's competitive position in global health, nutrition, and industry markets. At the date of the Prospectus, Roquette has a patent portfolio of over 4,000 granted patents or pending applications. These patents and applications represent technological advancements pertaining to Roquette's product portfolio, including its innovation pipeline, and the manufacture, use and applications of its products.

1.2.3.3 Strengthening Roquette sustainable development by 2030¹

In 2023, Roquette launched its life+nature programme aimed at renewing and strengthening its sustainable development approach by 2030. Over the coming years, Roquette is committed to decarbonising its activities by reducing its direct and indirect emissions, making its product offerings more sustainable by systematically integrating eco-design, while continuing to place people at the heart of its strategy in terms of health, safety, well-being, ethics, and inclusion - whether they are Roquette employees, suppliers, contractors, or local communities at its locations.

This programme was presented externally in 2024.

Driven by a constant desire for innovation and a long-term vision, Roquette has built this programme, fully integrated into the Group's strategy and activities, consisting of three engagement platforms:

- PRESERVE the planet: Protecting the planet and its resources, mitigating its impacts, and adapting.

Aware of its environmental footprint and the consequences of climate change on its activities, Roquette has built this platform around two main areas of work: mitigation via a vast decarbonisation plan validated by the SBTi to reduce its greenhouse gas emissions compared to 2021 by 25% by 2030 and adaptation of its value chain to climate hazards, with sustainable raw materials, optimised water management and resilient sources of supply.

- INVENT for the future: Innovation at the service of a sustainable offer.

Through the "INVENT for the future" commitment, Roquette's ambition is to anticipate and offer solutions designed to create shared value for its customers, society and the planet. Thanks to the integration of eco-design into its innovation processes and the implementation of a tool to assess the sustainability of its product portfolio, Roquette proposes a more sustainable offer that adapts to its customers' demand for sustainability and meets new consumer expectations. Spearheading this platform is an eco-design training programme that has been launched with Roquette's R&D and Innovation teams. Primarily focused on conducting life cycle assessments of all Roquette products by 2030, the programme will enable the development of new solutions aimed at reducing environmental footprint throughout their life cycle and contributing to an even stronger positive social impact.

- CARE for people: Employee safety, well-being at work, training, inclusion, community involvement...

Roquette maintains a bond of trust with all its partners, placing the safety of people, ethics, and social dialogue at the heart of their exchanges. In all its activities, the Group works for the respect of human rights and fundamental freedoms. Roquette offers its employees rich and varied career paths, and ensures their quality of life at work, respect for their diversity and development of their skills. The safety of everyone is also a priority.

¹ Objectives set up by 2030 are based on Roquette's historical perimeter.

By 2030, each employee will benefit of more than 25 hours of training each year. A key actor in the heart of the territories where it operates, Roquette also supports, all over the world, programmes in local communities with the backing of the Roquette Foundation for Health. More than 100 programmes will be set up each year near our sites by 2030.

More information on the objectives of life+nature is available on the website of Roquette.

2. BUSINESS OVERVIEW

Unless otherwise stated therein, all market positions of the Group mentioned in this section are based on Group estimates.

2.1 DESCRIPTION OF THE GROUP'S MAIN MARKETS

Over almost a century, Roquette has grown from a small starch factory in Lestrem, in the North of France, to a leading provider of plant-based ingredients, excipients and solutions that improve the quality and convenience of food, health, and bio-based industrial products. This development relies on the excellence of Roquette's industrial assets, and a constant appetite for innovation that has allowed Roquette to build solid positions in different markets that gravitate around two pillars: Nutrition & Bioindustry and Health and Pharma Solutions.

Roquette's manufacturing process is fully integrated, from the grain crushing step until the most highly functional ingredient production. Every component of the raw material is valued to optimise the operational performance, financial robustness and environmental footprint. Its extensive variety of products allows Roquette to serve a wide range of end-markets.

The Group serves global and large end-markets that are in consumer's everyday lives and that benefit from steady to strong growth, as illustrated below with a selection of key end-markets:

End - markets	Main Roquette ingredients at stake	Market sizing in €	CAGR % 20-24	CAGR % 25-29		
Prescription medicine	Starches, polyols, capsules, cellulose & alginates	~ 15 bn	+ 6 %	+ [5-8] %	Pharma and Nutraceuticals	Health
Consumer Healthcare	Starches, polyols, capsules, cellulose & alginates	~ 253 bn	+ 4 %	+ 4 %		
Bakery & snacks	Starches, proteins	~ 1032 bn	+ 3 %	+ 2 %	Food and Nutrition	
Confectionery	Polyols, liquid sugar	~ 259 bn	+ 1 %	+ [1-2] %		
Beverages	Liquid sugar	~ 668 bn	+ 3 %	+ 3 %		
Dairy	Proteins, liquid sugar	~ 666 bn	+ 1 %	+ [1-2] %		
Savoury	Starches, proteins	~ 621 bn	+ 1 %	+ 2 %		
Specialised nutrition	Fibers, proteins, clean label	~ 70 bn	+ 5 %	+ [3-4] %	Industry	Nutrition
Agriscience	Proteins, polyols, sugars, cellulose	~ 30 bn	+ 10 %	+ [9-10] %		
Bio-based solutions	Liquid sugar, proteins, starches	~ 130 bn	+ 4 %	+ [3-4] %		
Pet food	Starches, proteins, fibres	~ 110 bn	+ 6 %	+ [4-5] %	Animal Nutrition	
Aqua feed	Gluten	~ 60 bn	+ 5 %	+ [3-6] %		
Live stock	Fibres	~ 500 bn	+ 2 %	[- 1 - + 1] %		
Feed specialties	Sugar, polyols, proteins	~ 25 bn	+ 3 %	[- 2 - + 2] %		

Sources: Mordor Intelligence, MarketsAndMarkets, IQVIA Market Prognosis, IQVIA Institute, Euromonitor, Dunhamm Trimmer, Roland Berger, FMI, Grand View Research, Industry ARC, Grand View Research, Future Market Insights

Health & Pharma Solutions

Since January 2026, the Cosmetics business has been transferred to the Health & Pharma Solutions Business Unit. Unless otherwise specified, historical financial data presented in this Prospectus for periods prior to 2026 reflects the previous organizational structure with Cosmetics included in the Nutrition & Bioindustry Business Unit.

□ *Pharmaceuticals:*

The pharmaceutical market is a vast industry that involves the research, development, production, and distribution of drugs and medicines. This industry is highly regulated and requires significant investment in research and development, as well as extensive testing and clinical trials before a drug can be approved for use.

The pharmaceutical market is driven by new and innovative treatments, aging population that requires more healthcare services, improved access to medicine and rise of "lifestyle diseases" (e.g., obesity, diabetes, etc.).

The pharmaceutical market remains a critical component of the global healthcare industry. It plays a vital role in improving the quality of life for millions of people around the world and is expected to continue to grow in the years ahead.

The excipient market is a subset of the broader pharmaceutical industry that focuses on the development and production of inactive ingredients used in the formulation of drugs. Excipients are substances that are added to drugs to improve their stability, bioavailability, and other properties. They can also be used to help with drug delivery, such as by controlling the rate of drug release. To the extent that excipients generally represent 50 to 95% of the final drug product volume and cost around 1 to 5%, they have a crucial role in drug formulation.

□ *Biopharma*

The biopharmaceutical market specializes in drugs developed through biotechnology, such as therapeutic proteins, monoclonal antibodies, vaccines, and gene therapies. Biopharmaceuticals derive from biological sources, involving complex manufacturing and stringent regulatory oversight.

Key market drivers include continuous biotech innovation, which fosters new and effective treatments. Rising chronic disease rates, particularly cancer and diabetes, alongside an aging population, increase biopharmaceutical demand.

Challenges include high development costs (including numerous complex process steps during manufacturing of drug products), complex regulatory requirements, fierce market competition, and the need to protect intellectual property.

The biopharmaceutical market is rapidly growing, mainly driven by technological advances, as well as demographic changes, and evolving healthcare demands.

□ *Consumer Healthcare*

The Consumer Healthcare market is divided into two main areas:

□ OTC

The over-the-counter (OTC) market comprises non-prescription drugs available directly to consumers for self-care. Typical applications include pain relievers, cough & cold medications, allergy or sleep aid. Although not requiring a medical prescription to be purchased, OTC products are regulated as drugs.

Key drivers include increasing consumer demand for self-medication, convenience, and cost-effectiveness compared to prescription drugs. Growing health awareness and proactive wellness approaches further boost the market. Regulatory shifts allowing easier access to OTC products, along with expanding distribution channels like online pharmacies, also contribute to growth. The market benefits from continuous product innovation and marketing strategies aimed at educating consumers about safe and effective self-care options.

□ Vitamins, Dietary Supplements and Nutraceuticals

The Vitamins, Dietary Supplements and Nutraceuticals market comprises ingestible products intended to complement the diet and support health, wellness, and specific physiological functions. Unlike OTC medicines, these products are generally regulated as foods or dietary supplements rather than drugs, and they do not require pre-market authorization for therapeutic claims (depending on jurisdiction).

Products are typically positioned for preventive health, lifestyle optimization and condition support rather than treatment of diagnosed diseases. Dosage forms increasingly mirror pharmaceutical formats (tablets, capsules, softgels, stick packs, gummies, powders), creating partial convergence with pharma manufacturing standards — albeit under lighter regulatory constraints.

□ *Cosmetics*

The Cosmetics/ Beauty & Personal Care (BPC) market comprises products intended for external application on the skin, hair, nails, lips, teeth or mucous membranes for cleansing, protection, beautification, odor control, or maintenance of appearance.

The market includes skin care (moisturizers, anti-aging, serums, sun care, dermo cosmetics), hair care (shampoos, conditioners, styling, treatments), color cosmetics / make-up, oral care (toothpaste, mouthwash – cosmetic positioning), and personal hygiene (soaps, shampoos, deodorants, etc.).

Formulations typically combine functional ingredients (emollients, thickeners, surfactants, film formers, carriers, preservatives), where Roquette mainly plays, but also active ingredients (anti-aging, brightening, soothing, UV filters), and sensory components (perfumes, textures, visual appearance). The industry is characterized by rapid product cycles, strong branding, and high marketing intensity.

Trends in the Health & Pharma Solutions markets

The Health & Pharma Solutions markets are expected to continue to grow due to the following market trends:

- aging population and rising chronic diseases;
- increased regulations and more stringent quality requirements in the industry;
- shift towards animal free, natural, and organic solutions, especially in dietary supplements;
- increasing consumers interests in preventive healthcare and personalized nutrition;
- demand for traceability, supply continuity and product security.

Nutrition & Bioindustry

Food and Nutrition

The food and nutrition market covers bakery, confectionery, specialised nutrition, beverages, and savory and dairy products segments. These segments are highly demanding and driven by consumer needs like boosting nutritional value and enhancing taste and texture.

Plant-based ingredients for the food and nutrition market can be made from a variety of plant-based sources including corn, wheat, and pea. The food and nutrition market is driven by a number of factors, including rising concerns about the environmental impact of animal agriculture, growing awareness of the health benefits of plant-based diets, and increasing demand for ethical and sustainable food products.

The food and nutrition market is highly competitive, with a wide range of companies offering a variety of products to meet consumer demand. The industry is also highly innovative, with companies investing heavily in research and development to create new and innovative plant-based products. The food and nutrition market is less regulated than the pharmaceutical or nutraceutical markets, with fewer safety and efficacy standards in place. However, companies are still subject to some regulations, particularly when it comes to labelling and marketing claims.

Overall, the food and nutrition market is expected to continue to grow driven by continuous growth of solid food & beverages underlying, penetration of healthier and innovative functional solutions improving customer experience (sugar free, clean labels, indulgence) and need for better nutritive solutions especially proteins.

Animal Nutrition

The animal nutrition market is a large sector of activity that consumes mainly raw materials and feedstuffs known as coproducts coming from different industries such as milling, sugar beet, oils and starch industries.

Plant-based animal nutrition products are marketed as natural and environmentally friendly alternatives to traditional animal feed ingredients that may contain animal-derived ingredients or synthetic additives. The plant-based animal nutrition market is driven by consumer demand for products that are safe and sustainable.

Plant-based animal nutrition products include a wide range of products for livestock, pets and fish, including feedstuffs rich in protein, oils, fibre or starch. They can be nutrition and/or functionality providers and are issued from raw material such as soya, wheat, corn, potatoes and peas. The plant-based animal nutrition market is highly competitive, with a wide range of companies offering a variety of products to meet consumer demand. The industry is also highly innovative, with companies investing heavily in research and development to create new and innovative plant-based products.

While there are strong safety and regulation standards in place, companies are now subject to additional sustainability concerns with notably their footprints and the one from animals they feed.

The plant-based animal nutrition market is expected to keep its importance to feed the large diversity of animals. The industry is also likely to see continued innovation and development of new plant-based animal nutrition products that can meet the evolving needs and preferences of consumers.

Bioindustry

The bio-based market is a growing industry that focuses on the development and production of materials made from renewable plant-based sources, for the purposes of agriscience, paper and board, fermentation, performance materials, biofuel, home care and oral care. These materials are marketed as sustainable and eco-friendly alternatives to traditional materials that are derived from non-renewable sources and most of the time from petrochemistry (or oil).

The bio-based materials market is driven by a number of factors, including rising concerns about the environmental impact of non-renewable materials, increasing demand for sustainable products, and government initiatives to promote the use

of renewable materials. Bio-based materials can include a wide range of products, including bioplastics, biofuels, biopolymers, biomaterials for many markets such as construction, packaging, household, chemistry.... They can be made from a variety of plant-based sources, such as cereals (corn, wheat, ...), sugarcane, and soybeans.

Trends in the Nutrition & Bioindustry markets

The Nutrition & Bioindustry markets are expected to continue to grow due to the following market trends:

Food & Nutrition:

- increasing consumer focus on nutritional quality, including higher protein intake and fibre enrichment
- reformulation initiatives driven by sugar reduction policies and evolving dietary guidelines
- demand for plant-based and alternative protein solutions
- continued demand for clean label and simplified ingredient lists

Bioindustry:

- decarbonisation initiatives and the progressive transition toward renewable feedstocks
- substitution of petrochemical-based materials with plant-based alternatives where technically and economically feasible
- regulatory frameworks supporting renewable fuels and bio-based materials in certain jurisdictions
- industrial production cycles and raw material price dynamics


2.2 DESCRIPTION OF THE GROUP'S MAIN BUSINESS ACTIVITIES

2025 figures in the following section reflect the previous organisational structure, with cosmetics business included under Nutrition & Bioindustry Business Unit.


The Group operates more than 40 industrial sites throughout the world, processing around six million tonnes of agricultural raw materials per year with the support of 11,000 employees.

For the financial year ended 31 December 2025, the Group generated a turnover of €4,877 million, out of which €4,778 million come from the sales of manufactured goods ("**BU sales**"), the remaining sales mainly being energy sales, and a Current operating income and net income amounting to €232 million and €-265 million, respectively.

The charts below represent the split of the Group's turnover by geographical area and the raw material consumption by botanical origin for the financial year ended 31 December 2025:



RAW MATERIAL CONSUMPTION SPLIT



2.2.1 Product families and product types


2.2.1.1 Product families

Serving a wide range of end-markets, pharmaceuticals and nutraceuticals, food and nutrition, animal nutrition and industry markets, Roquette makes plant-based ingredients from raw materials, mainly potato, corn, wheat, pea, and cellulose, for more than 700 everyday products.

At Roquette, ingredients are produced through an integrated manufacturing model. Depending on how far the processing steps go, the product is categorised into a product family that can be used in diverse markets, segments, and applications.

	HPS					NBI
	Pharmaceuticals	Consumer Healthcare	Cosmetics	Food & Nutrition	Animal Nutrition	Bioindustry
SEGMENTS	Oral Dosage Injectables Dialysis Biopharma	Nutraceuticals Dietary Supplements Over-the-counter (OTC)	Skin Care Hair Care Makeup Sun Care Oral Care Toiletries	Bakery and Snacks Confectionery Specialized Nutrition Savory Dairy Beverages	Aquafeed and Juvenile Feeds Calf Milk Replacers Farm Animal Feed Pet Food Piglet Nutrition Premixes and Veterinary Products	Agriscience Fermentation Paper and Board Performance Materials & Construction Home Care and Industrial Cleaning Biofuel
KEY PRODUCT FAMILIES	Sugars Polyols Proteins Caramel	Starches Proteins Fibres	Starches Polyols Fermentation products Alginates Cellulosics	Starches Sugars Polyols Dextrins Cellulose and derivatives Alginates Film-Coating Systems Capsule technologies	Starches Sugars Polyols Dextrins Cellulose and derivatives Alginates Film-Coating Systems Capsule technologies	Starches Cyclodextrins Polyols Organic Acids

The chart below represents the split of the Group's total sales by market for the financial year ended 31 December 2025:



Some of the key product families are:

Starches (native and modified)

Roquette offers over 300 native and modified starches derived from corn, wheat, potatoes, tapioca, and peas. Native starches are natural polysaccharides extracted directly from plants, while modified starches undergo chemical or physical treatments to develop their functionalities, mainly related to texture.

Sugars (dry and liquid)

Nutritive carbohydrates and sugars from cereals offer nutritional and physiological benefits contributing to provide energy to our body. Roquette has developed a wide range of cereal sugars with numerous applications. Cereal sugars like maltodextrin, glucose syrup and dextrose are crucial in food and pharmaceutical applications, such as infant nutrition products and injectable pharmaceutical preparations.

Cyclodextrins

Roquette is a pioneer in the industrial development of beta-cyclodextrins, obtained through biotransformation of starch. Roquette's cyclodextrins are used primarily as encapsulants of molecules in pharmaceuticals, seed treatment and cosmetics.

Fermentation products

From renewable raw materials such as corn, Roquette has an extensive range of organic acids and gluconic derivatives including gluconic acid, glucono-delta-lactone (GDL), sodium gluconate, and succinic acid. Some application examples include use as acidifying agents in food applications, buffering agents for pharma, or plant-based alternatives in hair care or skin care products.

Caramel

Roquette's caramel portfolio includes products from caramel colour to caramel specialty to provide customers with the right colour, texture and taste to the final product.

Proteins and Derivatives

As one of the world leaders in pea protein, Roquette has over 40 years of experience in researching and producing plant proteins. The raw materials Roquette uses include corn, wheat, potatoes, peas, rice and fava beans.

Fibers (dry)

Fiber plays a key role in food and nutrition with several nutritional and health benefits. Roquette offers both soluble and insoluble fibers that enrich the diet with a beneficial effect on nutrition, health and overall well-being. *Polyols (liquid and powder)*

Today, Roquette is a recognized leader in polyols that include mannitol, sorbitol, maltitol, xylitol and isosorbide. Polyols can be used in many ways, for example, as sugar alternatives in food products, pharmaceutical excipients to help manufacture tablets, active pharmaceutical ingredients for injectable solutions, and sustainable alternatives to petrochemical products in performance materials like packaging.

Cellulose and derivatives and alginates

Roquette's portfolio includes alginate products sourced from seaweed, along with a broader range of cellulose-derived solutions for pharmaceutical, nutraceutical, biopharmaceutical, industrial, personal care and food applications.

Capsules

Capsules contain the active ingredient and excipients (inactive substances to encapsulate the active ingredient). Roquette's solutions for solid oral forms offer customers a diversified range of hard capsules for various pharmaceutical and nutraceutical applications.

Equipment

Capsule manufacturing equipment to optimise the entire softgel encapsulation process.

2.2.1.2 Product types

Overall, Roquette's products can be classified into two types:

Commodities	Specialties
<p>Commodities are products coming from the early steps of the integrated production process. They are easily replaceable products with low level of specificities.</p> <p>They can be split into four sub-types: basic commodities (starch and liquid sugar), differentiated commodities (modified starches, dextrose, and liquid polyol), ethanol, and first products (products derived from the first steps of the raw material transformation process).</p> <p>Commodity type products aim to satisfy a standard need of a large number of customers, which are very sensitive to price, and which have a lot of direct and/or indirect substitutes easily and quickly implementable.</p>	<p>Specialties are products that go further in the integrated production process and that require expertise, higher level of quality and know-how.</p> <p>Specialty type products include in particular powder polyols, fibres, organic acid, maltodextrin, capsules, mannitol and sorbitol.</p> <p>Specialty type products aim to satisfy a set of specific needs of customers with a desire for customization (eg. wide range of product / services availability, patent, specialised process or specification, regulatory match, outstanding quality, bespoke service, etc....).</p>


As at 31 December 2025, the commodity-type and the specialty-type products represent respectively 44% and 56% of the Group's sales.

2.2.2 Principal activities

The Group is organised around two Business Units ("BU") to ensure that the appropriate level of service is provided to each customers' profile, serving its customers across all markets:

- the Nutrition & Bioindustry Business Unit (the "NBI BU") operates on three main markets: food and nutrition, animal nutrition and bioindustry. The Nutrition & Bioindustry Business Unit (including cosmetics) represents, as at 31 December 2025, 73% of the Group's sales; and
- the Health & Pharma Solutions Business Unit (the "HPS BU") covers the pharmaceuticals, consumer healthcare and cosmetics markets². The Health & Pharma Solutions Business Unit (excluding cosmetics) represents, as at 31 December 2025, 27% of the Group's sales.

Each Business Unit operates across multiple regions and includes several products.



While the NBI BU's sales are mainly composed of commodity-type products, the Health & Pharma Solutions BU's sales are predominantly composed of specialty-type products, that respond to specific needs of patients and customers and require expertise and higher level of quality and know-how, thus they significantly contribute to the profitability of the Group.

2.2.2.1 Nutrition & Bioindustry

The NBI BU develops, manufactures and commercialises plant-based ingredients derived primarily from corn, wheat, potato and pea, serving food, feed and industrial end-markets worldwide.

NBI operates an integrated production model whereby agricultural raw materials are processed through successive transformation steps. Early-stage processing generates starch and sugar streams and related co-products, which are further transformed into either commodity-type products or higher value-added specialty ingredients. This integrated model enables the Group to optimise raw material valorisation across multiple end-markets.

(b) Product types

The NBI BU works as an integrated model made of two main product types: commodities and specialties.

The main NBI BU commodities are the following: native starch, liquid sugar and liquid polyol.

² As of January 2026, the Cosmetics business was transferred to HPS

The main NBI BU specialties are the following: food modified starch, dextrin, maltodextrin, powder polyol, fibres, pea proteins and organic acid.

As at 31 December 2025, the commodities and specialties represent respectively 58% and 42% of the NBI BU's sales.

(c) Portfolio structure

NBI's activities are structured around 2 major segments comprising ten sub-segments.

Food & Nutrition Specialties

This segment comprises higher value-added ingredients used in food and beverage applications. These products typically require formulation expertise, technical support and compliance with stringent quality and regulatory standards.

The segment is organised into four sub-segments:

- Mouthfeel: including native and modified starches, clean label starches, etc. designed to improve texture, stability, viscosity and sensory properties in food and beverage applications
- Healthier Food: including sugar management solutions (notably polyols), soluble fibers, etc. supporting reformulation, sugar reduction and nutritional enrichment
- Colors: primarily caramel-based food colours and related specialty ingredients used in beverages and processed foods
- Proteins: primarily pea protein isolates and derivatives used in plant-based food, sports nutrition and specialised nutrition applications

These sub-segments address global food and beverage manufacturers and are supported by application laboratories and customer technical services.

Food & Nutrition Specialties increased from 33% to 42% of sales between 2023 and 2025, driven by proteins and fibers.

Bioindustries & Commodities

This segment comprises early-step products and selected industrial applications deriving from starch and sugar streams generated through the integrated model.

It is organised into six sub-segments:

- Commodity EMEA
- Commodity Americas
- Commodity Asia

These three sub-segments comprise basic and differentiated starch-based products, including native starches, liquid sugars, dextrose and liquid polyols, primarily sold to industrial food and fermentation customers.

- Biofuel: including bioethanol

- Paper & Board: starch-based solutions used in paper manufacturing applications
- Bio-industries Specialties: ingredients dedicated to fermentation, industrial biotechnology and performance material applications

Products within this segment are generally more exposed to raw material price fluctuations and competitive commodity market dynamics.

First-products

Certain co-products generated at early stages of the integrated production process are valorised into animal nutrition applications, including pet food, aqua feed and livestock feed.

These streams are considered first products within the meaning of the Group's integrated production model. The related economics are therefore reflected as a credit against variable costs within the production chain rather than as standalone commercial product lines.

Operational organisation

Operationally, the NBI BU is organised along three geographic units:

- Food & Nutrition (Food specialties Europe & Food specialties and commodities Americas)
- Bio-industries & Commodities (Europe)
- Asia Nutrition & Bioindustry

This organisation reflects the geographic distribution of production assets and customer markets while maintaining global coordination of product platforms and technical capabilities.

(d) Market segments

The NBI BU operates across three principal end-markets: (i) Food & Nutrition, (ii) Bioindustry and (iii) Animal Nutrition. Through its integrated production model, NBI supplies both early-step products and higher value-added specialty ingredients derived primarily from corn, wheat, potato and pea.

As at 31 December 2025, the Food and Nutrition market represents approximately 50% of the NBI BU's sales. In this market, Roquette delivers products to several segments, providing a wide range of functionalities:

Food & Nutrition

The Food & Nutrition market covers a broad range of applications, including bakery, confectionery, specialised nutrition, beverages, savoury products, dairy applications and plant-based alternatives.

Within these applications, NBI supplies ingredients providing functionality such as texturising, stabilisation, sugar reduction, fibre enrichment and protein fortification.

Market dynamics are influenced by structural factors including:

- increasing consumer focus on nutritional quality, including higher protein intake and fibre enrichment
- reformulation initiatives driven by sugar reduction policies and evolving dietary guidelines

- demand for plant-based and alternative protein solutions
- continued demand for clean label and simplified ingredient lists

The competitive landscape includes global starch processors and specialty ingredient companies competing on price, innovation capability, quality standards, supply reliability and regulatory compliance.

Bioindustry

The Bioindustry market includes applications in fermentation, biofuels, paper and board, performance materials and industrial biotechnology.

NBI supplies starch- and sugar-based ingredients used as fermentation substrates, renewable carbon sources, process inputs or functional materials in industrial applications.

Market dynamics are influenced by:

- decarbonisation initiatives and the progressive transition toward renewable feedstocks
- substitution of petrochemical-based materials with plant-based alternatives where technically and economically feasible
- regulatory frameworks supporting renewable fuels and bio-based materials in certain jurisdictions
- industrial production cycles and raw material price dynamics.


Animal Nutrition

Animal Nutrition applications primarily relate to the valorisation of co-products generated at early stages of the integrated processing model.

These products are used in pet food, aqua feed and livestock feed applications and typically consist of protein-rich, fibre-rich or starch-based streams derived from cereal and pea processing.

The animal nutrition market is influenced by feed cost dynamics, agricultural commodity availability and sustainability considerations across livestock and aquaculture value chains.

NBI COMPETITIVE LANDSCAPE




(e) Market environment and positioning

The NBI BU can be segregated in two main competitive environments:

- starch commodity industry, which relates to Roquette’s Bioindustry and Animal Nutrition markets,
- food specialty-type industry, which relates to Roquette’s Food and Nutrition market.

Starch commodity industry

In this industry environment, Roquette is considered as a pure starch player, along with competitors such as Ingredion, Tate&Lyle (in Europe), Primient and Avebe. Pure players are companies for which manufacturing, marketing, and selling starch and starch-derivative products (e.g. liquid sugars, native starch, liquid polyols, etc.) is at the heart of their day-to-day activities and represents a significant portion of their overall volumes sold. Some competitors also come from sugar players, such as Tereos. Sugar players have historically operated in the sucrose / saccharose markets, which represent their main portion of revenues, but they have entered the starch commodity market as an adjacency to their historical business to complement their existing offering. Lastly, large commodity-type trading companies, such as Cargill or ADM, are competitors for whom starch / starch-derivates products represents a small portion of their overall revenues as they are present in numerous food commodity-type markets.




Sources: press releases, annual reports

The starch commodity industry is a CAPEX intensive industry. Roquette's large starch plants in Europe and India allow the Group to cover the main consumption areas and to have a significant position in these regions. The Group is a worldclass player in sugar management, texture, fibre, protein enrichment and plant-based (non-soy) protein. Moreover, over the years, Roquette has accumulated know-how and expertise in the industry, which enable the Group to better valorise all part of the grains it transformed (e.g. the 20-30% of starch co-products contained in grains) and ultimately improve financial performance.

Food specialty industry

In the Food specialty industry, three main competition categories are identified:

- direct competition (starch-industry): players competing directly against Roquette in multiple categories (e.g., bulking agents, texturants, sweeteners, prebiotics, plant-based proteins, etc.) with starch-based products;
- direct competition (outside of starch-industry): players competing directly against Roquette in multiple categories with alternatives/ substitutes of starch-based products (e.g. inulin, hydrocolloids, high-intensity sweeteners, soy-based proteins, etc.);
- adjacent competition: food ingredients players not directly competing against Roquette, actives in others ingredients field (e.g., flavors, colorants, enzymes, vitamins, probiotics, animal proteins, etc.).



Sources: press releases, annual reports

In this industry environment, built almost a century of expertise, Roquette has developed the know-how to turn cereals and vegetables into high-quality and easy-to-use ingredients for customers around the world. Roquette’s ability to manufacture high quality products with good and consistent functionalities is recognised in the marketplace. Its global manufacturing footprint enables to serve key account customers around the world. In terms of product offering, Roquette has a wide portfolio of specialty products, especially the large range of polyols used for diverse functionalities and needs.

2.2.2.2 Health & Pharma Solutions

The **Health & Pharma Solutions (HPS) Business Unit** develops and manufactures high-quality excipients, biopharmaceutical ingredients, and APIs, supporting pharmaceutical and consumer healthcare companies in addressing complex drug delivery challenges.

Positioned as a drug delivery solutions partner, HPS serves attractive and structurally growing end-markets through comprehensive, technically differentiated formulation solutions across the value chain.

The 2023 acquisition of Qualicaps marked a strategic inflection point, accelerating Roquette’s evolution from a leading excipient supplier to an integrated drug delivery solutions provider. This transformation strengthens Roquette’s ability to support pharmaceutical companies from formulation development to finished dosage solutions, reinforcing its ambition to become a reference partner within the global pharmaceutical ecosystem.

On 1st May 2025, Roquette completed the acquisition of IFF Pharma Solutions from International Flavors & Fragrances Inc. This transaction significantly expands Roquette’s presence in the global excipients market. It also reinforces Roquette’s footprint in the United States and substantially enhances its formulation expertise, innovation capabilities, and drug delivery R&D platform.

(b) Product types

The HPS Business Unit provides a comprehensive portfolio of specialty drug delivery technologies addressing three core pharmaceutical markets: oral dosage, parenteral, and biopharma applications.

Oral Drug Delivery

HPS offers a broad range of functional excipients and delivery systems for solid oral dosage forms, including cellulosic polymers and modified release excipients (strengthened through the acquisition of IFF Pharma Solutions), Polyols, Pharmaceutical starches, seaweeds-based ingredients and hard capsules

Parenteral Applications

HPS supplies high-purity and functional excipients designed for injectable formulations, including Pyrogen-free nutrients, Osmotic agents and Low-endotoxin excipients

Biopharma Applications

HPS supports biologics and advanced therapies with specialized excipients and formulation expertise, leveraging Low-endotoxin, high-purity ingredients, advanced cellulosic and functional excipients (from IFF Pharma Solutions)

(c) Organisation

The HPS BU consolidates the business of all regions and markets.

As at 31 December 2025, approximately half of the sales are made in Europe, and the rest is split between Americas and Greater Asia, and to a lesser extent, China.

(d) Market segments

Roquette is a global trusted drug delivery partner serving attractive and growing end-markets. The HPS BU is divided into three markets:

- Pharmaceuticals
- Consumer Healthcare
- Cosmetics

Pharmaceuticals

The pharmaceuticals activity is divided into the following three sub-segments:

- Oral dosage;
- Parenteral/ Injectables/ Dialysis;
- Biopharma

Oral dosage

The Group produces pharmaceutical excipients, mainly fillers, binders and hard capsules for the oral dosage market. The high-quality solutions are easily adaptable to most manufacturing technologies and are customized to address customers' needs. Moreover, it also offers naturally derived excipients and hard capsules for the nutraceutical and over-the-counter markets. The solutions allow the enhancement of the design, texture and taste, and active the delivery of the dosage for easy to take and nonprescription medicines.

In this market, Roquette delivers products to several segments, providing a wide range of functionalities:

- **Tablets:** excipients designed for solid oral dosage forms covering pharmaceutical, over-the-counter and nutraceuticals. Roquette is a worldclass' supplier of mannitol, sorbitol and pharma starches;

- **Liquids:** excipients designed for liquid oral dosage forms covering pharmaceutical and over-the-counter. Roquette is a worldclass supplier of liquid polyol with customised and cost-effective solutions;
- **Capsules:** made of hard gelatine or hydroxypropyl methyl cellulose covering pharmaceutical, over-the-counter and nutraceuticals. Roquette is a global leader in pharmaceutical capsules.

Parenteral & Biopharma

The Group produces high purity substance or mixture of substances intended to be used in the manufacture of a medicinal product and that, when used in its production, becomes an active ingredient of that product intended to exert a pharmacological, immunological or metabolic action with a view to restoring, correcting or modifying physiological functions or to make a medical diagnosis ("**APIs**") and raw materials for the biopharma market.

In this market, Roquette delivers products to several segments, providing a wide range of functionalities:

- **Small molecules:** APIs and raw materials for injectable dosage forms and dialysis solutions. Roquette is a worldclass supplier of pyrogen-free nutrients and osmotic agents;
- **Large molecules:** Pharma-grade raw material and formulation excipients for cell culture in Biopharma.

Consumer Healthcare

The consumer healthcare activity is divided into the following segments:

- OTC;
- Vitamins, Dietary Supplements and Nutraceuticals;
 - OTC

The over-the-counter (OTC) market comprises non-prescription drugs available directly to consumers for self-care. Typical applications include pain relievers, cough & cold medications, allergy or sleep aid. Although not requiring a medical prescription to be purchased, OTC products are regulated as drugs.

Key drivers include increasing consumer demand for self-medication, convenience, and cost-effectiveness compared to prescription drugs. Growing health awareness and proactive wellness approaches further boost the market. Regulatory shifts allowing easier access to OTC products, along with expanding distribution channels like online pharmacies, also contribute to growth. The market benefits from continuous product innovation and marketing strategies aimed at educating consumers about safe and effective self-care options.

- Vitamins, Dietary Supplements and Nutraceuticals

Most products are regulated as Food products.

The Vitamins, Dietary Supplements and Nutraceuticals market comprises ingestible products intended to complement the diet and support health, wellness, and specific physiological functions. Unlike OTC medicines, these products are generally regulated as foods or dietary supplements rather than drugs, and they do not require pre-market authorization for therapeutic claims (depending on jurisdiction).

Products are typically positioned for preventive health, lifestyle optimization and condition support rather than treatment of diagnosed diseases. Dosage forms increasingly mirror pharmaceutical formats (tablets, capsules, softgels, stick packs, gummies, powders), creating partial convergence with pharma manufacturing standards — albeit under lighter regulatory constraints.

Cosmetics

Roquette has an historical presence in oral care (liquid polyols) and has developed as well plant-based alternatives to existing synthetic raw materials with same level of performances and affordability, offering a large range of plant-based biodegradable ingredients for cosmetics products (skincare, colour cosmetics, hair care, oral care, fragrance) providing both sensorial and functional benefit. Leveraging on its 90 years of experience in plant-based ingredients, Roquette offers a full-range of high-performing concepts for personal care, covering skin care, colour cosmetics, hair care, oral care and fragrance.


In October 2020, the Group opened its first expertise centre, located in La Plaine-Saint-Denis, in the Paris region (France), to support and boost innovation and cooperation in the field of cosmetics. This site is an important milestone in Roquette's development strategy and willingness to be recognised as the B2B expert in plant-based ingredients for cosmetics for the years to come.

(e) Distribution and Customers

The HPS BU has a customer centric model built on long-term relationship and intimacy providing collaborative technical assistance and product development expertise. Strong from its broad and complementary range of capabilities, Roquette has developed a broad range of customers. As at 31 December 2025, excluding Qualicaps, the top 10 direct customers represent approximately 30% of the HPS BU's sales and are with international drug companies across the value chain. Distributors represent approximately 25-30% of the BU's sales.

(f) Market environment and positioning

Roquette benefits from a strong reputation, a global presence, with a long history of supplying pharma and nutraceutical markets. The quality of the Group's product is recognised by the market, as it has a proven track record of ability to manufacture consistently products with good functionality. Its depth and breadth of portfolio cover a large set of needs for pharma customers, for both liquid and solid applications. Moreover, Roquette has built solid innovation capabilities around the world to support product development and technical assistance, ensuring close relationship with its customers.



(1) Note: Relative Market Share (Total Sales/ Total Sales of competitor)

Source: Kline, Roquette Management estimates

2.2.2.3. Raw materials supply and margin management

In order to secure its supply in raw materials, the Group sources raw materials from multiple traders, representing a large community of farmers, and buys from traders sourcing from "any origin". Most regions have a local supplier. Roquette continuously works on extending the suppliers baseline and origin.

Supplier contracts can be long or short term, depending on the region. Short term contracts have fixed prices and include conditions such as incoterms & volumes, whereas longer contracts have "open prices" (based on an index).

In addition, to secure the profitability of its business, the Group has a margin management process in place on the commodity market which is mainly based on a 'back-to-back' strategy to lock the variable costs, as much as possible, when offering a price to a customer. The commodity market is a market that is strongly correlated to the costs of raw materials, thus considered as volatile. This strategy allows the Group to address and manage financial and liquidity risk related to the cost of raw materials, to provide a better visibility on financial outcomes and to seize market opportunities within the limits defined by the Group's risk management framework. The objective is to land at 100% of coverage for end of year contracted volume and specifically to each area.

3. SELECTED FINANCIAL INFORMATION

3.1 KEY FINANCIAL INFORMATION

The selected financial information presented below is extracted from the English translation of the Issuer's audited consolidated financial statements for the financial year ended 31 December 2025 and from the Issuer's audited consolidated financial statements for the financial year ended 31 December 2024, prepared in accordance with International Financial Reporting Standards (IFRS), as adopted by the European Union.

KPMG S.A. and Deloitte & Associés have audited and rendered audit reports on the consolidated financial statements of the Issuer for the years ended 31 December 2024 and 31 December 2025, which are incorporated by reference in this Prospectus.

Selected financial information from the consolidated income statement

<i>(in thousands of euros)</i>	31/12/2024	31/12/2025
Turnover	4,494,743	4,876,525
Current operating income	252,228	231,633
Operating income	183,862	(89,217)
Financial result	(64,830)	(110,023)
Income from companies accounted for by the equity method	(5,086)	(3,916)
Income tax	(53,379)	(62,139)
Net income	60,566	(265,296)

Profit or loss, Group share	59,556	(266,426)
Net income from non-controlling interests	1,010	1,130

Selected financial information from the consolidated balance sheet


<i>(in thousands of euros)</i>	31/12/24	31/12/25
ASSETS, out of which:		
Net fixed assets	2,970,757	4,794,532
Working Capital	849,886	928,124
LIABILITIES, out of which:		
Equity	3,399,502	2,876,029
Provisions and employee benefits	93,881	155,257
Net financial debt	237,213	2,389,518

Selected financial information from the consolidated cash flow statement

<i>(in thousands of euros)</i>	31/12/2024	31/12/2025
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD	156,351	307,658
Net cash flow from operating activities	514,727	569,976
Net cash flow from investment activities	(1,457,969)	(1,452,215)
Net cash flow from financing activities	1,077,344	1,213,820
Change in cash flow	151,307	357,661
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD	307,658	665,319


3.2 HISTORICAL PERFORMANCE

The diagram below presents the evolution of the Turnover of the Group for the period 2020-2025:



**CAGR means Compound Annual Growth Rate*

The diagram below presents the evolution of the Current EBITDA (as defined below) of the Group for the period 2020-2025:




(1) Current EBITDA = Current Operating Income plus Amortizations and Depreciations line in the P&L and, in 2025, excluding IFRS 3 effect related to the inventory step-up due to the Purchase Price Allocation ("PPA"). This indicator includes, in particular, gains and losses on disposals of fixed assets, the impacts of insurance proceeds and investment grants, and excludes the effects of write-downs on current assets, which are part of the Current operating income. Please note that this definition has been used for the purposes of the Prospectus as it derives from audited aggregates of the consolidated financial statements

**CAGR means Compound Annual Growth Rate*

The diagram below presents the evolution of the Operating cash-flow for the period 2020-2025:


OPERATING CASH-FLOW(1) (€m)



(1) Operating Cash-Flow = Operating cash flow corresponds to the Cash-Flow generated by operating activities (from the consolidated cash flow statement), plus the change in net working capital, the unrealized financial result on operating receivables and payables, the “net impairment of current assets” (impacts the operating cash flow) and “other reconciling items”.

The diagram below presents the evolution of the investments (excluding M&A) for the period 2020-2025:

INVESTMENTS, excl. M&A (€m)



3.3 FINANCING POLICY

3.3.1 Group Net Debt

The Group’s net debt increased from €237 million for the financial year ended on 31 December 2024 to €2,390 million for the financial year ended on 31 December 2025 (including the impact of the IFF Pharma Solutions acquisition), and is composed as follow:

(in thousands of euros)	31/12/2024	31/12/2025
Non-current financial debt	1,367,194	2,485,479
Current financial debt	423,691	699,523
Non-current financial assets*	(1,244,458)	(29,608)
Cash and cash equivalents	(309,214)	(765,876)
Net financial debt	237,213	2,389,518

* with respect only to short-term and long-term investments and receivables from equity interests as stated in Note 16 "Current and non-current financial assets" of the 2025 Consolidated Financial Statements.

The current and non-current financial debts are detailed hereunder:

<i>(in thousands of euros)</i>	31/12/2024				31/12/2025			
	< 1 year	2 to 5 years	> 5 years	Total	< 1 year	2 to 5 years	> 5 years	Total
Bonds issues	(540)	50,840	845,913	896,213	(111)	94,663	1,382,751	1,477,302
Bank loans	278,339	364,190	4,486	647,015	67,821	883,769	3,514	955,103
Rent debt (IFRS 16)	37,849	60,837	38,895	137,581	48,666	71,203	48,379	168,248
Other financial debts	97,818	1,802	230	99,850	469,521	1,117	85	470,722
Accrued interest	8,670	-	-	8,670	13,069	-	-	13,069
Bank overdrafts	1,556	-	-	1,556	100,557	-	-	100,557
Financial debt	423,692	477,669	889,525	1,790,885	699,523	1,050,751	1,434,728	3,185,002

3.1.2 Debt structure

The "Bonds issues" debt item referred to in the table above corresponds to:

- three issues of bonds in US Private Placements ("USPP") :
 - one issue in 2022 for a nominal of €300 million will be amortized with 6 instalments of €50 million each from 2029 to 2034;
 - one issue in November 2025 of 450,000,000 USD, divided into four tranches due in 2032, 2035, 2037 and 2040;
 - one issue in December 2025 of 200,000,000 EUR, divided into three tranches due in 2032, 2035, 2037.

USPP documentation includes two financial covenants:

- **A leverage covenant:** the level of the net debt / EBITDA ratio measured based on the current consolidated IFRS financial statements. As of 31 December 2025, the limit for this covenant was 4.0x. The covenant limit is established at 4.0x as of 30 June 2026, 3.5x as of 31 December 2026, and 3.25x effective from 30 June 2027 onwards. This limit may be temporarily adjusted to 4.0x in the event of an acquisition. The covenant limit is set at 4.0x as at June 30, 2026, at 3.5x as at 31 December 2026 and at 3.25x as from June 30, 2027 and after. Such limit can be temporarily reset at 4.0x in case of acquisition.
- **A consolidated net worth covenant:** minimum amount of consolidated equity equal to 950 million euros.

As of 31 December 2025, these financial covenants have been met.

- one issue of senior public bonds:
 - issue in November 2024 of 600,000,000 EUR, 3.774 per cent. notes due 25 November 2031.

In November 2024, Roquette issued €600 million in hybrid bonds recognised as equity in IFRS and therefore not included in the "Bond issues" debt item in the table above and thus contributing to the significant reduction in net debt as referred to above.

The "Banks loans" debt item referred to in the table above corresponds mainly to (a) a syndicated term loan implemented in 2023 for €360 million, (b) a term loan implemented in 2025 for \$350 million and (c) a term loan implemented in 2025 for €275 million.

The Group has revolving credit facilities available with its bank pool for a total amount of €763 million as at 31 December 2025, which are regularly renewed when coming to maturity.

The syndicated term loan implemented in 2023 for € 460 million is amortized every year with 3 instalments for €50 million each from 2024 to 2026, then € 100 million in 2027 and € 210 million in 2028.


The "Other financial debts" debt item €471 million referred to in the table above is composed mainly of short-term marketable securities (with a maturity of one year or less), as well as deferred payments in relations with the IFF Pharma Solutions, and cash-pooling debt with Roqfam. The Negotiable European Commercial Paper (NEU CP) program was set up in 2016 for a maximum amount available of €500 million drawn up to €360 million as of 31 December 2025.

The "Outstanding bank overdrafts" debt item referred to in the table above includes the bank overdrafts and unconfirmed financing lines.

The "Rent debt (IFRS 16)" debt item referred to in the table above concerns rentals and rental commitments that are recognized as debt since the application of IFRS 16 on 1 January 2019.

In 2025, the average financing rate is 3.8% (excluding IFRS 16) and the average interest rate on investments stands at 3.1%. At year-end 2025, the average debt maturity was 6.1 years.

FINANCIAL DEBT FEATURES AS OF DECEMBER 2025




(1) €765m Cash & Equivalents + €30m Non-current financial assets

(2) Includes other financial debts, accrued interest and bank overdrafts

The diagram below presents the Issuer's outstanding long term debt maturity schedule as of December 2025:

Please refer to the paragraph below "*Funding Policy*" of the section entitled "*Description of the Issuer*" of this Prospectus.



The Group follows the aggregates “Debt against financial institutions (excluding bank overdraft)” which is as follows. This aggregate excludes bank overdraft, transactional fees, rent debts (IFRS 16), other financial debt and accrued interest, and thus includes the nominal amounts of debts to financial institutions (banks and investors).

(in million of euros)


	2024	2025
Bond Loans (excluding transactional fees)	900	1 483
Term loan Qualicaps	410	360
Term Loan IFF EUR	0	275
Term Loan IFF USD	0	298
RCF drawdown	184	16
Short-term bank line	45	0
Other bank loans	12	10
Bank Loans (excluding transactional fees)	651	958
Negotiable debt securities (New CP)	90	360
Debt to financial institutions	1 641	2 801
Accrued interest	9	13
Transactional fees	-8	-9
Bank overdraft	2	101
Rent debt (IFRS16)	138	168
Other financial debt	10	111
Gross financial debt	1 791	3 185

3.1.4 Funding Policy

The funding policy of the Group aims at

- securing a liquidity level (cash available at sight and financing) strong enough to finance Group's needs and secure potential risks,
- prioritizing long term resources for long term needs,
- maintaining a global funding average maturity of five years,
- diversifying funding sources through bank financings and capital market financings, and
- preserving a solid investment grade rating. The Group in particular targets a Leverage ratio (i.e. the IFRS Net financial debt divided by Current EBITDA) in the range of 2.3 to 2.7 by 2027 and may consider adjustments of its asset portfolio to this end.

The diagram below presents the evolution of the Net financial debt and the Leverage ratio for the period 2021-2025:



(1) Restated leverage ratio = Net IFRS financial debt / Current EBITDA (see Restated leverage ratio definition below)

(2) Including a change in perimeter following the Qualicaps acquisition

(3) Based on the Combined Current EBITDA as described in the Restated leverage Ratio definition below

The Group centralizes cash at the Issuer level while limiting as much as possible the amount of cash at subsidiary level. The debt is also centralized at the Issuer level except for limited volumes for some entities of the Group such as Roquette India, Immoroc or Viadene.

3.4 KEY ALTERNATIVE PERFORMANCE INDICATORS

3.4.1 Definitions

The financial indicators defined below that are presented by the Issuer in this section are not defined in accordance with the IFRS accounting standards. However, the Issuer believes that these indicators provide useful supplementary information to investors as they facilitate the evaluation of the Issuer's performance. It is to be noted that, since not all companies calculate financial indicators in the same manner, these are not always comparable to indicators used by other companies. Accordingly, those financial indicators should not be considered as a substitute for those indicators which are specifically defined and customarily used within the IFRS accounting framework. Those alternative performance indicators are non-audited. The definitions below present alternative performance indicators along with an explanation of how these indicators can be reconciled with customarily used line items within the relevant accounting framework.

"**Current EBITDA**" means the Current Operating Income plus Amortizations and Depreciations and, in 2025, excluding IFRS 3 effect related to the inventory step-up due to the Purchase Price Allocation ("**PPA**"). This indicator includes, in particular, gains and losses on disposals of fixed assets, the impacts of insurance proceeds and investment grants, and excludes the effects of write-downs on current assets, which are part of the Current operating income. Please note that this definition has been used for the purposes of the Prospectus as it derives from audited aggregates of the consolidated financial statements.

The Group's Current EBITDA was as follows for the twelve months ended:

<i>(in millions of euros)</i>	31/12/2024	31/12/2025
Current Operating Income	252	232
+ Amortizations and Depreciations	288	355
+ IFRS 3 effect related to the inventory step-up due to the PPA	-	25
Current EBITDA	540	612

"**Current EBITDA margin**" corresponds to the Current EBITDA divided by the Turnover. The Group's Current EBITDA margin was as follows for the twelve months ended:

<i>(in millions of euros)</i>	31/12/2024	31/12/2025
Current EBITDA	540	612
/ Turnover	4,495	4,877
Current EBITDA margin	12.0%	12.6%

"**Current operating margin**" corresponds to the percentage of the Current operating income divided by the Turnover. The Group's Current operating margin was as follows for the twelve months ended:

<i>(in millions of euros)</i>	31/12/2024	31/12/2025
Current operating income	252	232
/ Turnover	4,495	4,877
Current operating margin	5.6%	4.7%

"Adjusted Net Result" corresponds to the Net Result excluding non-recurring items, associated taxes and any one-off tax or deferred tax

<i>(in millions of euros)</i>	31/12/2024	31/12/2025
Net result	61	(265)
- Non-recurring Items	68	321
- Tax associated to the non-recurring items	(15)	(25)
+/- One-off tax or deferred tax (In 2025: Roquette America deferred tax write off)	-	39
Adjusted Net Result	114	70

"Financial debt indicator" corresponds to the percentage of the Net financial debt divided by the Equity. The Group's Financial debt indicator was as follows for the twelve months ended:

<i>(in millions of euros)</i>	31/12/2024	31/12/2025
Net financial debt ⁽¹⁾	237	2,390
/ Equity	3,400	2,876
Financial debt indicator - %	7%	83%

"Net fixed assets" corresponds to the sum of the following aggregates: Goodwill, Intangible fixed assets, Tangible fixed assets, Investments in associates, Current and Non-current financial assets, minus Other current financial assets (with respect only to short-term investments and receivables from equity interests as stated in Note 16 "Current and non-current financial assets", that are included in the "Net financial debt" aggregate), minus the Non-current financial assets with respect only to long-term investments and receivables from equity interests as stated in Note 16 "Current and non-current financial assets", that are included in the "Net financial debt" aggregate as stated in Note 22 of the 2025 Consolidated Financial Statements. The Group's Net fixed assets was as follows for the twelve months ended:

<i>(in millions of euros)</i>	31/12/2024	31/12/2025
Goodwill	282	1 020
+ Intangible fixed assets	281	1 223
+ Tangible fixed assets	2 373	2 492
+ Investments in associates	8	13
+ Non-current financial assets	71	75
+ Current financial assets	1 199	2
Other current financial assets (with respect only to short-term investments and receivables from equity interests as stated in Note 16 "Current and non-current financial assets", that are included in the "Net financial debt" aggregate)	1 198	-
Non-current financial assets (with respect only to long-term investments and receivables from equity interests as stated in Note 16 "Current and non-current financial assets", that are included in the "Net financial debt" aggregate)	46	30
Net fixed assets	2 971	4 795

⁽¹⁾"**Net financial debt**" corresponds to the following aggregates in the balance sheet: Current and Non-current financial debt, minus non-current financial assets (with respect only to long-term investments and receivables from equity interests as stated in Note 16 "Current and non-current financial assets" of the 2025 Consolidated Financial Statements) and Cash and cash equivalents, and minus Other current financial assets (with respect only to short-term investments and receivables from equity interests as stated in Note 16 "Current and non-current financial assets", that are included in the "Net financial debt" aggregate). The Group's Net financial debt was as follows for the twelve months ended:

<i>(in millions of euros)</i>	31/12/2024	31/12/2025
Non-current financial debt	1 367	2 485
+ Current financial debt	424	700
- Cash and cash equivalents	309	766
- Other current financial assets (with respect only to short-term investments and receivables from equity interests as stated in Note 16 "Current and non-current financial assets", that are included in the "Net financial debt" aggregate)	1 198	-
- Non-current financial assets (with respect only to long-term investments and receivables from equity interests as stated in Note 16 "Current and non-current financial assets")	46	30
Net financial debt	237	2 390

"**Provisions and employee benefits**" corresponds to the sum of the following aggregates: Current and Non-current provisions, and Current and Non-current employee benefits. The Group's Provisions and employee benefits was as follows for the twelve months ended:

<i>(in millions of euros)</i>	31/12/2024	31/12/2025
Non-current employee benefits	73	110
+ Current employee benefits	5	5
+ Non-Current provisions	1	21
+ Current provisions	15	18
Provisions and employee benefits	94	155

"**Restated leverage ratio**" corresponds to the Net financial debt divided by the combined Current EBITDA (as adjusted in 2025, with the four months (January to April) of IFF Pharma Solution business acquired from 1st May 2025 as described in Note 2 of the 2025 Consolidated Financial Statements, the "**Combined Current EBITDA**").

The Group's Leverage ratio was as follows for the twelve months ended, including:

<i>(in millions of euros)</i>	31/12/2024	31/12/2025
Net financial debt	237	2 390
/ Current EBITDA	540	612
+ IFF Pharma Solutions 2025 estimated Current EBITDA Jan. to Apr.	-	75
Combined Current EBITDA	-	687
Restated leverage ratio	0.44x	3.48x

"**Sales**" correspond to the revenue generated by the Group by the sale of goods, either manufactured or traded, at gross value, meaning netted from resales and miscellaneous sales, before any rebates and discounts and excluding side activities.

<i>(in millions of euros)</i>	31/12/2024	31/12/2025
Turnover	4 495	4 877
- Other sales	115	99
Sales	4 380	4 778

The other sales are primarily comprised of sales of energy produced by the cogeneration units of the Group's industrial sites.

"**Working Capital**" corresponds to the sum of the inventories, accounts receivable and similar accounts, tax assets, other current assets; less other, accounts payables and similar accounts, tax debt, social debt and other payables, all coming from the financial statements. The Group's Working Capital was as follows for the twelve months ended:

<i>(in millions of euros)</i>	31/12/2024	31/12/2025
Inventories	836	1,082
+ Accounts receivable and similar accounts	632	671
+ Tax assets	58	89
+ Social receivables	1	1
+ Debtors suppliers	14	15
+ Margin call	4	5
+ Other receivables	34	55
- Accounts payable and similar accounts	449	625
- Creditor customer	24	27
- Tax debts	37	46
- Social debts	169	178
- Other payables	50	113
Working Capital	850	928

3.4.2 Presentation of the key alternative performance indicators

The following table presents the Group's key alternative performance indicators for the twelve-month periods shown.

<i>(in millions of euros)</i>	31/12/24	31/12/25
ASSETS		
Net fixed assets	2 971	4 795
Working Capital	850	928
Other assets	264	131
LIABILITIES		
Equity	3 400	2 876

Provisions and employee benefits	94	155
Net financial debt	237	2 390
Other liabilities	353	433

	31/12/2024	31/12/2025
Current EBITDA – in millions of euros	540	612
Current EBITDA margin - %	12.0	12.6
Current operating margin - %	5.6	4.7
Financial debt indicator - %	7	83
Restated leverage ratio	0.44x	3.48x
Sales – in millions of euros	4,380	4,778

4. SOCIAL AND ENVIRONMENTAL RESPONSIBILITY

4.1 SAFETY

4.1.1. Employees safety

Employees safety is essential to Roquette and serves as the foundation that underpins each of the Group’s actions.

Strong commitments are reiterated in Roquette’s safety policy built around four major principles:

- compliance with local laws and internal health and safety standards;
- identification, assessment, and control of occupational risks;
- implementation of robust operational procedures, drawn from our internal experience and international best practices
- development of a continuous improvement culture involving all stakeholders on our sites.

Over the past decade, safety has been set as a top priority by the management, who have implemented action plans in all of their sites to raise employee awareness and strengthen their engagement to safety. For every worker in Roquette’s sites, including contractors, incidents and accidents are reported and addressed through preventive and corrective action plans.

Roquette regularly takes steps to develop a safety culture among all employees, making them aware of the importance of looking after their own safety and that of others. In this regard, thousands of safety visits are carried out in the field each year, involving an ever-increasing number of employees, with the aim of reporting and addressing any minor warning sign that could potentially lead to an accident. This proactivity is essential to an effective prevention.

The Group continues to set increasingly ambitious objectives each year. The table below presents our 2026 objectives as well as our metrics for the last 2 years:

	2026 Objectives	2024	2025
Workplace accident frequency rate (FR)	FR1: 1.00	1.68	1.23
	FR2: 2.00	3.56	2.28

ISO 45001 certification of Roquette industrial sites is another strong marker of the Group commitment: 51% of them are certified to date. Roquette is aiming for achieving and maintaining 100% certification rate by 2030.

4.1.2. Process safety

Process safety is an interdisciplinary engineering domain focusing on the study, prevention, and management of large-scale fires, explosion, and chemical accidents.

Roquette Process Safety Management System is based on 6 pillars:

- (a) Risk assessment

Every process is subject to a risk analysis then a risk assessment in view of our tolerability and acceptability criteria.

- (b) Safety Barriers control

Technical and Organizational Safety Barriers are established in order to mitigate the risks. Technical and Organizational Safety Barriers are subject to a preventive maintenance programme as well as periodic inspection.

- (c) Management Of Change

Every project of change, whether organizational or technical, is the subject of a preliminary assessment seeking that it has not potential to create a non-acceptable industrial risk.

- (d) Events Recording and Treatment

All process safety events are reported and registered via the Group reporting tool, Incidents, Near Misses and Observations.

- (e) Emergency Management

Each industrial site provides an operational emergency management plan.

- (f) Continuous Improvement

On each site, an action plan is established and periodically reviewed which aims at maintaining the As Low As Reasonable Practicable ("**ALARP**") status for all existing process risks that require ALARP demonstration.

4.1.3. Product safety

Making production processes and operations traceable, visible and reliable is key to ensure Roquette product safety. For Roquette, product compliance is one of the top Group priorities. For more than 20 years, Roquette's sites have been applying the best quality methods and are certified as compliant with several recognised international standards suitable for food and pharmaceutical markets (FSSC 22000, ISO 9001, EFISC, etc.), complemented where required by pharmaceutical quality practices such as Good Manufacturing Practices (GMP).

The Group uses the Hazard Analysis Critical Control Point (HACCP) approach, a method for analyzing and controlling product safety that is accepted in the food industry and aligned with recognised quality risk management principles applied in pharmaceutical ingredient manufacturing. This applies to all stages in the manufacturing process: from receiving raw materials and packaging to final delivery to customers. In addition, in 2023, Roquette completed FSSC 22000 (Food Safety System Certification) certification on the last remaining production facilities and now 100% of its food production sites are certified.

4.2 SUSTAINABLE DEVELOPMENTS

Life+nature programme

Please refer to the section entitled "Strengthening Roquette sustainable development by 2030" of this Prospectus.

Sustainable rating

In January 2026, the Group obtained a score of 84/100 from EcoVadis, allowing it to retain its gold medal for the second consecutive year and to continue its progress, with a gain of 29 points since the launch of the life+nature program in 2023. This performance places Roquette in the Top 5% of more than 130,000 companies evaluated worldwide on rigorous criteria encompassing environmental impact, human resources management, business ethics, and social responsibility, highlighting the strength and consistency of our sustainable development approach.

At the same time, Roquette obtained a B rating for both Climate and Water in the CDP evaluation, marking an improvement compared to the D score received in 2024. These recognitions illustrate the transparency and effectiveness of the actions undertaken by the Group in favour of decarbonization, energy transition, and responsible water management, supported by clear objectives and structured action plans.

4.3 VALUES AND ETHICS & COMPLIANCE

The Roquette culture, and its industrial and commercial success, is built on four values: authenticity, excellence, forward-looking, well-being. The four values are enshrined in the Group's code of conduct, which is available on the website of the Issuer (<https://www.roquette.com>). The code of conduct sets out clearly the ethical expectations and legal standards by which each of our directors, officers, executive management, and all our employees are required to act.

Roquette has implemented a robust global ethics and compliance programme which is designed to prevent, detect, and remediate any unethical, improper, or illegal behaviour. Roquette has a zero tolerance for bribery, corruption, or fraud in all their forms, and has in particular implemented a programme that complies with the French law known as Sapin II and the French Anti-Corruption Agency guidelines, as well as the US Foreign Corrupt Practices Act and other applicable anti-bribery and corruption laws in the jurisdictions in which it conducts business. The Group's Code of Conduct, policies, and procedures also prohibit any violation of antitrust, trade controls, modern slavery, data protection, and insider trading laws. In addition to the code of conduct, Roquette has published a supplier code of conduct and a distributor code of conduct.

Roquette has a third-party hotline reporting system known as SpeakUp, which is hosted by People In Touch, and which is available on the website of the Issuer (<https://www.roquette.com>). Employees, customers, suppliers, and the public at large are encouraged to report any unethical, improper, or illegal behaviour. A report may be made anonymously, in any almost any language, and is received and investigated confidentially. Roquette has published a whistleblower guide which describes the protections afforded to whistleblowers under applicable law and Roquette's policy.

4.4 ROQUETTE FOUNDATION FOR HEALTH

The Roquette Foundation for Health (the "**Fondation**") promotes healthier lifestyles and shares positive eating habits through supported projects in the fields of food, nutrition, and health.

Through the projects it supports, the Foundation's mission is to primarily act in favor of children and young adults across four areas of intervention: facilitating access to healthy and sustainable food for the most vulnerable, improving knowledge on the links between food and health, promoting sustainable eating habits that are beneficial to health, ensuring sustainable agricultural systems.

Since its creation in November 2017, the Roquette Foundation for Health has financially supported more than 70 projects and 3 research prizes in favor of healthy nutrition for our well-being.

4.5 UNITED NATIONS GLOBAL COMPACT

Roquette has been a member of the United Nations Global Compact since 2009. The United Nations Global Compact brings together companies, organizations, United Nations agencies, labor stakeholders and civil society around 10 universally recognised principles relating to human rights, international labor standards, the environment and the fight against corruption. Each year, Roquette promotes actions in support of these 10 principles and its approach to sustainable development is aligned with the United Nations' Sustainable Development Goals.

4.6 ORGANIZATIONAL STRUCTURE

The Issuer is the ultimate holding company of the Group.

The chart below sets out the corporate structure of the Group and its principal subsidiaries as of 31st December 2025:

4.7 TREND INFORMATION

2026 and further trend


The outlook for 2026 aligns with the trends observed in the second half of 2025, marked by a continued decline in raw material and energy costs, persistent pricing pressure—particularly in sugars, whose market prices are weakening in Europe—and an overall environment of heightened political and economic uncertainty. Despite these conditions, Roquette remains confident in its strategic trajectory. The 2025 acquisition of IFF Pharma Solutions has reinforced the Group’s leadership in the pharmaceutical sector and strengthened its overall balance and resilience. Looking ahead, Roquette anticipates robust growth in food industry ingredients and pharmaceutical excipients, alongside market-share gains across its commodity businesses.

To sustain competitiveness, financial performance, and long-term value creation in these conditions, the company launched in January 2026 a comprehensive strategic company plan, by the name of ‘Shift & Lead’.

‘Shift & Lead’ builds on Roquette’s strong foundations as a diversified and resilient company, supported by family ownership and a long-term vision, to strengthen operational excellence, innovation, financial discipline, and cash generation. This strategic plan aims to sustain growth and fully unlock the value of the company’s recent acquisitions, which enhance its leadership positions and open new pathways for profitable expansion. The group has set clear and ambitious financial objectives for 2030 : increase in turnover from €4.9 billion to €6.0 billion, increase in EBITDA from €0.6 billion to €1.2 billion, €250 million net savings to support competitiveness.

As at February 28, 2026, the debt “Debt against financial institutions (excluding bank overdraft)” has increased to €2,876 million (comparing to €2,801 million as at 31 December 2025), following an increase of the RCF drawdown.

Please find below the Group’s Current EBITDA from 2018 which demonstrates the strong and sustainable performance of the Group:



*The Group applied the new standard IFRS 16 on 1 January 2019. This standard replaced IAS 17 and the IFRIC 4, SIC 15 and SIC 27 interpretations. The impacts of the first-time application of IFRS 16 in the income statement for the 2019 financial year were as follows: increase in depreciation expense of €30.7 million and in the cost of net financial debt of €3.8 million, coming as compensation to the drop in rental expense. The impact of the application of this standard on net income is not significant.

5. PROFIT FORECASTS OR ESTIMATES

The Issuer does not disclose profit forecasts or estimates.

6. ADMINISTRATIVE AND MANAGEMENT BODIES

6.1 BOARD OF DIRECTORS

The Issuer is a *société anonyme* with a board of directors (*conseil d'administration*) (the "**Board of Directors**"). To assist the Board of Directors, four committees were created:

- the Audit and Finance Committee;
- the Nomination and Remuneration Committee;
- the Ethics and Sustainability Committee;
- the Strategy Committee.

As of the date of this Prospectus, the Board of Directors is composed of:

Name	Position	Other principal activities outside the Issuer
Mr Edouard ROQUETTE	<ul style="list-style-type: none"> - Director and Chairman of the Board - Remuneration and Nomination Committee - Strategy Committee 	<ul style="list-style-type: none"> - Manager of STARHAVEN SC - Manager of STARLINEL SCI - Chairman of RGCA SA - Representative of ROQUETTE FRERES SA, as President of ROQUETTE SILADOUR SAS - Representative of ROQUETTE SILADOUR SAS, as President of VIADENE SAS - Director and Chairman of ROQFAM SAS
Ms Lise NOBRE	<ul style="list-style-type: none"> - Independent Director - Audit and Finance Committee (Chairman) - Remuneration and Nomination Committee 	<ul style="list-style-type: none"> - Director of COMPAGNIE DAHER SA and Chairman of the Governance Committee - Member of the Investment Committee of BLUESTER CAPITAL (Bluester Fund V and Cairn III)
Mr Antoine FADY	<ul style="list-style-type: none"> - Independent Director - Remuneration and Nomination Committee (Chairman) - Strategy Committee 	<ul style="list-style-type: none"> - Director of ROQFAM SAS
Ms Véronique DEMOLLIENS	<ul style="list-style-type: none"> - Director representing employees - Audit and Finance Committee 	<ul style="list-style-type: none"> - None
Mr Amaury ROQUETTE	<ul style="list-style-type: none"> - Director - Remuneration and Nomination Committee - Strategy Committee 	<ul style="list-style-type: none"> - Director of RGCA SA - Director of VIADENE SAS - Director of ROQFAM SAS - Director of the following DSM-FIRMENICH entities: ACTION PIN (France), FIRESPA (Spain), FIRMINING (China) and DRT-ANTHEA (India) - Member of the Management Committee of the Perfume & Beauty division of DSM-FIRMENICH, and Chairman of the Ingredient unit
Mr Pierre LUZEAU	<ul style="list-style-type: none"> - Independent Director - Strategy Committee (Chairman) 	<ul style="list-style-type: none"> - Director of SEQENS - Director of BIOLANE AGROSCIENCES - President of LUZ DE AGUA SAS

	<ul style="list-style-type: none"> - Ethics and Sustainability Committee 	
Mr Frédéric VANHOYE	<ul style="list-style-type: none"> - Director representing employees - Ethics and Sustainability Committee - Audit and Finance Committee 	<ul style="list-style-type: none"> - None
Ms Aurélie ROUSSEAU	<ul style="list-style-type: none"> - Director - Ethics and Sustainability Committee (Chairman) - Audit and Finance Committee 	<ul style="list-style-type: none"> - Director of RGCA SA - Director of VIADENE SAS
Mr Denis DELLOYE	<ul style="list-style-type: none"> - Director - Ethics and Sustainability Committee - Strategy Committee 	<ul style="list-style-type: none"> - Manager of SUGAR INVEST SARL - Director of RGCA SA - Director of VIADENE SAS
Ms Lucrèce FOUFOPOULOS	<ul style="list-style-type: none"> - Independent Director - Audit and Finance Committee - Strategy Committee 	<ul style="list-style-type: none"> - Director of SIKA AG, SUISSE - Director of AMCOR - Director of ROYAL VOPAK - Director of TRONOX - Director of QUAKER HOUGHTON
Ms Clémence OSSENT	<ul style="list-style-type: none"> - Director - Audit and Finance Committee - Ethics and Sustainability Committee 	<ul style="list-style-type: none"> - Director of RGCA SA - Director of VIADENE SAS - Director of ROQFAM SAS
Mr Olivier DELAMEA	<ul style="list-style-type: none"> - Independent Director - Remuneration and Nomination Committee - Ethics and Sustainability Committee 	<ul style="list-style-type: none"> - President and Chairman of the Board of CF&R Gestion - Legal representative of EDELWEISS VERWALTUNG GMBH - Permanent Representative of EDELWEISS VERWALTUNG GMBH as Director of EDELWEISS GMBH & CO KG - Legal representative of FROMUNION - Legal representative of SAVENCIA FROMAGE & DAIRY BENELUX - Chairman of the Board of GERARD (TIAJIN) FOOD - Chairman of the Board of MANTEQUERIAS ARIAS - Chairman of the Board of SAVENCIA FROMAGE & DAIRY ITALY - Director of SB INTERNATIONAL - Director of BSI - Director of FERRARI - Director of SAVENCIA FROMAGE & DAIRY SINGAPORE - Director of LA COMPAGNIE FROMAGERE - Chairman of the Supervisory Board of NOVOMILK - Chairman of the Supervisory Board of SAVENCIA FROMAGE & DAIRY SK - Member of the Supervisory Board of SAVENCIA FROMAGE & DAIRY HUNGARY

		<ul style="list-style-type: none"> - Managing Director of PYAL-DELMEA - Managing Director of SAVENCIA SA - Director of COMPAGNIE LAITIERE EUROPEENNE - President and Chairman of the Participant Council of INNOVERT - Representative of SAVENCIA FROMAGE & DAIRY INTERNATIONAL as Board Member of SAVENCIA TRADING EGYPT - Permanent Representative of SAVENCIA FROMAGE & DAIRY EUROPE as Director of PJB ADVANCE
--	--	--

The professional address of each of the members of the Board of Directors is the registered office of the Issuer (1, rue de la Haute Loge, 62136 Lestrem, France).

6.2 CHIEF EXECUTIVE OFFICER

The Issuer is managed by a chief executive officer (*directeur général*) ("CEO"). As of the date of this Prospectus, the CEO of the Issuer is Mr Thierry FOURNIER.

As of the date of this Prospectus, the CEO does not perform any other activities outside the Issuer.

The professional address of the CEO is the office of the Issuer (101, avenue de la République, 59100 La Madeleine, France).

6.3 EXECUTIVE COMMITTEE

To assist the CEO, a non-statutory executive committee meets regularly to implement the Group's strategy and ensure its operational management.

As of the date of this Prospectus, such non-statutory executive committee is composed of:

- Mr Thierry FOURNIER, CEO Health & Pharma Solutions;
- Mr Pascal LEROY, CEO Nutrition & Bioindustry;
- Mr Cédric GARRIGUES, Chief Financial Officer;
- Ms Delphine DESRUMAUX, General Counsel & Chief Transformation Officer;
- Mr Xavier GALLIOT, Chief Sustainability & Stakeholder Engagement Officer;
- Mr Marc PEETERS, Chief Human Resources Officer;
- M. Michael MANOUVRIER, Chief Digital and Information Officer.

At the date of this Prospectus, no member of the non-statutory executive committee performs any significant activity outside the Issuer.

The members of the non-statutory executive committee have their business addresses at the Issuer's registered office (1, rue de la Haute Loge, 62136 Lestrem, France).

6.4 MAJOR SHAREHOLDERS

As of the date of this Prospectus, the share capital of the Issuer amounts to €8,812,908 divided into 2,937,636 fully paid-up ordinary shares.

As of the date of this Prospectus, the Issuer is controlled by ROQFAM a *société par actions simplifiée* organized under the laws of France and registered with the commercial register of Arras under number 932 918 550, having its registered office at 1 rue de la Haute Loge, 62136 Lestrem ("**ROQFAM**"), which holds 84.08% of the share capital and voting rights of the Issuer. The main shareholders of ROQFAM are individual members of the Roquette family, who together own 100% of ROQFAM. No other shareholder holds more than 10% of the share capital and voting rights of the Issuer.

As at the date of this Prospectus, the measures implemented to ensure a non-abusive control over the Issuer include: (i) the dissociation of the functions of Chairman of the Board and of Chief Executive Officer, (ii) the presence of independent directors on the Board of Directors (see section 6.1 above) and (iii) the existence of specific Board committees (see section 6.1 above).

As at the date of this Prospectus, there is no arrangement known to the Issuer, the operation of which may at a subsequent date result in a change of control of the Issuer.

6.5 LEGAL AND ADMINISTRATION PROCEEDINGS

In the normal course of its business, Roquette is or may become a party to a number of administrative, legal and/or arbitration actions, suits and proceedings.

Neither the Issuer nor any member of the Group is or has been involved in any governmental, legal or arbitration proceedings (including any such proceedings that are pending or threatened of which the Issuer is aware) during a period covering at least the past twelve (12) months which may have, or have had in the recent past, significant effects on the financial position or profitability of the Issuer and/or the Group.

SUBSCRIPTION AND SALE

Crédit Agricole Corporate and Investment Bank, Goldman Sachs Bank Europe SE, Natixis and Société Générale (together the "**Joint Global Coordinators**"), BNP PARIBAS, Crédit Industriel et Commercial S.A. and J.P. Morgan SE (together with the Joint Global Coordinators, the "**Joint Bookrunners**") have jointly and severally agreed, pursuant to a subscription agreement (the "**Subscription Agreement**") dated 17 April 2026, subject to satisfaction of certain conditions, to procure subscribers and payment for, or failing which to subscribe and pay for Notes at an issue price of 100 per cent. of the principal amount of the Notes (the "**Issue Price**"), in each case less any applicable commission as separately agreed between the Joint Bookrunners and the Issuer. The Issuer will also reimburse the Joint Bookrunners in respect of certain of their expenses, and has agreed to indemnify the Joint Bookrunners against certain liabilities, incurred in connection with the issue of the Notes. The Subscription Agreement may be terminated in certain circumstances prior to payment to the Issuer.

United States

The Notes have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "**Securities Act**"), and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons except in certain transactions exempt from, or not subject to, the registration requirements of the Securities Act. Terms used in this paragraph have the meaning given to them by Regulation S under the Securities Act ("**Regulation S**"). The Notes are being offered and sold outside of the United States reliance on Regulation S.

Each Joint Bookrunner has agreed that it will not offer, sell or deliver the Notes, (a) as part of their distribution at any time or (b) otherwise, until 40 days after the later of the commencement of the offering and the issue date of the Notes, within the United States or to, or for the account or benefit of, U.S. persons except in accordance with Rule 903 of Regulation S. Accordingly, neither the Joint Bookrunners nor any of their respective affiliates, nor any persons acting on their behalf, have engaged or will engage in any directed selling efforts with respect to the Notes, and the Joint Bookrunners, their respective affiliates and any persons acting on their behalf have complied and will comply with the offering restrictions requirement of Regulation S. Each Joint Bookrunner has agreed that, at or prior to confirmation of sale of the Notes, it will have sent to each distributor, dealer or person receiving a selling concession, fee or other remuneration that purchases the Notes from it during the distribution compliance period a confirmation or other notice setting forth the restrictions on offers and sales of the Notes within the United States or to, or for the account or benefit of, U.S. persons.

In addition, until 40 days after the commencement of the offering of the Notes, an offer or sale of Notes within the United States by any dealer (whether or not participating in the offering) may violate the registration requirements of the Securities Act if such offer or sale is made otherwise than in accordance with an available exemption from, or in a transaction not subject to, registration under the Securities Act.

United Kingdom

Each of the Joint Bookrunners has represented, warranted and agreed that:

- (i) it has only communicated or caused to be communicated and will only communicate or cause to be communicated an invitation or inducement to engage in investment activity (within the meaning of Section 21 of the FSMA) received by it in connection with the issue or sale of the Notes in circumstances in which Section 21(1) of the FSMA does not apply to the Issuer; and
- (ii) it has complied and will comply with all applicable provisions of the FSMA with respect to anything done by it in relation to the Notes in, from or otherwise involving the United Kingdom.

Prohibition of Sales to United Kingdom Retail Investors

Each Joint Bookrunner has represented and agreed that it has not offered, sold or otherwise made available and will not offer, sell or otherwise make available any Notes to any retail investor in the UK. For the purposes of this provision, (a) the expression "retail investor" means a person who is neither (i) a professional client as defined in point (8) of Article 2(1) of Regulation (EU) No 600/2014 as it forms part of UK domestic law by virtue of the EUWA; nor (ii) a qualified investor as defined in paragraph 15 of Schedule 1 to the Public Offers and Admissions to Trading Regulations 2024; and

(b) the expression "**offer**" includes the communication in any form and by any means sufficient information on the terms of the offer and the Notes to be offered so as to enable an investor to decide to buy or subscribe to the Notes.

France

Each Joint Bookrunner has represented and agreed that, it has only offered or sold and will only offer or sell, directly or indirectly, any Notes to the public in France pursuant to an exemption under Article 1(4) of the Prospectus Regulation and under Article L. 411-2 of the French *Code monétaire et financier* and that the Prospectus or any other offering material relating to the Notes and such offers, sales and distributions have been and will be made in France only to qualified investors (*investisseurs qualifiés*), as defined in the Prospectus Regulation referred to and in Article L. 411-2 1° of the French *Code monétaire et financier*.

Prohibition of Sales to European Economic Area Retail Investors

Each Joint Bookrunner has represented and agreed that it has not offered, sold or otherwise made available and will not offer, sell or otherwise make available any Notes to any retail investor in the EEA.

For the purposes of this provision, the expression "retail investor" means a person who is one (or both) of the following:

- a) a retail client as defined in point (11) of Article 4(1) of MiFID II; or
- b) a customer within the meaning of Directive 2016/97/(EU), as amended, where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II.

This Prohibition of Sales to EEA Retail Investors' selling restriction is in addition to any other selling restrictions set out in this Prospectus.

General

No action has been or will be taken by the Issuer or the Joint Bookrunners that would, or is intended to, permit a public offer of the Notes or possession or distribution of this Prospectus or any other offering material relating to the Notes, in any country or jurisdiction where any such action for that purpose is required. Accordingly, each of the Joint Bookrunners has represented, warranted and agreed that it has not, directly or indirectly, offered or sold and will not, directly or indirectly, offer or sell any Notes or has not, directly or indirectly, distributed or published and will not, directly or indirectly, distribute or publish any offering circular, prospectus, form of application, advertisement or other document or information relating to the Notes in any country or jurisdiction except under circumstances that will, to the best of its knowledge and belief, result in compliance with any applicable laws and regulations and all offers and sales of Notes by it will be made on the same terms.

GENERAL INFORMATION

1. Authorisation

The Notes were issued pursuant to resolutions of the *Conseil d'administration* (Board of Directors) of the Issuer adopted on 11 February 2026 and a decision of the *Directeur financier*, of the Issuer dated 14 April 2026.

2. Approval by the AMF

This Prospectus has been approved by the AMF in France in its capacity as competent authority pursuant to the Prospectus Regulation and received the approval number 26-093 dated 17 April 2026. The AMF only approves this Prospectus as meeting the standards of completeness, comprehensibility and consistency imposed by the Prospectus Regulation. Such approval does not imply any verification on the accuracy of such information by the AMF and should not be considered as an endorsement of either the Issuer or the quality of the Notes that are the subject of this Prospectus and investors should make their own assessment as to the suitability of investing in the Notes.

This Prospectus will be valid until the date of admission of the Notes to trading on Euronext Paris. The obligation to supplement the Prospectus in the event of significant new factors, material mistakes or material inaccuracies will not apply when the Prospectus is no longer valid.

3. Admission to trading and listing fees

Application has been made for the Notes to be admitted to trading on Euronext Paris as from the Issue Date.

The estimated costs for the admission to trading of the Notes are €27,000 (including AMF and Euronext Paris fees).

4. Clearing systems

The Notes have been accepted for clearance through Clearstream and Euroclear with the Common Code number 334625010 and Euroclear France with the International Securities Identification Number (ISIN) FR0014017WJ3.

The address of Euroclear is 1 boulevard du Roi Albert II, 1210 Brussels, Belgium and the address of Clearstream is 42 avenue John Fitzgerald Kennedy, L-1855 Luxembourg, Grand-Duchy of Luxembourg. The address of Euroclear France is 10-12, place de la Bourse, 75002 Paris, France.

5. Conflict of interest

To the Issuer's knowledge and as of the date of this Prospectus, there is no potential conflict of interest between the duties of the members of the administrative, management and supervisory bodies of the Issuer and their private interests or their other duties.

6. No significant or material change

Save as disclosed in this Prospectus, there has been no significant change in the financial performance and/or financial position of the Issuer and the Group since 31 December 2025 and there has been no material adverse change in the prospects of the Issuer and the Group since 31 December 2025.

7. Legal proceedings

Neither the Issuer nor any member of the Group is or has been involved in any governmental, legal or arbitration proceedings (including any such proceedings that are pending or threatened of which the Issuer is aware) during a period covering at least the past twelve (12) months which may have, or have had in the recent past, significant effects on the financial position or profitability of the Issuer and/or the Group.

8. Material contracts

The Group has not entered into any material contracts which are not in the ordinary course of the Group's business and which could result in any member of the Group being under an obligation or entitlement that is material to the Group's ability to meet its obligations to holders of the Notes.

9. Financial statements

KPMG S.A. and Deloitte & Associés (all entities regulated by the *Haute Autorité de l'Audit* (H2A) and duly authorised as *Commissaires aux comptes*) have audited and rendered audit reports on the consolidated financial statements of the Issuer for the years ended 31 December 2024 and 31 December 2025.

The French auditors carry out their duties in accordance with the principles of *Compagnie Nationale des Commissaires aux Comptes* (CNCC) and are members of the *Compagnie Régionale de Versailles et du Centre*.

10. Documents

So long as any of the Notes are outstanding, the following documents can be inspected on the website of the Issuer (<https://www.roquette.com>):

- (i) the *statuts* of the Issuer;
- (ii) a copy of this Prospectus together with any supplement to this Prospectus;
- (iii) any documents incorporated by reference in this Prospectus; and
- (iv) all reports, letters and other documents, valuations and statements prepared by any expert at the Issuer's request of which is included or referred to in this Prospectus in respect of the issue of the Notes.

A copy of this Prospectus together with any supplement to this Prospectus and any document incorporated by reference will be available on the website of the Issuer (<https://www.roquette.com>). Copies of this Prospectus will also be available on the website of the *Autorité des marchés financiers* (www.amf-france.org).

Any websites included in this Prospectus are for information purposes only and the information in such websites does not form any part of this Prospectus unless that information is incorporated by reference into the Prospectus.

11. Yield

The yield to the First Reset Date of the Notes is equal to 6.000 per cent. *per annum* and is calculated at the Issue Date on the basis of the Issue Price. It is not an indication of future yield.

12. Currency

All references in this document to (i) "U.S. dollar" and "\$" are to the currency of the United States of America and (ii) "euro", "EUR" and "€" refer to the currency introduced at the start of the third stage of European economic and monetary union pursuant to the Treaty establishing the European Community (signed in Rome on 25 March 1957), as amended.

13. LEI number

The Legal Entity Identifier number of the Issuer is 969500FO141C5967KC72.

14. Interest

Save for any fees payable to the Joint Bookrunners as far as the Issuer is aware, no person involved in the issue of the Notes has any interest, including conflicting ones, that is material to the issue.

15. Joint Bookrunners

Certain of the Joint Bookrunners and their affiliates have engaged, and may in the future engage, in investment banking and/or commercial banking transactions with, and may perform services for, the Issuer and its affiliates in the ordinary course of business. Certain of the Joint Bookrunners and their affiliates may have positions, deal or make markets in the Notes, related derivatives and reference obligations, including (but not limited to) entering into hedging strategies on behalf of the Issuer and its affiliates, investor clients, or as principal in order to manage their exposure, their general market risk, or other trading activities. In addition, in the ordinary course of their business activities, the Joint Bookrunners and their affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers. Such investments and securities activities may involve securities and/or instruments of the Issuer or Issuer's affiliates. Certain of the Joint Bookrunners or their affiliates that have a lending relationship with the Issuer routinely hedge their credit exposure to the Issuer consistent with their customary risk management policies. Typically, such Joint Bookrunners and their affiliates would hedge such exposure by entering into transactions which consist of either the purchase of credit default swaps or the creation of short positions in securities, including potentially the Notes. The Joint Bookrunners and their affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or financial instruments and may hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. For the purpose of this paragraph the term "affiliates" includes also parent company.

16. Stabilisation

In connection with the issue of the Notes, Crédit Agricole Corporate and Investment Bank (the "**Stabilising Manager**") (or any person acting on behalf of the Stabilising Manager) may (but will not be required to) over-allot Notes or effect transactions within a specified period, with a view to supporting the market price of the Notes at a level higher than that which might otherwise prevail. However, stabilisation may not necessarily occur. Any stabilisation action may begin on or after the date on which adequate public disclosure of the terms of the offer of the Notes is made and, if begun, may cease at any time, but it must end no later than the earlier of 30 calendar days after the Issue Date and 60 calendar days after the date of the allotment of the Notes. Any stabilisation action or over-allotment must be conducted by the Stabilising Manager (or any person acting on behalf of the Stabilisation Manager) to the extent and in accordance with all applicable laws and rules.

The Issuer confirms the appointment of the Stabilising Manager as the central point responsible for adequate public disclosure of information, and handling any request from a competent authority, in accordance with Article 6(5) of Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 with regard to regulatory technical standards for the conditions applicable to buy-back programmes and stabilisation measures, including as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018.

17. Ratings

At the date of this Prospectus, the Issuer's long-term senior debt and short-term senior debt have been respectively rated BBB with a negative outlook and A-2 by S&P. The Notes have been rated BB+ by S&P. S&P is established in the European Union and is registered under the CRA Regulation and is included in the list of registered credit rating agencies published on the website of the ESMA (<https://www.esma.europa.eu/credit-rating-agencies/cra-authorisation>) in accordance with the CRA Regulation. A rating is not a recommendation to buy, sell or hold securities and may be subject to suspension, change or withdrawal at any time by the assigning credit rating agency without notice.

18. Forward-looking statements

This Prospectus contains or incorporates by reference objectives, forecasts or other forward-looking statements that may be identified by the use of words such as "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such objectives, forecasts or other forward-looking statements with respect to revenues, earnings, performance, strategies, prospects and other aspects of the businesses of the Group, as well as assumptions and analysis made by the Group in light of its perception of historical trends, current conditions and expected future developments and other factors it believes are appropriate in the circumstances. By their nature, forward-looking statements involve known and unknown risks, uncertainties and assumptions that could cause actual results, performance and the timing of events to differ materially from those expressed or implied by the forward-looking statements.

These forward-looking statements speak only as of the date on which the statements were made, and no obligation has been undertaken to publicly update or revise any forward-looking statements made in this Prospectus or elsewhere as a result of new information, future events or otherwise, except as required by applicable laws and regulations. Potential investors are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. These forward-looking statements do not constitute profit forecasts or estimates under Commission Delegated Regulation (EU) 2019/980, as amended, supplementing the Prospectus Regulation.

19. Benchmarks Regulation

Amounts payable under the Notes from and including the First Reset Date are calculated by reference to the Euro 5-Year Swap Rate which itself refers to ICESWAP2/EURSFIXA which itself refers to EUAMDB05 Index, which is provided by ICE Benchmark Administration Limited (the Administrator). As at the date of this Prospectus, the Administrator does not appear in the register of administrators and benchmarks established and maintained by ESMA pursuant to Article 36 of the Regulation (EU) No. 2016/1011, as amended (the "**Benchmarks Regulation**"). As far as the Issuer is aware, the transitional provisions in Article 51 of the Benchmarks Regulation apply, such that the Administrator is not currently required to obtain authorisation or registration (or, if located outside the European Union, recognition, endorsement or equivalence). As at the date of this Prospectus, the Administrator appears on the register of administrators and benchmarks established and maintained by the Financial Conduct Authority in the United Kingdom.

20. Third parties information

The information sourced from third parties has been accurately reproduced and, as far as the Issuer is aware and is able to ascertain from information published by that third parties, no facts have been omitted which would render the reproduced information inaccurate or misleading.

PERSON RESPONSIBLE FOR THE INFORMATION GIVEN IN THE PROSPECTUS

I hereby certify that the information contained in this Prospectus is, to the best of my knowledge, in accordance with the facts and contains no omission likely to affect its import.

ROQUETTE FRERES

1, rue de la Haute Loge
62136 Lestrem
France

Duly represented by:

Mr. Cédric Garrigues Chief Financial Officer (*Directeur financier*)

on 17 April 2026



This Prospectus has been approved by the AMF, in its capacity as competent authority under Regulation (EU) 2017/1129.

The AMF has approved this Prospectus after having verified that the information it contains is complete, coherent and comprehensible within the meaning of Regulation (EU) 2017/1129. This approval does not imply any verification on the accuracy of such information by the AMF.

This approval is not a favourable opinion on the Issuer and on the quality of the Notes described in this Prospectus. Investors should make their own assessment of the opportunity to invest in such Notes.

This Prospectus has been approved on 17 April 2026 and is valid until the date of admission of the Notes to trading on Euronext Paris and shall, during this period and in accordance with the provisions of article 23 of the Regulation (EU) 2017/1129, be completed by a supplement to the Prospectus in the event of significant new factors, material mistakes or material inaccuracies.

This Prospectus obtained the following approval number: 26-093.

Issuer

ROQUETTE FRERES

1, rue de la Haute Loge
62136 Lestrem
France

Joint Global Coordinators and Joint Bookrunners

Crédit Agricole Corporate and Investment Bank

12, place des États-Unis
CS 70052
92547 Montrouge Cedex
France

Goldman Sachs Bank Europe SE

Marienturm, Taunusanlage 9-10
D-60329 Frankfurt am Main
Germany

Natixis

7, promenade Germaine Sablon
75013 Paris
France

Société Générale

29, boulevard Haussmann
75009 Paris
France

Joint Bookrunners

BNP Paribas

16, boulevard des Italiens
75009 Paris
France

Crédit Industriel et Commercial S.A.

6, avenue de Provence
75452 Paris cedex 09
France

J.P. Morgan SE

Taunustor 1 (TaunusTurm)
60310 Frankfurt am Main
Germany

Fiscal Agent, Principal Paying Agent, Make-whole Calculation Agent and Calculation Agent

BNP PARIBAS

(acting through its Securities Services business)
Les Grands Moulins de Pantin 9, rue du Débarcadère
93500 Pantin
France

Auditors

KPMG S.A.

Tour EQHO
2 avenue Gambetta
CS60006
92066 Paris-La Défense Cedex
France

Deloitte & Associés

Tour Majunga
6 place de la Pyramide
92908 Paris La Défense Cedex
France

Legal Advisers

To the Issuer
Clifford Chance Europe LLP
1, rue d'Astorg
75008 Paris
France

To the Joint Bookrunners
Allen Overy Shearman Sterling LLP
32, rue François 1^{er}
75008 Paris
France